

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA**

SMART APPROACHES TO
MARIJUANA
220 Maryland Ave NE, Washington, DC
20002,

CANNABIS INDUSTRY VICTIMS
EDUCATING LITIGATORS
203 Main St, Suite 250, Flemington, NJ
08822,

AMERICANS AGAINST LEGALIZING
MARIJUANA
P.O. Box 158, Carmichael, CA 95609

Case No. 1:26-CV-01081-TNM

NORTH CAROLINIANS AGAINST
LEGALIZING MARIJUANA
1854 Hendersonville Rd, Suite 205,
Asheville, NC 28803,

CANNABIS IMPACT PREVENTION
COALITION, LLC
418 Broadway, Suite N, Albany, NY
12207,

CANNABIS INDUSTRY VICTIMS
SEEKING JUSTICE
418 Broadway, Suite N, Albany, NY
12207,

DRUG FREE AMERICA FOUNDATION
333 3rd Ave N, Suite 200, St. Petersburg,
FL 33701,

SAVE OUR SOCIETY FROM DRUGS
333 3rd Ave N, Suite 200, St. Petersburg,
FL 33701,

DRUG WATCH INTERNATIONAL
6981 Tepper Dr, Clifton, VA 20124,

HILLSBOROUGH COUNTY ANTI-
DRUG ALLIANCE
521 Lantern Circle, Temple Terrace, FL
33617,

ILLINOIS FAMILY INSTITUTE
PO Box 876, Tinley Park, IL 60477,

DAVID EVANS
10 Elmwood Lane, Asheville, NC 28803,

KENNETH FINN, M.D.
1716 Alpine Meadows Lane, Unit 1603,
Prescott, AZ 86303

MMJ INTERNATIONAL HOLDINGS,
INC.
101425 Overseas Highway, Suite 170, Key
Largo, FL 33037,

MMJ BIOPHARMA CULTIVATION,
INC.
101425 Overseas Highway, Suite 170, Key
Largo, FL 33037,

and

MMJ BIOPHARMA LABS, INC.
101425 Overseas Highway, Suite 170, Key
Largo, FL 33037,

Plaintiffs,

v.

ROBERT F. KENNEDY, JR., in his official
capacity as Secretary of Health and
Human Services,

THE UNITED STATES DEPARTMENT
OF HEALTH AND HUMAN SERVICES,

MEHMET OZ, M.D., in his official
capacity as Administrator of the Centers
for Medicare & Medicaid Services,

and

THE CENTERS FOR MEDICARE &
MEDICAID SERVICES,

Defendants.

**FIRST AMENDED COMPLAINT
FOR INJUNCTIVE AND DECLARATORY RELIEF**

Connor W. Mighell
TX Bar #24110107
D.D.C. Bar ID #TX0032
BURKE LAW GROUP, PLLC
1000 Main Street, Suite 2300
Houston, Texas 77002
Telephone: (832) 987-2214
Fax: (832) 793-0045
connor.mighell@burkegroup.law

Ilya Shapiro*
DC Bar #489100
BURKE LAW GROUP, PLLC
2001 L Street NW, Suite 500
Washington, D.C. 20036
ilya.shapiro@burkegroup.law
**Admission Pending*

Patrick Kenneally**
IL Bar #6286573
BURKE LAW GROUP, PLLC
205 N Michigan Avenue, Suite 810
Chicago, Illinois 60601
patrick.kenneally@burkegroup.law
***Pro Hac Vice Forthcoming*

Attorneys for Plaintiffs

I. INTRODUCTION¹

1. On March 20, 2026, the Centers for Medicare & Medicaid Services (“CMS”) created a program to distribute hemp-derived products containing the Schedule I substance delta-9 tetrahydrocannabinol (“THC”) to Medicare beneficiaries. CMS called this program the Substance Access Beneficiary Engagement Incentive (“BEI”). The BEI imposes binding rules on participating health care providers. These rules include how doctors and patients officially sign up and which doctors are eligible to distribute these products, create detailed implementation plans that must first be approved by CMS, set THC limits and other product specifications, and require quarterly reporting by providers. The BEI does not involve the Food and Drug Administration (“FDA”)’s medicine approval process.

2. CMS published no Notice of Proposed Rulemaking for the BEI, solicited no public comments, offered no reasonable explanation for its action, bypassed the Federal Register, gave 11 days’ notice before the BEI’s implementation, and contradicted *sub silentio* its own final rule (less than a year old) that declared cannabis products ineligible for supplemental Medicare coverage for chronically ill patients. 90 Fed. Reg. 15,792, 15,867 (Apr. 15, 2025).

3. The BEI violates the Administrative Procedure Act (“APA”) in three ways:
- a. *First*, the BEI’s obligations are the hallmarks of a legislative rule requiring notice-and-comment rulemaking under the APA. CMS’s

¹ In accordance with Section 6 of this Court’s Standing Order, Plaintiffs include attached a redline comparison of this First Amended Complaint with Plaintiffs’ Original Complaint. *See* Exhibit A.

failure to solicit notice and comment violated 5 U.S.C. §§ 553 and 706(2)(D). CMS cannot evade notice-and-comment by embedding a substantive rule in a participation agreement.

- b. *Second*, CMS reversed its prior rule without explanation, ignored well-documented health risks to elderly Americans (including a two-fold increase in cardiovascular death risk, an increase in the risk of developing or exacerbating mental health disorders, and pervasive contamination of CBD products), disregarded the absence of any FDA regulatory framework, and launched a program that violated the 0.4mg-per-container ceiling set by the 2026 Agriculture Appropriations Act by permitting the distribution of products with up to 3 mg of THC per serving. As such, the BEI is facially arbitrary, capricious, and not in accordance with law, in violation of 5 U.S.C. § 706(2).
- c. *Third*, the BEI exceeds CMS's statutory authority in violation of the major questions doctrine. Section 1115A of the Social Security Act, under which the BEI is promulgated, allows CMS to test payment and delivery models for Medicare services. It does not allow CMS to sanction the possession and use of illegal and dangerous Schedule I substances by Medicare patients without clear congressional authorization.

- 4. The BEI violates the Constitution in two ways:

- d. *First*, CMS's decision to provide advance notice of the BEI to hemp-industry stakeholders including Charlotte's Web, a major hemp product producer, while excluding similarly situated regulated parties such as the MMJ Plaintiffs, violates the Fifth Amendment's equal protection guarantee by intentionally treating similarly situated entities differently without any rational basis. The MMJ Plaintiffs, who have invested years and millions of dollars in the federal FDA botanical drug development pathway, received no notice of or opportunity to participate in the development of the BEI, while hemp-industry stakeholders who have not undertaken the same regulatory burdens were afforded advance notice and the opportunity to shape the program. This disparate treatment of similarly situated regulated parties—those developing cannabinoid products—without rational basis constitutes a class-of-one equal protection violation.
- e. *Second*, CMS's implementation of the BEI without notice-and-comment rulemaking, and without affording directly affected regulated parties such as the MMJ Plaintiffs any opportunity to be heard, violates the Fifth Amendment's due process guarantee. The BEI retroactively undermines the investment-backed expectations of parties who entered the federal pharmaceutical regulatory pathway in reliance on an established and consistently applied framework,

and deprives them of the economic value of their regulatory compliance without any process whatsoever.

5. CMS's action represents an unprecedented and unlawful assertion of binding decision-making authority that will profoundly affect the health of elderly Americans. CMS took this action without the guardrails imposed by the administrative process, without any reasoned explanation, in conflict with the agency's own recent APA-compliant determination, and without statutory authority. Plaintiffs bring this action under the APA, 5 U.S.C. § 701–706, and under the Constitution, amend. V, to vacate the BEI, declare it unlawful, and permanently enjoin its implementation.

II. PARTIES

A. Plaintiffs

6. Smart Approaches to Marijuana, Inc. ("SAM") is a corporation headquartered at 220 Maryland Ave NE, Washington, D.C. 20002 and incorporated in Virginia. SAM's mission includes education and advocacy regarding the public health and safety impacts of marijuana and cannabis policy. SAM operates concrete programmatic activities, including public health education campaigns directed at healthcare providers and patients, direct information services regarding cannabis-related health risks, and research and policy analysis programs. SAM is a participant in the ongoing Drug Enforcement Administration marijuana rescheduling proceedings as an interested party in opposition to the Notice of Proposed Rulemaking. *See* Exhibit B. The BEI directly impairs SAM's core programmatic activities by requiring SAM to redirect staff and resources from its ongoing patient and provider education programs to monitor, analyze, and provide direct informational services to its members and stakeholders

regarding the BEI's implications for vulnerable seniors, as well as engage in this litigation. The BEI provides marijuana products via a medical source, meaning that SAM's expenditure of resources opposing rescheduling of marijuana in administrative proceedings has been rendered essentially moot. SAM's injury is not abstract policy disagreement but concrete impairment of specific programmatic activities with a consequent drain on organizational resources. *See Havens Realty Corp. v. Coleman*, 455 U.S. 363, 379 (1982). In addition, SAM's donor, volunteer, and consultant David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. SAM also has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

7. Cannabis Industry Victims Educating Litigators ("CIVEL") is an organization based in New Jersey. CIVEL's mission includes educating legal professionals and the public about the harms caused by the cannabis industry. CIVEL represents the victims of the marijuana industry who have been, are being, or will actually be harmed by the challenged actions of CMS because the BEI will increase the use of marijuana, reduce the perception of its dangerousness, and lower medical standards for determining what constitutes a medicine. CIVEL thus has an active interest and not a mere casual interest in the problem presented. As a marijuana industry victims' legal support organization, CIVEL has a direct and particularized interest in the

implementation of federal and state law regarding “medical” marijuana in all of its forms. CIVEL operates concrete programmatic activities including legal education seminars, victim assistance programs, and community outreach. CIVEL is a participant in the ongoing administrative process opposing the rescheduling of cannabis before the Drug Enforcement Administration, and was granted associational standing by DEA Chief Administrative Law Judge John J. Mulrooney on November 19, 2024 in the matter of Schedules of Controlled Substances: Proposed Rescheduling of Marijuana, DEA Docket No. 1362, Hearing Docket No. 24-44. CIVEL was also recognized as having associational standing in *Botteon v. Murphy*, NJ Superior Court MID-L-002293 (2020), a New Jersey case concerning federal law preemption and the state marijuana law. The BEI has directly impaired CIVEL’s core programmatic activities by requiring CIVEL to divert staff time and resources from its victim assistance and legal education programs to monitor, analyze, and respond to the BEI and its implications for vulnerable seniors. The BEI program will apply to thousands of medical care providers that CIVEL will have to educate and monitor, and with the increase in hemp injuries caused by the BEI, there will be more litigation, potentially against the providers or ACOs whose patients will be injured, requiring CIVEL to devote more expertise and financial and legal educational resources to handle those cases. This diversion of resources constitutes a concrete and demonstrable injury to CIVEL’s organizational interests. In addition, CIVEL’s Senior Counsel and Executive Director David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare

relationship due to the BEI. Additionally, CIVEL has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

8. Americans Against Legalizing Marijuana (“AALM”) is a national non-profit volunteer organization based in California that is dedicated to providing information on the harms of marijuana to individuals and our country based on the premise “no use of any illegal drug and no illegal use of legal drugs.” Such drugs include “medical” marijuana, hemp-based products, THC, CBD, and other cannabinoids. The BEI has directly affected and interfered with AALM’s core programmatic activities beyond its issue advocacy or mission by requiring diversion of resources from its programs, including victim support and drug prevention education programs, public awareness campaigns, support and resources for medical professionals and attorneys working in fields impacted by cannabis use and abuse, and related operational activities. AALM’s consultant David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, AALM has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

9. North Carolinians Against Legalizing Marijuana (“NCALM”) is an organization based in Asheville, North Carolina, and is registered with the North Carolina Secretary of State for lobbying purposes. NCALM’s mission includes opposing the legalization of medical hemp-derived and marijuana products in North Carolina and advocating that only medicines produced and distributed with standard best-practice pharmaceutical protocols and approved by the FDA should be available to patients. NCALM operates concrete programmatic activities including legislative advocacy, public education campaigns, and policy analysis regarding the risks of marijuana. The BEI has directly affected and interfered with NCALM’s core programmatic activities beyond its issue-advocacy or mission, because the BEI authorizes the distribution of cannabis- and hemp-derived products that have not been approved by the FDA—the very outcome NCALM’s programs are designed to prevent. NCALM’s Executive Director David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, NCALM has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

10. Cannabis Impact Prevention Coalition, LLC (“CIPC”) is a corporation organized under the laws of the State of New York. CIPC’s mission is to prevent the negative social, health, public safety, and environmental impacts of marijuana. CIPC was

granted standing in *Cannabis Impact Prevention Coalition and Cannabis Industry Victims Seeking Justice, et al. v. Hochul*, Index No. 905386-23 (Albany County, NY), a case involving state laws regarding “medical” marijuana. CIPC operates concrete programmatic activities including public education, community outreach, and policy advocacy directed at reducing the harms caused by marijuana use. The BEI has directly affected and interfered with CIPC’s core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs. This diversion constitutes a concrete organizational injury. CIPC’s Executive Director David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, CIPC has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

11. Cannabis Industry Victims Seeking Justice (“CIVSJ”) is a corporation organized under the laws of the State of New York. CIVSJ’s mission is to make the marijuana industry legally accountable to its victims and to provide advocacy services to the many victims of the cannabis industry. CIVSJ was granted standing alongside Cannabis Impact Prevention Coalition, LLC in *Cannabis Impact Prevention Coalition and Cannabis Industry Victims Seeking Justice, et al. v. Hochul*, Index No. 905386-23 (Albany County, NY). CIVSJ operates concrete programmatic activities including victim advocacy, legal accountability initiatives, and public education regarding the harms

caused by the cannabis industry. The BEI has directly affected and interfered with CIVSJ's core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs. This diversion constitutes a concrete organizational injury. CIVSJ's Executive Director David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, CIVSJ has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

12. Drug Free America Foundation ("DFAF") is an incorporated nonprofit organization based in Florida. DFAF is a drug prevention and policy organization committed to developing strategies and educational programs that prevent drug use and promote sustained recovery. The BEI has directly affected and interfered with DFAF's core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs, including drug prevention education programs, student assistance initiatives, community outreach, workplace drug prevention programs, and related operational activities. DFAF's consultant and volunteer David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, DFAF has an informational interest in the administrative record that would have been developed had

the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

13. Save Our Society from Drugs (“SOS”) is an incorporated nonprofit organization based in Florida. Its mission includes establishing, promoting, and enabling sound drug laws and policies that will reduce illegal drug use, drug addiction and drug-related illness and death. The BEI has directly affected and interfered with SOS’s core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs, including drug prevention education programs, public awareness campaigns, community intervention initiatives, support and resources for professionals working in fields impacted by drug use and abuse, and related operational activities. SOS’s consultant and volunteer David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, SOS has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

14. Drug Watch International (“DWI”) is an incorporated nonprofit organization based in Virginia. Its mission includes promoting “healthy drug-free cultures” globally, advocating for the prohibition of and abstinence from all drugs including alcohol and tobacco, and opposing the legalization of drugs prohibited by national and international laws. The BEI has directly affected and interfered with DWI’s

core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs. Since the BEI was announced, DWI's board and members have spent considerable time on collecting and disseminating information about cannabis- and hemp-derived products and the BEI to its stakeholders and constituents, thus diverting members from the mission of Drug Watch International, Inc., which seeks to prevent the abuse of all drugs, not just cannabis, through education, prevention, and treatment. DWI's injury is not abstract policy disagreement but concrete impairment of specific programmatic activities with a consequent drain on organizational resources. DWI's interest in preventing the expansion of access to drugs has been directly and demonstrably harmed by the BEI. DWI possesses extensive expertise and data regarding the public health risks of cannabis- and hemp-derived products and the impact of expanded drug access on communities, which it would have submitted to the agency as part of a formal rulemaking proceeding. DWI's member David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, DWI has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

15. Hillsborough County Anti-Drug Alliance ("HCADA") is an incorporated nonprofit organization based in Florida. Its mission includes engaging in community-based alcohol, tobacco, and substance abuse education and prevention activities, as well

as participation in the development of related planning strategies statewide. The BEI has directly affected and interfered with its core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its other programs and activities, including legislative advocacy, education, community outreach, and volunteering. Additionally, HCADA has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

16. Illinois Family Institute (“IFI”) is an incorporated nonprofit organization based in Illinois. Its mission includes advancing public policy initiatives consistent with Judeo-Christian teachings and traditions, including opposition to access to illegal drugs, educating citizens so that they can better influence their local communities and the state. IFI possesses extensive expertise and data regarding the public health and moral risks of cannabis- and hemp-derived products and the impact of expanded drug access on communities. The BEI has directly affected and interfered with IFI’s core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs. IFI would have submitted detailed comments to CMS opposing the BEI had the agency complied with the notice-and-comment requirements of 5 U.S.C. § 553. IFI has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

17. David Evans is a 78-year-old Medicare beneficiary and a three-time cancer survivor who was treated for two forms of cancer while on Medicare, making him a member of the population most vulnerable to the cardiovascular, neurological, cognitive, and drug-interaction harms documented in the peer-reviewed literature regarding cannabis- and hemp-derived products. Mr. Evans is aligned with an ACO REACH participant provider and has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Mr. Evans is also the owner of a critical care nursing home that may be asked to participate in the BEI process, and he would have sought the opportunity to participate in notice-and-comment rulemaking on behalf of the nursing home before the BEI was implemented. Mr. Evans has extensive personal knowledge of and experience with the harms caused by cannabis and hemp-derived products and possesses extensive evidence of these harms, which he was denied the opportunity to submit to CMS.

18. Kenneth Finn, M.D. is a physician who practices comprehensive pain medicine in Prescott, Arizona. Dr. Finn is Board Certified in Physical Medicine and Rehabilitation, Pain Medicine, and Pain Management, and is certified in Cannabis Science through the University of Colorado. Dr. Finn was an associate professor for the University of Colorado Medical School, is former President of the American Board of Pain Medicine, and has served on their Exam Council for over 25 years. He is editor of Cannabis in Medicine: An Evidence-Based Approach (2020) and is Co-Vice President of the International Academy on the Science and Impacts of Cannabis. Dr. Finn is employed by an Accountable Care Organization (“ACO”). As a physician who practices pain

medicine and has extensive experience with cannabis-related patient care, Dr. Finn will be directly affected by the BEI because the lack of satisfactory research into the cannabis products authorized under the BEI, and the absence of any dosing guidelines or care standards from the FDA, renders him unable to competently prescribe or administer such products for his patients. His practice may lose any Medicare patients who wish to access substances under the BEI. Dr. Finn must also follow the BEI's legal requirements for any patient he has that elects to receive substances under the BEI, should his ACO opt into the ACO REACH Model. Additionally, due to the known adverse health effects of cannabinoid substances, Dr. Finn and his practice are likely to receive an increase in emergency room visits and may be sued for malpractice by patients that overuse cannabinoid and hemp-derived products due to a lack of dosing requirements or widespread adulteration of such retail products. The BEI exposes Dr. Finn to significant malpractice liability without any regulatory safe harbor or physician indemnification, and creates a dangerous regulatory cliff: the FY 2026 Agriculture Appropriations Act, effective November 2026, resets the legal THC threshold to 0.4 mg total hemp-derived THC per container, potentially rendering products recommended to patients today Schedule I controlled substances by Fall 2026 and creating retroactive legal exposure for physicians. Dr. Finn is aware that approximately 1,500 deaths have been reported in connection with FDA-approved Epidiolex alone, yet products distributed under the BEI are afforded no comparable adverse event reporting mechanisms. Dr. Finn is a participant in the ongoing Drug Enforcement Administration marijuana rescheduling proceedings as an interested party in opposition to the Notice of Proposed Rulemaking.

See Exhibit B. Dr. Finn was deprived of his right to participate in notice-and-comment rulemaking as an interested party. Additionally, Dr. Finn has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of his participatory interest in shaping the regulatory process through providing comments.

19. MMJ International Holdings, Inc. (“MMJIH”) is a corporation incorporated in Delaware with its principal business address at 101425 Overseas Highway, Suite 170, Key Largo, Florida 33037. MMJIH is a life sciences company established for the purpose of developing pharmaceutical cannabinoid therapeutics under the FDA’s botanical drug development framework, including the Botanical Drug Development Guidance for Industry. MMJIH serves as the parent company of MMJ BioPharma Cultivation, Inc. and MMJ BioPharma Labs, Inc., overseeing regulatory strategy, clinical development planning, chemistry, manufacturing, and controls preparation, and Investigational New Drug (“IND”) submissions for cannabinoid-based treatments targeting Huntington’s disease and multiple sclerosis. MMJIH has assembled a team of nationally recognized scientists and regulatory professionals, submitted IND applications to the FDA, and obtained Orphan Drug Designation for Δ 9-tetrahydrocannabinol and cannabidiol for the treatment of Huntington’s disease pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360bb). Over the past approximately eight years, MMJIH and its subsidiaries have invested over \$10 million into advancing pharmaceutical cannabinoid therapeutics through the formal federal FDA botanical drug development pathway and the DEA controlled-substance registration framework. The BEI has directly

and concretely injured MMJIH by (1) creating a federally supported pathway for the distribution of non-FDA-approved cannabinoid products to Medicare beneficiaries, thereby undermining the economic assumptions underlying MMJIH's multi-year pharmaceutical development investment, (2) diminishing the anticipated reimbursement differentiation between FDA-validated therapies and non-approved cannabinoid products, (3) adversely affecting investor confidence and capital-raising efforts, and (4) creating competitive disadvantage relative to entities that have not undertaken the rigorous scientific validation and regulatory compliance that MMJIH has pursued. MMJIH was excluded from any notice of the BEI and was deprived of the opportunity to participate in notice-and-comment rulemaking, despite being a directly affected regulated party with concrete interests at stake. Additionally, MMJIH has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

20. MMJ BioPharma Cultivation, Inc. ("MMJBC") is a corporation incorporated in Delaware with its principal business address at 101425 Overseas Highway, Suite 170, Key Largo, Florida 33037. MMJBC is a subsidiary of MMJIH formed to support the cultivation and production of pharmaceutical-grade cannabis plant material required for extraction and formulation of the active botanical drug substance used in MMJIH's IND programs. In December 2018, MMJBC submitted an application to the DEA for registration as a bulk manufacturer of marijuana active pharmaceutical ingredient for use in FDA-authorized clinical trials and drug development. MMJBC's cultivation facility in

Westerly, Rhode Island was designed to employ state-of-the-art automated growth chambers capable of generating medical marijuana with exacting and repeatable secondary metabolite profiles at production levels consistent with federal research supply requirements. MMJBC's bulk manufacturing registration application remains pending before the DEA Administrator. The BEI has directly and concretely injured MMJBC as part of the integrated pharmaceutical development platform it operates with MMJIH and MMJBL, by undermining the economic viability of the federal FDA and DEA regulatory pathway upon which MMJBC's operations depend. MMJBC was excluded from any notice of the BEI and was deprived of the opportunity to participate in notice-and-comment rulemaking. Additionally, MMJBC has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

21. MMJ BioPharma Labs, Inc. ("MMJBL") is a corporation incorporated in Delaware with its principal business address at 101425 Overseas Highway, Suite 170, Key Largo, Florida 33037. MMJBL is a subsidiary of MMJIH established to perform analytical testing, formulation support, and regulatory-grade characterization of botanical extracts used in MMJIH's drug development program. MMJBL obtained a DEA Schedule I analytical laboratory registration, issued following a DEA inspection and approval of the laboratory's physical security systems, recordkeeping controls, and diversion-prevention safeguards, consistent with its Rhode Island state authorization. The BEI has directly and concretely injured MMJBL as part of the integrated pharmaceutical development

platform it operates with MMJIH and MMJBC, by undermining the economic viability of the federal FDA and DEA regulatory pathway upon which MMJBL's operations depend. MMJBL was excluded from any notice of the BEI and was deprived of the opportunity to participate in notice-and-comment rulemaking. Additionally, MMJBL has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

B. Defendants

22. Defendant Robert F. Kennedy, Jr. is the Secretary of Health and Human Services. He is sued in his official capacity. Secretary Kennedy oversees the Department of Health and Human Services, which houses the Centers for Medicare & Medicaid Services, and bears ultimate responsibility for the adoption and implementation of the BEI.

23. Defendant United States Department of Health and Human Services ("HHS") is an executive department of the United States government responsible for administering federal healthcare programs, including the Medicare program.

24. Defendant Mehmet Oz, M.D. is the Administrator of the Centers for Medicare & Medicaid Services. He is sued in his official capacity. Administrator Oz publicly announced in December 2025, at the signing ceremony for Executive Order No. 14370, that "millions of Americans on Medicare" would become eligible to receive cannabis products "as early as April of next year—and at no charge if their doctors

recommend them.” Administrator Oz has played a central role in the development and public promotion of the BEI.

25. Defendant Centers for Medicare & Medicaid Services (“CMS”) is a federal agency within HHS. CMS administers the Medicare program and operates the Center for Medicare & Medicaid Innovation (“Innovation Center”), which developed and published the BEI.

III. JURISDICTION AND VENUE

26. Plaintiffs bring this action under the Administrative Procedure Act (“APA”), 5 U.S.C. §§ 701-706, and the Constitution, amend. V. The APA provides a right of review under 5 U.S.C. § 702 for persons adversely affected or aggrieved by agency action and under 5 U.S.C. § 704 for final agency action for which there is no other adequate remedy in a court.

27. This court has subject matter jurisdiction pursuant to 28 U.S.C. § 1331, 5 U.S.C. §§ 701-706 (APA) and 28 U.S.C. § 2201 (Declaratory Judgment Act). The relief requested is authorized by 28 U.S.C. § 2201 (declaratory judgment), 28 U.S.C. § 2202 (injunctive relief), and 5 U.S.C. §§ 701-706 (APA).

28. This Court has jurisdiction pursuant to 28 U.S.C. § 1331, which grants the district courts “original jurisdiction of all civil actions arising under the . . . laws . . . of the United States.”

29. Venue is appropriate in this Court pursuant to 28 U.S.C. § 1391(e)(1) because the defendants are officers and agencies of the United States and this action is

brought where the agency defendants maintain their principal offices. Venue is also appropriate under 5 U.S.C. § 703.

30. An actual, justiciable controversy exists between the parties within the meaning of 28 U.S.C. § 2201.

31. The federal Government has waived sovereign immunity in this action pursuant to 5 U.S.C. § 702.

32. Plaintiffs have exhausted all administrative remedies.

33. The agency action is final and ripe for review.

34. All Plaintiffs have standing because they are injured in fact because of the defendants' actions or omissions and this Court has the power to redress those injuries.

A. Final Agency Action

35. The BEI constitutes final agency action because it (1) “mark[s] the consummation of the agency’s decision-making process” and is “not . . . of a merely tentative or interlocutory nature” and (2) is an action “by which rights or obligations have been determined, or from which legal consequences will flow.” *Bennett v. Spear*, 520 U.S. 154, 177–78 (1997) (cleaned up); *see also United States Army Corps of Eng’rs v. Hawkes Co.*, 578 U.S. 590, 597 (2016). The BEI was published to CMS’s website on March 20, 2026, with an effective date of April 1, 2026. It imposes binding requirements regarding participant election, submission of an implementation plan, eligibility determinations, and quarterly reporting to CMS. These requirements complete CMS’s decision-making and produce concrete legal consequences for participating organizations and Medicare beneficiaries

aligned with them. *See Bennett*, 520 U.S. at 178 (action is final where it has “direct and appreciable legal consequences”).

B. The Section 1115A Review Bar Does Not Apply

36. Section 1115A of the Social Security Act, 42 U.S.C. § 1315a(d)(2), bars judicial review of “the selection of models for testing,” “the selection of organizations, sites, or participants,” and “the elements, parameters, scope, and duration” of Innovation Center models.

37. Plaintiffs do not challenge any of these enumerated decisions. Plaintiffs challenge the procedures CMS used to adopt and publish the BEI by bypassing APA rulemaking and exceeding its statutory authority. *See Regeneron Pharmaceuticals, Inc. v. United States HHS*, 510 F. Supp. 3d 29, 42 (S.D.N.Y. 2020) (holding that Section 1115A “does not bar review of the propriety of the procedures used” to establish models); *see also Bowen v. Michigan Academy of Family Physicians*, 476 U.S. 667, 670 (1986) (recognizing a “strong presumption that Congress intends judicial review of administrative action”).

C. Medicare Channeling Does Not Apply

38. Plaintiffs do not seek benefits determinations, reimbursement calculations, or participant-specific Medicare payment review. No adequate administrative remedy exists for this pre-enforcement APA challenge to CMS’s procedural deficiencies in adopting the BEI. *See Shalala v. Illinois Council on Long Term Care*, 529 U.S. 1, 19 (2000) (channeling requirements do not apply where they would result in “complete preclusion of judicial review”).

IV. STANDING

A. Competitor Standing

39. MMJ Plaintiffs have competitor standing under the doctrine established in *Sherley v. Sebelius*, 610 F.3d 69 (D.C. Cir. 2010), and its progeny.

40. MMJ Plaintiffs are direct and current competitors in the cannabinoid therapeutics market. MMJIH, through its subsidiaries MMJBC and MMJBL, has invested over \$10 million and eight years into developing pharmaceutical-grade cannabinoid therapeutics through the formal FDA botanical drug development pathway. MMJIH has submitted IND applications to the FDA for cannabinoid treatments targeting Huntington's disease (IND file number 137754) and multiple sclerosis (IND file number 140712). The FDA granted Orphan Drug Designation for MMJIH's Huntington's disease program. MMJBC has a pending bulk manufacturing application before the DEA for cultivation of pharmaceutical-grade cannabis for clinical trials, and MMJBL holds an active DEA Schedule I analytical laboratory registration.

41. The BEI causes an actual and imminent increase in competition against MMJ Plaintiffs. The BEI expands the competitive landscape by creating a federally supported pathway for non-FDA-approved cannabinoid products to reach Medicare beneficiaries—the same patient population that MMJ Plaintiffs' FDA-validated therapies would target.

42. The competitive injury to MMJ Plaintiffs is concrete and imminent. The BEI subjects MMJ Plaintiffs to direct competition from entities distributing non-FDA-approved cannabinoid products through Medicare without undertaking any of the

rigorous pharmaceutical development requirements that MMJ Plaintiffs have spent years and millions of dollars satisfying.

43. Moreover, MMJ Plaintiffs have suffered competitive injury because the challenged agency action permits entities (hemp-product distributors) to compete in a market (cannabinoid therapeutics for Medicare beneficiaries) where the plaintiffs (MMJ Plaintiffs pursuing FDA approval) previously enjoyed regulatory protection. This amounts to increased competitive activity that courts have recognized constitutes Article III injury.

44. MMJ Plaintiffs' competitive injuries are fairly traceable to the BEI and redressable by a favorable decision. Before the BEI, there was no federally supported reimbursement pathway for non-FDA-approved cannabinoid products in Medicare. The BEI created one. MMJ Plaintiffs' competitive disadvantage flows directly from the BEI's existence. An injunction vacating or staying the BEI would eliminate the competing access pathway, restoring the regulatory framework that previously required cannabinoid therapeutics to proceed through FDA approval before becoming eligible for Medicare reimbursement.

45. Finally, MMJ Plaintiffs satisfy the prudential standing requirement that their interests fall within the "zone of interests" protected by the statutes they invoke. MMJ Plaintiffs' interest in maintaining the integrity of the FDA drug approval framework, and in preventing CMS from creating alternative access pathways that circumvent that framework, falls squarely within the zone of interests protected by the

APA's procedural requirements and the statutory framework governing federal healthcare reimbursement for pharmaceutical products.

B. Organizational Standing

46. All Plaintiffs except for David Evans and Kenneth Finn, M.D. (collectively, the "Organizational Plaintiffs") have organizational standing to sue.

47. Organizational Plaintiffs' primary interest is in proper use of the FDA regulatory process for any cannabinoid products approved for medical use, as well as preventing the expansion of access to cannabis, hemp, and cannabinoid products not approved through this process. They have standing to challenge CMS's action in creating and instituting the BEI on their own behalf due to concrete and demonstrable injury to these respective interests.

48. Moreover, CMS's action has impaired specific, concrete programmatic activities undertaken by certain Organizational Plaintiffs, including direct patient education services, clinician training programs, community health intervention programs, and victim assistance operations, by requiring diversion of resources from these programs to counteract the public health and societal effects of the BEI. This constitutes an injury to each Organizational Plaintiff's respective organizational interests. *See People for the Ethical Treatment of Animals v. United States Department of Agriculture*, 797 F.3d 1087, 1094 (D.C. Cir. 2015).

49. Certain Organizational Plaintiffs have standing to challenge the BEI because counteracting it requires diversion of resources from their efforts to prevent rescheduling of cannabis through the administrative process. Specifically, SAM and

CIVEL are directly involved in ongoing DEA administrative proceedings opposing cannabis rescheduling.

50. MMJ Plaintiffs additionally have standing based on direct competitive and economic injury. The BEI created a federally supported pathway for the distribution of non-FDA-approved cannabinoid products to Medicare beneficiaries, thereby directly and concretely injuring MMJ Plaintiffs by undermining the economic assumptions underlying their multi-year, multi-million-dollar pharmaceutical development investment in the federal FDA botanical drug development pathway; diminishing the anticipated reimbursement differentiation between FDA-validated therapies and non-approved cannabinoid products; adversely affecting investor confidence, capital-raising efforts, and strategic partnership positioning; and creating competitive disadvantage relative to entities that have not undertaken the rigorous scientific validation and regulatory compliance that MMJ Plaintiffs have pursued. These injuries are concrete and particularized, actual and imminent, fairly traceable to CMS's adoption of the BEI, and redressable by a favorable decision vacating or enjoining the BEI.

51. MMJ Plaintiffs' standing is further supported by their status as directly affected regulated parties operating under active DEA oversight and FDA IND authorization. The BEI creates a two-track regulatory system in which entities like MMJ Plaintiffs that have complied with the federal pharmaceutical regulatory framework are subjected to the full weight of FDA and DEA regulatory requirements, while the BEI permits entities that have not undertaken any of those regulatory burdens to access a federally supported cannabinoid distribution pathway. An injunction vacating or staying

the BEI would eliminate the competing pathway, restoring the regulatory framework upon which MMJ Plaintiffs relied and protecting their investment in the FDA approval process.

C. Procedural Standing

52. All Plaintiffs assert the denial of their right to participate in notice and comment rulemaking under 5 U.S.C. § 553. They have suffered a “reasonably increased risk of injury” to their particularized interests due to CMS’s decision to create and institute the BEI without the required procedure. *Cap. Area Immigrants’ Rts. Coal. v. Trump*, 471 F. Supp. 3d 25, 38 (D.D.C. 2020); *see also Mendoza v. Perez*, 754 F.3d 1002, 1010 (D.C. Cir. 2014); *Massachusetts v. EPA*, 549 U.S. 497, 517–18 (2007); *Sugar Cane Growers Coop. of Fla. v. Veneman*, 289 F.3d 89, 94–95 (D.C. Cir. 2002). A plaintiff “who alleges a deprivation of a procedural protection to which he is entitled never has to prove that if he had received the procedure the substantive result would have been altered. All that is necessary is to show that the procedural step was connected to the substantive result.” *Veneman*, 289 F.3d at 94–95.

53. Plaintiffs’ concrete interests include: (1) the health and safety of their individual members who are Medicare beneficiaries exposed to the BEI, including Mr. Evans, who is a three-time cancer survivor particularly vulnerable to the health risks posed by the BEI, (2) the professional interests of physicians affected by the BEI, including Dr. Finn, who faces concrete professional and economic harm, (3) the informational interest in the administrative record that would have been developed through notice and comment rulemaking, (4) the participatory interest in shaping the regulatory outcome

through the procedures Congress established, and (5) the competitive and economic interests of MMJIH, MMJBC, and MMJBL (collectively, the “MMJ Plaintiffs”), whose multi-year investment in compliance with the FDA pharmaceutical regulatory pathway is directly impaired by CMS’s creation of a competing access pathway for Medicare patients to access non-FDA-approved cannabinoid products without notice or opportunity for comment. These are not abstract interests in “having the procedure observed.” They are concrete, particularized interests that the notice-and-comment process is designed to protect.

54. Plaintiffs SAM and CIVEL are also involved in ongoing administrative proceedings opposing the DEA’s efforts to expand access to cannabis through rescheduling under the Controlled Substances Act. *See* Exhibit B (order granting SAM and CIVEL standing in DEA administrative proceeding). They are injured specifically by their inability to comment on the BEI, which expands distribution of cannabinoid products to Medicare patients, as they are involved in administrative proceedings opposing rescheduling of cannabis that remain ongoing.

55. MMJ Plaintiffs are directly affected regulated parties operating under active DEA oversight and FDA IND authorization. They were deprived of any notice of the BEI, and of any opportunity to comment—effectively, of due process. Had CMS conducted notice-and-comment rulemaking, MMJ Plaintiffs would have submitted detailed comments addressing, among other things, the protection of the FDA drug approval framework, patient safety and dose reproducibility, reliance interests of sponsors following the established FDA pathway for botanical drugs, competitive harm to FDA-

compliant developers, the impact on clinical trial incentives, and the need for coordination between CMS and FDA.

D. Individual and Associational Standing

56. David Evans is a 78-year-old Medicare beneficiary with individual standing to sue. Mr. Evans is a three-time cancer survivor who was treated for two forms of cancer while on Medicare, as well as a concussion due to a fall. His cancer may return and he will have to face additional treatment while on Medicare. As a senior citizen enrolled in Medicare, Mr. Evans is a member of the population most vulnerable to the cardiovascular, neurological, cognitive, and drug-interaction harms documented in the peer-reviewed literature regarding these products.

57. Mr. Evans is a Medicare beneficiary who is aligned with Hopscotch Primary Care, PLLC. This provider has joined ACO REACH as part of Physicians Healthcare Collaborative ACO. Because his primary care provider participates in ACO REACH, Mr. Evans faces imminent implementation of a program that will make hemp-derived THC products and other cannabis-derived products available through his healthcare provider beginning April 1, 2026. He may be offered products under the BEI by his own healthcare provider.

58. Mr. Evans was deprived of his right to participate in notice-and-comment rulemaking as an interested party. Mr. Evans is opposed to expanded access to cannabis- and hemp-derived products that have not been proven safe and effective through the FDA approval process, and does not want such unapproved products provided by or through his Medicare provider, due to their serious and well-documented health risks.

Mr. Evans also possesses extensive evidence of the harms caused by these products, including personal knowledge derived from decades of professional and volunteer experience assisting persons harmed by cannabis use. Because there was no opportunity for public comment on the BEI, Mr. Evans could not submit this evidence to CMS.

59. Mr. Evans is also the owner of a critical care nursing home that may be asked to participate in the BEI process. As the owner, he would have sought the opportunity to participate in notice-and-comment rulemaking on behalf of the nursing home before the BEI was implemented.

60. Dr. Kenneth Finn is a physician with individual standing to sue. Dr. Finn practices comprehensive pain medicine in Prescott, AZ. He is employed by an ACO. As a physician who practices pain medicine, and a nationally recognized expert in the harmful effects of unregulated hemp-derived and cannabinoid products, Dr. Finn is directly and concretely affected by the BEI. The BEI requires participating physicians to make individual clinical determinations that the use of eligible hemp products is appropriate for specific beneficiaries, yet CMS does not provide clinical guidelines, evidence-based thresholds, or diagnostic criteria to support such determinations. CMS has explicitly stated it “does not make claims regarding the therapeutic value of these products,” yet the program requires physicians to make a documented clinical determination that hemp use is “safe and appropriate” for a specific patient. Making that determination without recognized clinical guidelines, an FDA approval framework, or an established evidence base creates significant professional risk, particularly in the elderly Medicare population. The BEI also exposes Dr. Finn to significant malpractice

liability: adverse events traceable to physician-endorsed hemp use create direct malpractice exposure, and unlike DEA-registered controlled substance frameworks or FDA-approved drug programs, the BEI contains no explicit indemnification language for participating physicians, no regulatory safe harbor protecting physicians who rely in good faith on their ACO's implementation plan, and no mechanism for physicians to obtain binding CMS guidance on borderline eligibility questions before dispensing. Furthermore, the BEI creates a dangerous regulatory cliff for physicians: the FY 2026 Agriculture Appropriations Act, effective November 2026, resets the legal THC threshold to 0.4 mg total hemp-derived THC per container, potentially rendering products recommended to patients today Schedule I controlled substances by Fall 2026 and creating retroactive legal exposure for physicians whose patient charts document endorsement of now-illegal products. CMS has not provided guidance on how participating physicians should wind down or transition patients if the threshold change takes effect.

61. Dr. Finn was deprived of his right to participate in notice-and-comment rulemaking as an interested party. Additionally, Dr. Finn has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of his participatory interest in shaping the regulatory process through providing comments.

62. The following Plaintiffs have associational standing: SAM, CIVEL, AALM, NCALM, CIPC, CIVSJ, DFAF, SOS, and DWI (collectively, the "Associational Plaintiffs").

63. At least one identified member of each Plaintiff, namely Mr. David Evans, has standing to sue in his own right. Mr. Evans is (1) a donor, consultant, and volunteer for SAM, (2) Executive Director and Senior Counsel of CIVEL, (3) a donor, consultant, and member of AALM, (4) Executive Director of NCALM, CIPC, and CIVSJ, (5) a consultant and volunteer of DFAF, (6) a consultant and volunteer of SOS, and (7) a member of DWI.

64. The interests each Associational Plaintiff seeks to protect—including public health, product safety, and lawful agency procedure—are germane to their purposes.

65. Finally, neither the claims asserted nor the declaratory and injunctive relief requested requires the participation of individual members.

V. LEGAL STANDARD

66. Under 5 U.S.C. § 706(2), a reviewing court shall “hold unlawful and set aside agency action, findings, and conclusions found to be . . . arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law; . . . in excess of statutory jurisdiction, authority, or limitations, or short of statutory right; [or] without observance of procedure required by law”

67. The court must examine whether the agency has “examined the relevant data and articulate[d] a satisfactory explanation for its action including a rational connection between the facts found and the choice made.” *Motor Vehicle Manufacturers Ass’n v. State Farm Mutual Automobile Insurance Co.*, 463 U.S. 29, 43 (1983). Agency action must be “reasonable and reasonably explained.” *FCC v. Prometheus Radio Project*, 592 U.S. 414, 423 (2021).

68. Under *Loper Bright Enterprises v. Raimondo*, 603 U.S. 369 (2024), courts must “exercise their independent judgment in deciding whether an agency has acted within its statutory authority, as the [APA] requires.” *Id.* at 413. Courts “need not and under the APA may not defer to an agency interpretation of the law simply because a statute is ambiguous.” *Id.*

VI. FACTUAL ALLEGATIONS

A. The CMS Innovation Center

69. Section 1115A of the Social Security Act, 42 U.S.C. § 1315a, established the Center for Medicare & Medicaid Innovation (“Innovation Center”) within CMS. The Innovation Center’s statutory purpose is to test “innovative payment and service delivery models” to reduce program expenditures “while preserving or enhancing the quality of care” for “individuals who are enrolled under such titles and . . . for defined populations with deficits in care leading to poor clinical outcomes or potentially avoidable expenditures.” 42 U.S.C. § 1315a(a)(1).

70. The specific models at issue are ACO REACH (a model for accountable care organizations), the Enhancing Oncology Model or EOM (a model for oncology care), and the LEAD Model (an upcoming model for community-level addiction and overdose treatment). These are payment and delivery models.

71. ACO REACH brings together doctors, hospitals and other healthcare providers into a single team called an Accountable Care Organization (ACO). *See Innovation Models: ACO REACH*, Ctrs. for Medicare & Medicaid Servs., <https://www.cms.gov/priorities/innovation/innovation-models/aco-reach>. These teams coordinate patient care, making sure patients get the right tests, follow-up, and

preventative services to reduce duplication or unnecessary procedures. *Id.* If the ACO keeps costs below a benchmark while meeting quality standards, the team shares in the savings thereby encouraging providers to work together efficiently to focus on preventive care, chronic disease management, and patient outcomes rather than simply the number of services delivered. *Id.* Currently, there are approximately 74 ACOs made up of approximately 126,000 providers and organizations providing care to approximately 1.7 million Medicare beneficiaries. *Id.*

72. The EOM focuses on Medicare patients with certain cancers and tests a new way of paying oncology practices. See *Innovation Models: EOM*, Ctrs. for Medicare & Medicaid Servs., <https://www.cms.gov/priorities/innovation/innovation-models/eom>. Participating clinics are given bundled payments or target budgets for patients' entire course of cancer treatment, rather than being paid separately for every test or procedure. *Id.* The incentive is that if the clinic keeps costs within the target and meets quality and outcome goals, it can earn shared savings bonuses. *Id.* Based on the most recent publicly available information, the total number of Medicare participants is unknown. *Id.* However, 28 physician group practices and one commercial payer are participating, accounting for approximately 2,000 practitioners across more than 350 care sites. *Id.*

73. The BEI also applies to another payment model, LEAD, which does not begin until January 1, 2027. See *LEAD (Long-Term Enhanced ACO Design) Model*, Ctrs. for Medicare & Medicaid Servs., <https://www.cms.gov/priorities/innovation/innovation-models/lead>.

74. Section 1115A was designed to test new payment and care delivery approaches for Medicare and Medicaid. The purpose of Innovation Center models under Section 1115A is to improve care quality, lower costs, and promote value-based care by encouraging best medical and financial practices through financial incentives or shared savings/risk arrangements—not to serve as a distribution system for specific consumer products.

B. CMS’s Position on Cannabis Products

75. In April 2025, CMS issued a final rule, effective June 3, 2025, that states that “medical marijuana or derivatives, such as cannabis oil, cannot be covered by [Medicare Advantage] organizations as they are illegal substances under Federal law.” 90 Fed. Reg. 15,792, 15,867 (Apr. 15, 2025) (codifying “cannabis products” as non-allowable special supplemental benefits for the chronically ill (“SSBCI”)).

76. To date, CMS has not rescinded this rule.

77. Yet, the BEI allows access to cannabis products for Medicare Advantage beneficiaries. This contradictory position was issued without any reasoned explanation.

C. Executive Order No. 14370

78. On December 18, 2025, President Donald J. Trump signed Executive Order No. 14370, titled “Increasing Medical Marijuana and Cannabidiol Research.”

79. At the signing ceremony, CMS Administrator Oz publicly stated that “millions of Americans on Medicare” would become eligible to receive cannabis and hemp-derived products “as early as April of next year – and at no charge if their doctors recommend them.” This announcement predated any agency action by three months and signaled a predetermined outcome.

D. The Substance Access BEI

80. On March 20, 2026, CMS published the BEI on its website.

81. The BEI is an optional feature embedded in participation agreements for ACO REACH and EOM (effective April 1, 2026) and the LEAD Model (effective January 1, 2027).

82. For participants in ACO REACH and EOM who elect the BEI, it is a binding, generally applicable framework that imposes legal obligations on participants and their aligned beneficiaries.

83. The BEI imposes the following mandatory program mechanics, which include: (a) participant election; (b) submission of a CMS-required implementation plan; (c) CMS approval of the implementation plan, with CMS retaining authority to reject or suspend participation; (d) physician determination of beneficiary eligibility, including that the beneficiary is over 18 years of age and does not have a disqualifying condition²; (e) shared decision-making with beneficiaries; (f) cannabis and hemp-derived products provided are limited to 0.3% delta-9 THC per dry weight of the product and in products that are ingested orally, no more than 3 mg per serving of total tetrahydrocannabinols; (g) a \$500 annual cap per beneficiary; and (h) quarterly reporting obligations.

² Beneficiaries are not eligible for the BEI if they are not aligned to a participating organization, meets the model's frailty exclusion, is pregnant or breastfeeding, or if a physician does not determine the product is appropriate. See *Substance Access Beneficiary Engagement Incentive*, Centers for Medicare & Medicaid Services (accessed Mar. 27, 2026), <https://www.cms.gov/priorities/innovation/substance-access-beneficiary-engagement-incentive>. Public-facing CMS documents do not reveal the actual list of "disqualifying conditions" for the BEI.

84. CMS claims that Medicare does not pay for the cannabis products or hemp-derived THC products approved under the BEI directly, and that they are funded at the expense of participants. However, the limited information available about the BEI makes this unclear.

85. On April 1, 2026, the BEI went into full effect.

E. Absence of Notice and Comment

86. CMS issued no notice of proposed rulemaking and solicited no public comments before announcing and instituting the BEI.

87. CMS provided no formal administrative record before announcing and instituting the BEI.

88. CMS provided no reasonable or reasoned explanation for the BEI or for its departure from its April 2025 final rule, 90 Fed. Reg. 15,792, 15,867.

89. The BEI was not published in the Federal Register, but was announced on March 20, 2026 with a near-immediate effective date of April 1, 2026.

90. Public statements by hemp-industry stakeholders and later reporting suggest that selected stakeholders had advance notice of the BEI before CMS publicly announced the BEI.

91. On December 18, 2025, Charlotte's Web announced that it was prepared to participate as a CBD provider in a potential Innovation Center pilot. *Charlotte's Web Serves as a Premier CBD Partner for Landmark Medicare and Medicaid Pilot Program*, Charlotte's Web (Dec. 18, 2025), <https://investors.charlottesweb.com/press-releases/press-release->

[details/2025/Charlottes-Web-Serves-as-a-Premier-CBD-Partner-for-Landmark-Medicare-and-Medicaid-Pilot-Program/default.aspx](#).

92. Charlotte’s Web co-founder Jared Stanley confirmed on February 13, 2026 that the program was “internally finalized” by CMS weeks prior, without public announcement or opportunity to comment, and referred to a “briefing” when discussing the pilot program’s anticipated scope. Kyle Jaeger, *Federal Agency Finalized Rule for CBD Medicare Coverage Pilot Program Weeks Ago, Key Hemp Stakeholder Says, Marijuana Moment* (Feb. 13, 2026), <https://www.marijuanamoment.net/federal-agency-finalized-rule-for-cbd-medicare-coverage-pilot-program-weeks-ago-key-hemp-stakeholder-says/>.

93. On information and belief, Charlotte’s Web, a major hemp company, along with other hemp companies that received briefings and communications from CMS regarding the BEI, collaborated with CMS in shaping and finalizing the BEI.

94. At no point was the public afforded any opportunity to participate in the development of the BEI.

95. At no point was MMJIH or any of its subsidiaries, who are directly affected by the BEI’s market-distorting effects, afforded any opportunity to participate in the development of the BEI.

96. CMS knows how to comply with the APA when it chooses to do so. On April 6, 2026, CMS published the Contract Year 2027 final rule in the Federal Register after full notice-and-comment rulemaking, receiving about 42,632 comments. *See* 91 Fed. Reg. 17,384 *et seq.* (Apr. 6, 2026) (“CY2027 Rule”).

97. In the CY2027 Rule, CMS acknowledged that it “does not regulate cannabis and hemp-derived cannabis products” and that its “authority does not extend to the direct regulation of cannabis-derived products.” *Id.* at 17,432–17,433. CMS further stated that “any changes to SSBCI requirements will be made by requesting public comment on a proposed regulation through a Notice of Proposed Rulemaking.” *Id.* at 17,433.

98. The CY2027 Rule confirmed that the only cannabis-derived products currently permissible under applicable federal law are hulled hemp seed, hemp seed protein powder, and hemp seed oil—not the panoply of hemp-derived THC and CBD products that the BEI authorizes for medical distribution. *Id.* at 17,432.

99. The contrast between CMS’s adherence to APA procedures for the CY2027 Rule and its complete bypass of notice-and-comment for the BEI demonstrates the arbitrariness of the action at issue, contradicts the premise of the BEI by limiting hemp-derived products for distribution, and underscores the unlawfulness of the BEI’s implementation.

F. Conflict with the 2026 Agriculture Appropriations Act

100. The 2026 Agriculture Appropriations Act, signed by the President, sets a total THC limit of 0.4 mg per container for hemp-derived products, effective November 2026.

101. CMS’s BEI permits 3 mg of total THC per serving, which is more than seven times the statutory limit.

102. CMS’s only response to this conflict has been that it “will adjust its definition in accordance with the law.” *See Substance Access Beneficiary Engagement*

Incentive, Centers for Medicare & Medicaid Services (accessed Mar. 27, 2026), <https://www.cms.gov/priorities/innovation/substance-access-beneficiary-engagement-incentive>.

103. CMS has provided no details on when or how this adjustment will occur nor why it promulgated a program in explicit conflict with clearly established law.

104. Accordingly, CMS launched a program it already knows to be inconsistent with enacted federal law.

G. Conflict with Established and Documented Health Risks of Existing Cannabis and Hemp-Derived THC Products for Medicare Populations

105. The BEI allows elderly Americans to access cannabis products, which contain substances that provably cause harm to their health.

106. A 2025 narrative review published in the Journal of the American Medical Association (“JAMA”) of 124 recent randomized controlled trials and meta-analysis found that the evidence that cannabis “treats” disorders such as pain, anxiety, post-traumatic stress disorder (“PTSD”), insomnia, and most other hyped uses is weak or non-existent. M. Hsu et al., *Therapeutic Use of Cannabis and Cannabinoids: A Review*, JAMA (Nov. 26, 2025).

107. The position of the American Psychiatric Association (“APA”) as of December of 2025 is that “[t]here is insufficient evidence that cannabis is an effective treatment for any psychiatric disorder.” AM. PSYCHIATRIC ASS’N, *Position Statement in Opposition to Cannabis as Medicine for Psychiatric Disorders* (approved by Board of Trustees Dec. 2025 and Assembly Nov. 2025).

108. The scientific evidence documenting cardiovascular, neurological, and other health risks from cannabis and hemp-derived THC products is substantial and directly relevant to the Medicare population, which consists predominantly of adults over 65 (the population most vulnerable to these harms).

109. Heart disease is the leading cause of death among Americans over 65.

110. A June 2025 meta-analysis published in *Heart* (BMJ), encompassing 24 studies and approximately 200 million participants, found that cannabis use was associated with a two-fold risk of cardiovascular death, a 29% higher risk of acute coronary syndrome, and a 20% higher risk of stroke. Wilhelm Storck et al., *Cardiovascular Risk Associated with the Use of Cannabis and Cannabinoids: A Systematic Review and Meta-Analysis*, 111 *Heart* 1047 (2025).

111. A 2024 study published in the *Journal of the American Heart Association*, analyzing data from approximately 434,000 U.S. adults, found that daily cannabis users had a 25% higher risk of heart attack and a 42% higher risk of stroke compared to non-users, with risk increasing in a dose-response fashion with more frequent use. Abra M. Jeffers et al., *Association of Cannabis Use with Cardiovascular Outcomes Among US Adults*, 13 *J. Am. Heart Ass'n* e030178 (2024).

112. A May 2025 study published in *JAMA Cardiology* by researchers at the University of California, San Francisco, found that chronic cannabis use—whether smoked or consumed as THC-containing edibles—was associated with vascular endothelial dysfunction comparable to that observed in tobacco smokers. Vascular function in chronic cannabis users was reduced by approximately 50% compared to non-

users. See Leila Mohammadi et al., *Association of Endothelial Dysfunction with Chronic Marijuana Smoking and THC-Edible Use*, JAMA Cardiology (May 28, 2025).

113. Memory and cognitive impairment are already prevalent concerns among older adults. THC products appear to worsen these outcomes.

114. A 2025 study found that individuals who presented to the emergency room due to cannabis use were at a 1.5-fold to 3.9-fold increased risk of dementia diagnosis within five years, relative to individuals with all-cause acute care visits and the general population. Daniel T. Myran et al., *Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis*, 82 JAMA Neurology 570–79 (June 2025).

115. A 2021 study found that long-term marijuana users scored significantly lower on measures of executive function, processing speed, and general cognition than non-users, and that more frequent and more recent use was negatively associated with working memory. Katie Stypulkowski & Rachel E Thayer, *Long-Term Recreational Cannabis Use Is Associated with Lower Executive Function and Processing Speed in a Pilot Sample of Older Adults*, J. Geriatric Psychiatry Neurology (Sept. 2021).

116. A 2020 study found that fewer than 250 older adults have been included in cannabis studies to date, meaning that there is a substantial body of potential harm to that population that remains unknown to science. Brooke Porter et al., *Cannabidiol (CBD) Use by Older Adults for Acute and Chronic Pain*, 47 J. Gerontological Nursing 7, 6–15 (July 2021).

117. A study examining trends in emergency department visits associated with cannabis use among older adults in California from 2005 to 2019 found that cannabis-related emergency department visits increased by 1,804%, with older Black adults having the highest visit rate and the largest absolute increase. B. Han et al., *Trends in Emergency Department Visits Associated with Cannabis Use Among Older Adults in California, 2005–2019*, 71 J. Am. Geriatr. Soc. 4, 1267–74 (Apr. 2023).

118. CMS did not address this research gap before launching a program directed at older adults.

119. A study examining the health effects of cannabis use for medical and non-medical purposes in older adults found that the available evidence suggests cannabis use may be associated with greater frequencies of depression, anxiety, cognitive impairment, substance use and problematic substance use, accidents and injuries, and acute healthcare use. D. Wolfe et al., *Impacts of Medical and Non-Medical Cannabis on the Health of Older Adults: Findings from a Scoping Review of the Literature*, PLOS ONE (Feb. 17, 2023).

120. Commercially available CBD products are pervasively contaminated and mislabeled. M.O. Bonn-Miller et al., *Labeling Accuracy of Cannabidiol Extracts Sold Online*, 318 JAMA 17 at 1708–09 (2017).

121. A peer-reviewed 2022 study published in *Science of the Total Environment*, analyzing 516 CBD products sold in the United States, found that only 42% of products fell within $\pm 10\%$ of the CBD content claimed on the manufacturer's label. Among 121 edible CBD products tested, lead was detected in 42%, mercury in 37%, arsenic in 28%, and cadmium in 8%. Four edible products exceeded the California Proposition 65

threshold for daily lead consumption in two servings. Hannah Gardener et al., *Heavy Metal and Phthalate Contamination and Labeling Integrity in a Large Sample of US Commercially Available Cannabidiol (CBD) Products*, 851 Sci. Total Env't 158110 (2022).

122. These contamination and accuracy risks are especially acute for older adults, who must carefully manage their medical intake and who are particularly vulnerable to pathogen and toxin exposures. Stacy Cooper Bailey et al., *Longitudinal Investigation of Older Adults' Ability to Self-Manage Complex Drug Regimens*, 68 J. Am. Geriatrics Soc'y 569 (2020); John F. Risher et al., *The Elderly as a Sensitive Population in Environmental Exposures: Making the Case*, 7 Int'l J. Env'tl. Res. Pub. Health 228 (2010).

123. A 2025 study found that even small doses of CBD can cause significant elevations in liver enzymes (specifically alanine aminotransferase and aspartate aminotransferase), indicative of possible liver injury, which can lead to fatigue and jaundice—issues of special concern for older adults seeking to avoid unnecessary hospitalizations. Jeffry Florian, et al., *Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial*, 185 JAMA Internal Medicine 9, 1070–78 (July 2025).

124. A 2021 review found that a wide variety of drugs in common use by older people, from blood pressure medications to antifungals, belong to a class called CYP3A4 inhibitors that can interact with CBD and increase the bioavailability of its active chemicals, leading to possible adverse effects. Brooke Porter et al., *Cannabidiol (CBD) Use by Older Adults for Acute and Chronic Pain*, 47 J. Gerontological Nursing 7, 6–15 (July 2021).

125. The same review noted that older adults can suffer from a condition in which protein binding is inhibited, which can also lead to elevated bioavailability and unintentionally higher dosing. *Id.*

126. It also noted that patient safety is a concern with CBD use, and that poison phone calls for CBD have increased from 3 in 2014 to 2,218 in 2020. *Id.*

127. CMS created and instituted the BEI despite the extensive scientific evidence demonstrating that cannabis products, hemp-derived THC products, and CBD will harm elderly Americans.

128. To date, CMS has not conducted or published any analysis of whether the products permitted under the BEI are lawful under federal law, safe for the Medicare populations at issue, or consistent with the agency's obligations under existing statutory frameworks. CMS has explicitly stated it "does not make claims regarding the therapeutic value of these products," yet the BEI requires participating physicians to make a documented clinical determination that hemp use is "safe and appropriate" for a specific patient—without providing clinical guidelines, evidence-based thresholds, or diagnostic criteria to support such determinations.

129. CMS has not addressed the cardiovascular risks documented in peer-reviewed meta-analyses, the vascular dysfunction findings involving THC edibles, the pervasive contamination and mislabeling of commercially available CBD products, the drug-interaction risks for older adults on common medications, or the near-total absence of clinical research on cannabis use in populations over 65.

130. Neither the FDA nor the BEI imposes any meaningful safeguards to prevent product adulteration, ensure quality control, or require independent testing. Products distributed under the BEI are afforded no adverse event reporting mechanisms comparable to those required for FDA-approved pharmaceuticals, and approximately 1,500 deaths have been reported in connection with FDA-approved Epidiolex alone—a product that, unlike BEI-authorized products, underwent rigorous FDA safety review.

H. Federal Legal Status of Cannabis Products and Hemp-Derived THC Products

131. Cannabis, including delta-9 THC, remains a Schedule I controlled substance under the Controlled Substances Act (“CSA”), 21 U.S.C. §§ 801–901.

132. Current retail hemp-derived THC products are derived by distilling delta-9 THC and other cannabinoids from hemp plants into a concentrated substance and mixing it into consumable products. As such, hemp-derived THC products contain illegal Schedule I compounds, sometimes (due to mislabeling and poor regulation) in amounts higher than the 0.3% permitted for hemp-derived products under Federal law. The hemp-derived product industry exploits this regulatory loophole for profit, to the tune of \$5.5 billion. Beau R. Whitney, *An Economic Impact Analysis of the Hemp Cannabinoid Industry in Texas* (Mar. 2025), <https://texashempbusinesscouncil.com/wp-content/uploads/2025/07/2024-An-Economic-Impact-Analysis-of-the-Hemp-Cannabinoid-Industry-in-Texas-Whitney-Economics-03-25-Public-Facing-1.pdf>.

133. The FDA has not approved hemp-derived THC products for medical use. Epidiolex, a CBD product that may be used to treat rare seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex, has been approved

by the FDA, but has not been tested for safety for people over the age of 55. See *EPIDIOLEX New Drug Application Letter*, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210365orig1s000ltr.pdf.

134. Besides the existing botanical drug approval framework, the FDA has stated that no federal regulatory framework for CBD or hemp-derived products exists.

135. The FDA has identified specific safety risks associated with CBD and hemp-derived THC products, including liver injury, drug interactions, and harm to vulnerable populations, and has stated that it has “not found adequate information showing how much CBD can be consumed, and for how long, before causing harm.”

136. These FDA warnings are consistent with the peer-reviewed evidence of cardiovascular, neurological, contamination, drug-interaction, and other health risks from current retail cannabinoid and hemp-derived products detailed above.

I. MMJ Plaintiffs’ Regulatory History and Competitive Injury

137. MMJIH initiated formal regulatory engagement with the FDA’s Center for Drug Evaluation and Research in August 2018 through submission of Pre-Investigational New Drug meeting requests for its cannabinoid drug candidates MMJ-001, intended for treatment of Huntington’s disease, and MMJ-002, intended for treatment of multiple sclerosis. The FDA acknowledged these submissions and opened regulatory files, including IND file number 137754 associated with the Huntington’s disease program and IND file number 140712 associated with the multiple sclerosis program.

138. On January 29, 2019, the FDA's Office of Orphan Products Development granted Orphan Drug Designation for Δ^9 -tetrahydrocannabinol and cannabidiol for the "treatment of Huntington's disease" pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act. *See* 21 U.S.C. § 360bb.

139. MMJBC submitted an application to the DEA in December 2018 for registration as a bulk manufacturer of marijuana-active pharmaceutical ingredient for use in FDA-authorized clinical trials.

140. The DEA commenced its pre-registration Section 303 investigation on June 22, 2021, which concluded with a final on-site visit on October 24, 2021, during which all DEA questions were satisfactorily answered, all security systems and protocols were reviewed, and MMJBC demonstrated that all security and diversion conditions followed applicable regulations.

141. MMJBC's bulk manufacturing registration application remains pending before the DEA Administrator.

142. MMJBL obtained a DEA Schedule I analytical laboratory registration following DEA inspection and approval of its facility's physical security systems, recordkeeping controls, and diversion-prevention safeguards.

143. Over the past approximately eight years, the MMJ Plaintiffs have invested over \$10 million into pharmaceutical cannabinoid development through the formal FDA regulatory pathway.

144. These investments include, but are not limited to: (1) IND submissions and regulatory engagement with the FDA, (2) orphan drug designation positioning for

Huntington's disease, (3) DEA registration activity, including the Schedule I analytical laboratory registration and the pending bulk manufacturing application, (4) formulation development and stability studies conducted in collaboration with Catalent Pharma Solutions, (5) analytical testing and chromatographic characterization performed by Avanti Rx Analytics Inc., (6) regulatory consulting engagements with Haffner Associates, LLC, (7) a development summit and portfolio strategy engagement with Parexel International (IRL) Limited, (8) FDA regulatory counsel services provided by Baker & Hostetler LLP, and (9) engagement of Seaport Global Securities LLC as lead financial advisor in connection with a proposed capital raise of approximately \$45 million in debt and equity securities.

145. MMJ Plaintiffs undertook these investments with the clear expectation that FDA approval would provide the necessary regulatory foundation for coverage determinations of cannabinoid-based treatments and therapeutics by Medicare and other third-party payers.

146. The BEI permits clinician-guided distribution of hemp-derived cannabinoid products outside the FDA drug approval framework, while MMJ Plaintiffs pursuing IND-based botanical drug development remain subject to full pharmaceutical regulatory requirements.

147. By introducing federally supported access to non-FDA-approved cannabinoid products, CMS has weakened incentives for investment in validated botanical drug development programs, created a competitive disadvantage for FDA-compliant developers, and directly impacted the MMJ Plaintiffs' Huntington's disease

program by undermining recruitment pathways, investor confidence, and long-term exclusivity expectations associated with IND-stage cannabinoid therapeutics targeting serious neurological disease.

148. MMJ Plaintiffs were excluded from prior notice of the BEI, while other purveyors of cannabis- and hemp-derived THC and CBD products—including Charlotte’s Web—received advance notice of and may have collaborated with CMS in shaping the BEI. These entities operate outside the FDA IND-authorized pharmaceutical development pathway and would benefit from the BEI’s reimbursement structure without undertaking the rigorous scientific validation and regulatory compliance that MMJ Plaintiffs have pursued.

149. The ongoing operation of the BEI causes continuing and compounding harm to the MMJ Plaintiffs. Each day the BEI remains in effect, unvalidated cannabinoid products gain market access and consumer acceptance in the Medicare population, the competitive landscape for cannabinoid therapeutics is further distorted, the MMJ Plaintiffs’ regulatory investments are further devalued, and the integrity of the federal drug-approval framework upon which the MMJ Plaintiffs relied is further eroded.

VII. PLAINTIFFS’ CLAIMS FOR RELIEF

First Claim for Relief

THE BEI VIOLATED THE APA’S NOTICE-AND-COMMENT REQUIREMENTS (Violation of 5 U.S.C. §§ 552(a)(1), 553, 706(2)(D))

150. The plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through 149 as though fully set forth herein.

151. The BEI constitutes a “legislative rule” in that it imposes legally binding obligations on participating organizations, creates a new benefit structure, establishes detailed eligibility criteria, requires CMS approval processes, and has “the force and effect of law.” *Perez v. Mortgage Bankers Ass’n*, 575 U.S. 92, 96 (2015) (quoting *Chrysler Corp. v. Brown*, 441 U.S. 281, 302–303 (1979)). A legislative rule is one that “effects a substantive regulatory change to the statutory or regulatory regime.” *Mendoza v. Perez*, 754 F.3d 1002, 1006 (D.C. Cir. 2014) (quotation omitted).

152. Agencies cannot “avoid notice and comment simply by mislabeling their substantive pronouncements.” *See Azar v. Allina Health Services*, 587 U.S. 566, 575 (2019) (courts look to “the *contents* of the agency’s action, not the agency’s self-serving *label*, when deciding whether statutory notice-and-comment demands apply” (emphasis in original)).

153. “[A]ny contract provisions that are legislative [in character] are subject to § 553’s notice and comment requirements.” *American Hospital Ass’n v. Bowen*, 834 F.2d 1037, 1054 (D.C. Cir. 1987). CMS “may not hide behind its authority to contract in order to evade the APA.” *Id.* (quoting district court).

154. No exception to the APA’s notice-and-comment requirement applies. The BEI is not an interpretive rule because it does not merely clarify an existing statute or regulation. Rather, the BEI creates entirely new programmatic requirements. *See Tennessee v. Dep’t of Educ.*, 104 F.4th 577, 608 (6th Cir. 2024) (legislative rules have “the force and effect of law” and are “subject to notice and comment”). The BEI is not a general statement of policy because it has binding effect through mandatory implementation

mechanics on participating providers. And it is not a rule of agency organization, procedure, or practice because it directly affects the rights and obligations of participating organizations and Medicare beneficiaries.

155. The BEI is not a benefits determination exempt from notice and comment under 5 U.S.C. § 553(a)(2). CMS itself asserts that the BEI does not involve Medicare paying for products directly. No new entitlement is created and no Medicare claim is submitted. Instead, the BEI imposes a binding regulatory framework on participating providers that governs what products they may distribute, how they must screen patients, what implementation plans they must submit for CMS approval, and what reports they must file. Such a framework is not a benefit within the meaning of 5 U.S.C. § 553(a)(2) and is not exempt from notice or comment. Reading 5 U.S.C. § 553(a)(2) to exempt the BEI from notice-and-comment would eviscerate those protections precisely when they are most needed: when CMS is adopting an unprecedented program implicating public health, federal drug law, and healthcare policy.

156. Section 1115A does not expressly exempt CMS from APA rulemaking requirements. Under 5 U.S.C. § 559, a subsequent statute supersedes the APA's rulemaking provisions only if it "does so expressly." An exemption is express only when Congress "has established procedures so clearly different from those required by the APA that it must have intended to displace the norm." *Asiana Airlines v. FAA*, 134 F.3d 393, 397 (D.C. Cir. 1998). Section 1115A contains no such express exemption.

157. CMS adopted and published a generally applicable policy with legal effect without the Federal Register publication required for substantive rules under the APA

and the Federal Register Act, 44 U.S.C. § 1505. The failure to publish in the Federal Register independently violates 5 U.S.C. § 552(a)(1). *See Appalachian Power Co. v. EPA*, 208 F.3d 1015, 1020 (D.C. Cir. 2000) (an agency “can inform those affected simply by posting its new guidance or memoranda or policy statement on its web site,” but this does not satisfy statutory publication requirements for substantive rules).

158. The precedent from CMS’s own prior use of Section 1115A authority is instructive. When CMS issued an Interim Final Rule implementing Most Favored Nation (“MFN”) drug pricing using Section 1115A authority without notice-and-comment, multiple federal courts enjoined the rule for failing to satisfy the good-cause exception. *See Regeneron Pharms.*, 510 F. Supp. 3d at 29. The same principle applies here: CMS cannot use Section 1115A to avoid the APA’s core procedural protections simply by embedding a policy change in a participation agreement rather than a formal rule.

159. The BEI was adopted and published without observance of procedure required by law, in violation of 5 U.S.C. § 706(2)(D).

Second Claim for Relief
THE BEI IS ARBITRARY AND CAPRICIOUS
(Violation of 5 U.S.C. § 706(2)(A))

160. The plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through 159 as though fully set forth herein.

161. The BEI is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.

162. First, CMS’s decision to allow access to cannabis- and hemp-derived products to Medicare recipients, without analysis or explanation, differs from its

approach in a final rule issued only one year ago that cannabis- and hemp-derived products were ineligible for Medicare coverage. CMS has also provided no explanation for its sudden decision to allow access to substances it previously affirmed, in its published April 2025 rule, were illegal under federal law. When an agency changes course, it must provide “a reasoned explanation for disregarding facts and circumstances that underlay or were engendered by the prior policy.” *Encino Motorcars, LLC v. Navarro*, 579 U.S. 211, 222 (2016) (quoting *FCC v. Fox Television Stations, Inc.*, 556 U.S. 502, 516 (2009)). An “unexplained inconsistency” renders a changed policy arbitrary and capricious. *Children’s Hospital Ass’n of Texas v. Azar*, 933 F.3d 764, 773 (D.C. Cir. 2019). CMS quietly inserted the BEI into participation agreements without any explanation for why the prior position is no longer appropriate and has not, to date, provided any analysis for its action.

163. Second, CMS entirely failed to consider important hazards that arise from this policy reversal. The agency did not address:

- f. the federal legal status of the products under the CSA;
- g. the substantial and growing peer-reviewed evidence of adverse health outcomes or risks associated with the use of cannabis- and hemp-derived THC products by an aging and vulnerable population, namely the risk of cardiovascular harm, liver injury, dangerous drug interactions with medications commonly used by older adults, cognitive harms risk, and pervasive contamination and mislabeling;
- h. the absence of an FDA regulatory framework for CBD;

- i. the near-total absence of clinical research on cannabis use in populations over 65; or
- j. the conflict with the FY2026 Agriculture Appropriations Act's THC limits.

Each of these failures independently renders the BEI arbitrary and capricious. *See State Farm*, 463 U.S. at 43 (agency action is arbitrary and capricious if the agency “entirely failed to consider an important aspect of the problem”).

164. Third, CMS's THC limit of 3 mg per serving directly conflicts with the 2026 Agriculture Appropriations Act's limit of 0.4 mg per container, effective November 2026. CMS's admission that it “will adjust its definition in accordance with the law” is itself an acknowledgment that the current program conflicts with enacted and unambiguous federal law. A deliberate decision to launch a program that the agency already knows will be inconsistent with federal law is arbitrary agency action.

165. Fourth, CMS has not demonstrated that the BEI satisfies the statutory prerequisites of Section 1115A, which limits testing to models for “defined populations with deficits in care leading to poor clinical outcomes or potentially avoidable expenditures.” 42 U.S.C. § 1315a(a)(1). The BEI is available to any aligned beneficiary over age 18 without a disqualifying condition. Far from targeting a defined population or reasonably limiting eligibility based on statutory criteria, the model's scope effectively encompasses nearly all Medicare beneficiaries, regardless of clinical outcomes or incurred expenditures, so long as they are aligned with an ACO REACH, EOM, or LEAD participating provider.

166. Accordingly, the BEI is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law, in violation of 5 U.S.C. § 706(2)(A).

Third Claim for Relief
THE BEI EXCEEDS CMS'S STATUTORY AUTHORITY
AND VIOLATES THE MAJOR QUESTIONS DOCTRINE
(Violation of 5 U.S.C. § 706(2)(C))

167. The plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through 166 as though fully set forth herein.

168. Under *West Virginia v. EPA*, 597 U.S. 697 (2022), in “extraordinary cases” where an agency asserts authority of vast economic and political significance, “the agency . . . must point to ‘clear congressional authorization’ for the power it claims.” *Id.* at 723 (quoting *Utility Air Regulatory Grp. v. EPA*, 573 U.S. 302, 324 (2014)). The major questions doctrine applies when the agency’s action is “unheralded” and represents a “transformative expansion” of its authority under vague statutory language, and the regulation is of “vast economic and political significance.” *Nebraska v. Su*, 121 F.4th 1, 14 (9th Cir. 2024).

169. CMS has acted in excess of its statutory authority under Section 1115A by creating—for the first time in history—federally sanctioned access to cannabis products and hemp-derived THC products through Innovation Center program amendments, without APA rulemaking, without clear congressional authorization, and in violation of federal law.

170. No Innovation Center precedent exists for distributing specific consumer products to beneficiaries. Innovation Center models are used to test payment methods, not to increase access to unapproved drugs.

171. Congress never authorized CMS to use the Innovation Center to facilitate access to products containing substances listed as Schedule I under the CSA.

172. The political and policy significance of the program, as evidenced by Administrator Oz's public statements and the Executive Order that preceded it, is considerable.

173. The BEI's potential reach across multiple models covering substantial Medicare populations, the unprecedented nature of CMS's facilitating access to any specific consumer product, and the absence of any prior Innovation Center precedent for distributing specific products to beneficiaries all confirm that this is an extraordinary assertion of authority requiring clear congressional authorization. *See Missouri v. Biden*, 112 F.4th 531, 537 (8th Cir. 2024) (applying the major questions doctrine where the government asserted "an unheralded power to regulate a significant portion of the American economy" under a long-extant statute (quoting *Util Air Regul. Grp.*, 573 U.S. at 324)).

174. Under *Loper Bright Enterprises v. Raimondo*, 603 U.S. 369 (2024), the court must exercise independent judgment and not merely defer to CMS's assertion that its action falls within Section 1115A authority.

175. The BEI exceeds CMS's statutory jurisdiction, authority, or limitations, in violation of 5 U.S.C. § 706(2)(C).

Fourth Claim for Relief
THE BEI IS NOT IN ACCORDANCE WITH LAW
(Violation of 5 U.S.C. § 706(2)(A))

176. The plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through 175 as though fully set forth herein.

177. The BEI is “not in accordance with law” because it conflicts with controlling federal statutes.

178. The BEI’s THC limits conflict with the 2026 Agriculture Appropriations Act, which sets a total THC limit of 0.4 mg per container for hemp-derived products, effective November 2026.

179. The BEI conflicts with the Controlled Substances Act. It facilitates access to products that contain substances illegal under the CSA, including cannabis, delta-9 THC, and other cannabinoids.

180. The FDA has only approved Epidiolex, a CBD medication, but has not approved any other hemp-derived THC products for medical use and has identified specific safety risks including liver injury, drug interactions, and other harms.

181. CMS did not conduct or publish any compliance analysis for the BEI before creating and authorizing it. 90 Fed. Reg. 15,792, 15,867 (Apr. 15, 2025). *See PDK Labs., Inc. v. DEA*, 362 F.3d 786, 797–98 (D.C. Cir. 2004) (an agency must “bring its experience and expertise to bear” and evaluate the statutory status of a drug-related product when that status is unclear). In fact, a prior APA-compliant process completed less than one year prior determined that the health effects of medical marijuana, containing the same or comparable ingredients as hemp-derived cannabinoids, were not sufficient to justify use by Medicare patients.

Fifth Claim for Relief
CMS DENIED EQUAL PROTECTION

(Violation of U.S. Const. amend. V)

182. The MMJ Plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through 181 as though fully set forth herein.

183. The Fifth Amendment's equal protection guarantee, applicable to the federal government through the Due Process Clause, prohibits the government from treating similarly situated parties differently without a rational basis.

184. The BEI creates a two-track regulatory system that violates the equal protection guarantee. The MMJ Plaintiffs are companies that have complied in good faith with the federal pharmaceutical regulatory framework—investing years and over \$10 million into IND submissions, orphan drug designation, DEA registrations, CMC development, and clinical trial preparation—and are subjected to the full weight of FDA and DEA regulatory requirements. Meanwhile, the BEI permits entities that have not undertaken any of these regulatory burdens, including Charlotte's Web and other hemp-industry stakeholders, to access a federally supported cannabinoid reimbursement pathway for the same Medicare patient populations.

185. On information and belief, CMS provided advance notice of the BEI to hemp-industry stakeholders including Charlotte's Web, while excluding similarly situated regulated parties such as MMJ Plaintiffs from any notice of or opportunity to participate in the development of the BEI. Charlotte's Web co-founder Jared Stanley confirmed on February 13, 2026 that the program was "internally finalized" by CMS weeks prior, without public announcement or opportunity to comment, and referred to a "briefing" when discussing the pilot program's anticipated scope.

186. This disparate treatment of similarly situated regulated parties—those developing cannabinoid therapies for the same patient populations—was intentional and lacks any rational basis. Both the MMJ Plaintiffs and the hemp-industry stakeholders who received advance notice seek to provide cannabinoid products to Medicare beneficiaries. Yet CMS chose to inform and involve only the latter group in the BEI’s development, while deliberately excluding the former.

187. The MMJ Plaintiffs have been singled out for differential treatment as a “class of one” because they were intentionally treated differently from others similarly situated and there is no rational basis for the difference in treatment. *See Village of Willowbrook v. Olech*, 528 U.S. 562, 564 (2000) (“Our cases have recognized successful equal protection claims brought by a ‘class of one,’ where the plaintiff alleges that she has been intentionally treated differently from others similarly situated and that there is no rational basis for the difference in treatment.” (citations omitted)).

188. The government’s selective engagement with certain cannabinoid industry participants while excluding others who have undertaken greater regulatory compliance constitutes arbitrary and irrational government action.

Sixth Claim for Relief
CMS DENIED PROCEDURAL DUE PROCESS
(Violation of U.S. Const. amend. V)

189. All Plaintiffs who have asserted procedural injury reallege and incorporate by reference the allegations contained in Paragraphs 1 through 188 as though fully set forth herein.

190. The Fifth Amendment's Due Process Clause prohibits the federal government from depriving persons of liberty or property without due process of law. Procedural due process requires, at a minimum, notice and an opportunity to be heard before the government takes action that affects a party's protected interests. Substantive due process prohibits arbitrary government action that infringes on fundamental rights or destroys property interests without adequate justification.

191. All Plaintiffs who asserted the denial of their right to participate in notice-and-comment rulemaking under 5 U.S.C. § 553 suffered a procedural due process violation. CMS implemented the BEI without conducting traditional notice-and-comment rulemaking, without affording any opportunity for public participation, and without publishing the BEI in the Federal Register. The BEI took effect on April 1, 2026, just eleven days after its publication on CMS's website.

192. The Plaintiffs, as interested parties with concrete interests at stake—including the health and safety of Medicare beneficiaries, the informational interest in the administrative record, the participatory interest in shaping the regulatory process, and the competitive and economic interests of the MMJ Plaintiffs—were entitled to notice and an opportunity to participate in a rulemaking proceeding that would fundamentally alter the reimbursement landscape for cannabinoid products in the Medicare system. CMS afforded them no such opportunity.

193. The BEI also implicates substantive due process concerns by retroactively undermining the investment-backed expectations of MMJ Plaintiffs. MMJ Plaintiffs entered the federal pharmaceutical regulatory pathway in reliance on an established and

consistently applied framework: cannabinoid therapies intended for treatment of disease must proceed through FDA drug approval before becoming eligible for Medicare reimbursement. Over approximately eight years, the MMJ Plaintiffs invested over \$10 million into pharmaceutical cannabinoid development through this formal FDA regulatory pathway.

194. The BEI's creation of an alternative reimbursement channel for unapproved cannabinoid products without notice, without comment, and without any opportunity for affected parties to be heard deprives the MMJ Plaintiffs of the economic value of their regulatory compliance without any process whatsoever. This arbitrary government action, which undermines the reliance interests of parties who followed the established federal pathway in good faith, constitutes a denial of substantive due process.

VIII. PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in their favor and grant the following relief:

- a. A declaration that the BEI was adopted and published in violation of the APA's notice-and-comment requirements, 5 U.S.C. § 553, and the Federal Register publication requirements of 5 U.S.C. § 552(a)(1);
- b. A declaration that the BEI is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law under 5 U.S.C. § 706(2)(A);
- c. A declaration that the BEI exceeds CMS's statutory authority under Section 1115A and is in excess of statutory jurisdiction, authority, or limitations under 5 U.S.C. § 706(2)(C);

- d. A declaration that the BEI violates the Fifth Amendment's equal protection guarantee by intentionally treating similarly situated regulated parties differently without any rational basis;
- e. A declaration that the BEI violates the Fifth Amendment's Due Process Clause by depriving Plaintiffs of procedural due process and by arbitrarily undermining the substantive due process rights of the MMJ Plaintiffs;
- f. An order vacating and setting aside the BEI;
- g. A permanent injunction prohibiting Defendants from implementing, applying, or enforcing the BEI;
- h. An award of costs and attorneys' fees as permitted by law; and
- i. Such other and further relief as the Court deems just and proper.

Date: April 13, 2026

Respectfully submitted,

/s/Connor W. Mighell

Connor W. Mighell

TX Bar #24110107

D.D.C. Bar ID #TX0032

BURKE LAW GROUP, PLLC

1000 Main Street, Suite 2300

Houston, Texas 77002

Telephone: (832) 987-2214

Fax: (832) 793-0045

connor.mighell@burkegroup.law

Ilya Shapiro*

DC Bar #489100

BURKE LAW GROUP, PLLC
2001 L Street NW, Suite 500
Washington, D.C. 20036
ilya.shapiro@burkegroup.law
**Admission Pending*

Patrick Kenneally**
IL Bar #6286573
BURKE LAW GROUP, PLLC
205 N Michigan Avenue, Suite 810
Chicago, Illinois 60601
patrick.kenneally@burkegroup.law
***Pro Hac Vice Forthcoming*

Attorneys for Plaintiffs

CERTIFICATE OF SERVICE

I hereby certify that, on April 13, 2026, I electronically filed the foregoing First Amended Complaint for Declaratory and Injunctive Relief and its attendant Exhibits, and this Certificate of Service, along with an attached Corporate Disclosure Statement, with the Clerk of Court for the United States District Court for the District of Columbia by using the CM/ECF system.

/s/Connor W. Mighell
Connor W. Mighell

EXHIBIT A

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA

SMART APPROACHES TO
MARIJUANA
220 Maryland Ave NE, Washington, DC
20002,

CANNABIS INDUSTRY VICTIMS
EDUCATING LITIGATORS
203 Main St, Suite 250, Flemington, NJ
08822,

[AMERICANS AGAINST LEGALIZING
MARIJUANA](#)
[P.O. Box 158, Carmichael, CA 95609](#)

NORTH CAROLINIANS AGAINST
LEGALIZING MARIJUANA
1854 Hendersonville Rd, Suite 205,
Asheville, NC 28803,

CANNABIS IMPACT PREVENTION
COALITION, LLC
418 Broadway, Suite N, Albany, NY
12207,

CANNABIS INDUSTRY VICTIMS
SEEKING JUSTICE
418 Broadway, Suite N, Albany, NY
12207,

DRUG FREE AMERICA FOUNDATION
333 3rd Ave N, Suite 200, St. Petersburg,
FL 33701,

SAVE OUR SOCIETY FROM DRUGS
333 3rd Ave N, Suite 200, St. Petersburg,
FL 33701,

DRUG WATCH INTERNATIONAL
6981 Tepper Dr, Clifton, VA 20124,

Case No. 1:26-CV-
01081-TNM

HILLSBOROUGH COUNTY ANTI-
DRUG ALLIANCE
521 Lantern Circle, Temple Terrace, FL
33617,

ILLINOIS FAMILY INSTITUTE
PO Box 876, Tinley Park, IL 60477,

and

DAVID EVANS
10 Elmwood Lane
Asheville, NC 28803,

KENNETH FINN, M.D.
1716 Alpine Meadows Lane, Unit 1603,
Prescott, AZ 86303

MMJ INTERNATIONAL HOLDINGS,
INC.
101425 Overseas Highway, Suite 170, Key
Largo, FL 33037,

MMJ BIOPHARMA CULTIVATION,
INC.
101425 Overseas Highway, Suite 170, Key
Largo, FL 33037,

and

MMJ BIOPHARMA LABS, INC.
101425 Overseas Highway, Suite 170, Key
Largo, FL 33037,

Plaintiffs,

v.

ROBERT F. KENNEDY, JR., in his official
capacity as Secretary of Health and
Human Services,

THE UNITED STATES DEPARTMENT
OF HEALTH AND HUMAN SERVICES,

MEHMET OZ, M.D., in his official
capacity as Administrator of the Centers
for Medicare & Medicaid Services,

and

THE CENTERS FOR MEDICARE &
MEDICAID SERVICES,

Defendants.

**FIRST AMENDED COMPLAINT
FOR INJUNCTIVE AND DECLARATORY RELIEF**

~~Patrick Kenneally~~

~~—Connor W. Mighell~~

~~——TX Bar #24110107~~

~~D.D.C. Bar ID #TX0032~~

BURKE LAW GROUP, PLLC

1000 Main Street, Suite 2300

Houston, Texas 77002

Telephone: (832) 987-2214

Fax: (832) 793-0045

~~——connor.mighell@burkegroup.law~~

Ilya Shapiro*

DC Bar #489100

BURKE LAW GROUP, PLLC

2001 L Street NW, Suite 500

Washington, D.C. 20036

ilya.shapiro@burkegroup.law

*Admission Pending

Patrick Kenneally**

IL Bar #6286573

BURKE LAW GROUP, PLLC

205 N Michigan Avenue, Suite 810

Chicago, Illinois 60601

patrick.kenneally@burkegroup.law

——**Pro Hac Vice Forthcoming

~~——connor.mighell@burkegroup.law~~

—Attorneys for Plaintiffs

I. INTRODUCTION¹

1. On March 20, 2026, the Centers for Medicare & Medicaid Services (“CMS”) created a program to distribute hemp-derived products containing the Schedule I substance delta-9 tetrahydrocannabinol (“THC”) to Medicare beneficiaries. CMS called this program the Substance Access Beneficiary Engagement Incentive (“BEI”). The BEI imposes binding rules on participating health care providers. These rules include how doctors and patients officially sign up and which doctors are eligible to distribute these products, create detailed implementation plans that must first be approved by CMS, set THC limits and other product specifications, and require quarterly reporting by providers. The BEI does not involve the Food and Drug Administration (“FDA”)’s medicine approval process.

2. CMS published no Notice of Proposed Rulemaking for the BEI, solicited no public comments, offered no reasonable explanation for its action, bypassed the Federal Register, gave ~~eleven~~¹¹ days’ notice before the BEI’s implementation, and contradicted *sub silentio* its own ~~April 2025~~ final rule (less than a year old) that declared cannabis products ineligible for supplemental Medicare coverage for chronically ill patients. 90 Fed. Reg. 15,792, 15,867 (Apr. 15, 2025).

3. The BEI violates the Administrative Procedure Act (“APA”) in three ways:

4.a. *First*, the BEI’s obligations are the hallmarks of a legislative rule requiring notice-and-comment rulemaking under the APA. CMS’s

¹ In accordance with Section 6 of this Court’s Standing Order, Plaintiffs include attached a redline comparison of this First Amended Complaint with Plaintiffs’ Original Complaint. See Exhibit A.

failure to solicit notice and comment violated 5 U.S.C. §§ 553 and 706(2)(D). CMS cannot evade notice-and-comment by embedding a substantive rule in a participation agreement.

5.b. *Second*, CMS reversed its prior rule without explanation, ignored well-documented health risks to elderly Americans (including a two-fold increase in cardiovascular death risk, an increase in the risk of developing or exacerbating mental health disorders, and pervasive contamination of CBD products), disregarded the absence of any FDA regulatory framework, and launched a program that violated the 0.4mg-per-container ceiling set by the 2026 Agriculture Appropriations Act by permitting the distribution of products with up to 3 mg of THC per serving. As such, the BEI is facially arbitrary, capricious, and not in accordance with law, in violation of 5 U.S.C. § 706(2).

6.c. *Third*, the BEI exceeds CMS's statutory authority in violation of the major questions doctrine. Section 1115A of the Social Security Act, under which the BEI is promulgated, allows CMS to test payment and delivery models for Medicare services. It does not allow CMS to sanction the possession and use of illegal and dangerous Schedule I substances by Medicare patients without clear congressional authorization.

4. The BEI violates the Constitution in two ways:

d. First, CMS's decision to provide advance notice of the BEI to hemp-industry stakeholders including Charlotte's Web, a major hemp product producer, while excluding similarly situated regulated parties such as the MMJ Plaintiffs, violates the Fifth Amendment's equal protection guarantee by intentionally treating similarly situated entities differently without any rational basis. The MMJ Plaintiffs, who have invested years and millions of dollars in the federal FDA botanical drug development pathway, received no notice of or opportunity to participate in the development of the BEI, while hemp-industry stakeholders who have not undertaken the same regulatory burdens were afforded advance notice and the opportunity to shape the program. This disparate treatment of similarly situated regulated parties – those developing cannabinoid products – without rational basis constitutes a class-of-one equal protection violation.

e. Second, CMS's implementation of the BEI without notice-and-comment rulemaking, and without affording directly affected regulated parties such as the MMJ Plaintiffs any opportunity to be heard, violates the Fifth Amendment's due process guarantee. The BEI retroactively undermines the investment-backed expectations of parties who entered the federal pharmaceutical regulatory pathway in reliance on an established and consistently applied framework,

and deprives them of the economic value of their regulatory compliance without any process whatsoever.

7.5. CMS's action represents an unprecedented and unlawful assertion of binding decision-making authority that will profoundly affect the health of elderly Americans. CMS took this action without the guardrails imposed by the administrative process, without any reasoned explanation, in conflict with the agency's own recent APA-compliant determination, and without statutory authority. Plaintiffs bring this action under the APA, 5 U.S.C. § 701-706, and under the Constitution, amend. V, to vacate the BEI, declare it unlawful, and permanently enjoin its implementation.

II. PARTIES

A. Plaintiffs

8.6. Smart Approaches to Marijuana, Inc. ("SAM") is a corporation headquartered at 220 Maryland Ave NE, Washington, D.C. 20002 and incorporated in Virginia. SAM's mission includes education and advocacy regarding the public health and safety impacts of marijuana and cannabis policy. SAM operates concrete programmatic activities, including public health education campaigns directed at healthcare providers and patients, direct information services regarding cannabis-related health risks, and research and policy analysis programs. SAM is a participant in the ongoing Drug Enforcement Administration marijuana rescheduling proceedings as an interested party in opposition to the Notice of Proposed Rulemaking. *See* Exhibit AB. The BEI directly impairs SAM's core programmatic activities by requiring SAM to redirect staff and resources from its ongoing patient and provider education programs to monitor, analyze, and provide direct informational services to its members and stakeholders

regarding the BEI's implications for vulnerable seniors, as well as engage in this litigation. The BEI provides marijuana products via a medical source, meaning that SAM's expenditure of resources opposing rescheduling of marijuana in administrative proceedings has been rendered essentially moot. SAM's injury is not abstract policy disagreement but concrete impairment of specific programmatic activities with a consequent drain on organizational resources. *See Havens Realty Corp. v. Coleman*, 455 U.S. 363, 379 (1982). In addition, SAM's donor, volunteer, and consultant David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. SAM also has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

9.7. Cannabis Industry Victims Educating Litigators ("CIVEL") is an organization based in New Jersey. CIVEL's mission includes educating legal professionals and the public about the harms caused by the cannabis industry. CIVEL represents the victims of the marijuana industry who have been, are being, or will actually be harmed by the challenged actions of CMS because the BEI will increase the use of marijuana, reduce the perception of its dangerousness, and lower medical standards for determining what constitutes a medicine. CIVEL thus has an active interest and not a mere casual interest in the problem presented. As a marijuana industry victims' legal support organization, CIVEL has a direct and particularized interest in the

implementation of federal and state law regarding “medical” marijuana in all of its forms.

CIVEL operates concrete programmatic activities including legal education seminars, victim assistance programs, and community outreach. CIVEL is a participant in the ongoing administrative process opposing the rescheduling of cannabis. The BEI has directly impaired CIVEL’s core programmatic activities by requiring diversion of resources from its victim assistance and legal education programs, before the Drug Enforcement Administration, and was granted associational standing by DEA Chief Administrative Law Judge John J. Mulrooney on November 19, 2024 in the matter of Schedules of Controlled Substances: Proposed Rescheduling of Marijuana, DEA Docket No. 1362, Hearing Docket No. 24-44. CIVEL was also recognized as having associational standing in *Botteon v. Murphy*, NJ Superior Court MID-L-002293 (2020), a New Jersey case concerning federal law preemption and the state marijuana law. The BEI has directly impaired CIVEL’s core programmatic activities by requiring CIVEL to divert staff time and resources from its victim assistance and legal education programs to monitor, analyze, and respond to the BEI and its implications for vulnerable seniors. The BEI program will apply to thousands of medical care providers that CIVEL will have to educate and monitor, and with the increase in hemp injuries caused by the BEI, there will be more litigation, potentially against the providers or ACOs whose patients will be injured, requiring CIVEL to devote more expertise and financial and legal educational resources to handle those cases. This diversion of resources constitutes a concrete and demonstrable injury to CIVEL’s organizational interests. In addition, CIVEL’s Senior Counsel and Executive Director David Evans is a Medicare beneficiary aligned with an

ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, CIVEL has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

8. Americans Against Legalizing Marijuana ("AALM") is a national non-profit volunteer organization based in California that is dedicated to providing information on the harms of marijuana to individuals and our country based on the premise "no use of any illegal drug and no illegal use of legal drugs." Such drugs include "medical" marijuana, hemp-based products, THC, CBD, and other cannabinoids. The BEI has directly affected and interfered with AALM's core programmatic activities beyond its issue advocacy or mission by requiring diversion of resources from its programs, including victim support and drug prevention education programs, public awareness campaigns, support and resources for medical professionals and attorneys working in fields impacted by cannabis use and abuse, and related operational activities. AALM's consultant David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, AALM has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and

has been deprived of its participatory interest in shaping the regulatory process through providing comments.

~~10.9.~~ North Carolinians Against Legalizing Marijuana (“NCALM”) is an organization based in Asheville, North Carolina, and is registered with the North Carolina Secretary of State for lobbying purposes. NCALM’s mission includes opposing the legalization of medical hemp-derived and marijuana products in North Carolina and advocating that only medicines produced and distributed with standard best-practice pharmaceutical protocols and approved by the FDA should be available to patients. NCALM operates concrete programmatic activities including legislative advocacy, public education campaigns, and policy analysis regarding the risks of marijuana. The BEI has directly affected and interfered with NCALM’s core programmatic activities beyond its issue-advocacy or mission, because the BEI authorizes the distribution of cannabis- and hemp-derived products that have not been approved by the FDA—the very outcome NCALM’s programs are designed to prevent. NCALM’s Executive Director David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, NCALM has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

~~11.10.~~ Cannabis Impact Prevention Coalition, LLC (“CIPC”) is a corporation organized under the laws of the State of New York. CIPC’s mission is to prevent the negative social, health, public safety, and environmental impacts of marijuana. CIPC was granted standing in Cannabis Impact Prevention Coalition and Cannabis Industry Victims Seeking Justice, et al. v. Hochul, Index No. 905386-23 (Albany County, NY), a case involving state laws regarding “medical” marijuana. CIPC operates concrete programmatic activities including public education, community outreach, and policy advocacy directed at reducing the harms caused by marijuana use. The BEI has directly affected and interfered with CIPC’s core programmatic activities beyond its issue-advocacy or mission: by requiring diversion of resources from its programs. This diversion constitutes a concrete organizational injury. CIPC’s Executive Director David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, CIPC has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

~~12.11.~~ Cannabis Industry Victims Seeking Justice (“CIVSJ”) is a corporation organized under the laws of the State of New York. CIVSJ’s mission is to make the marijuana industry legally accountable to its victims and to provide advocacy services to the many victims of the cannabis industry. CIVSJ was granted standing alongside Cannabis Impact Prevention Coalition, LLC in Cannabis Impact Prevention Coalition and

Cannabis Industry Victims Seeking Justice, et al. v. Hochul, Index No. 905386-23 (Albany County, NY). CIVSJ operates concrete programmatic activities including victim advocacy, legal accountability initiatives, and public education regarding the harms caused by the cannabis industry. The BEI has directly affected and interfered with CIVSJ's core programmatic activities beyond its issue-advocacy or mission: by requiring diversion of resources from its programs. This diversion constitutes a concrete organizational injury. CIVSJ's Executive Director David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, CIVSJ has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

13.12. Drug Free America Foundation ("DFAF") is aan incorporated nonprofit organization based in Florida. DFAF is a drug prevention and policy organization committed to developing strategies and educational programs that prevent drug use and promote sustained recovery. The BEI has directly affected and interfered with DFAF's core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs, including drug prevention education programs, student assistance initiatives, community outreach, workplace drug prevention programs, and related operational activities. DFAF's consultant and volunteer David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been

injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, DFAF has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

14.13. Save Our Society from Drugs (“SOS”) is [aan incorporated](#) nonprofit organization based in Florida. Its mission includes establishing, promoting, and enabling sound drug laws and policies that will reduce illegal drug use, drug addiction and drug-related illness and death. The BEI has directly affected and interfered with SOS’s core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs, including drug prevention education programs, public awareness campaigns, community intervention initiatives, support and resources for professionals working in fields impacted by drug use and abuse, and related operational activities. SOS’s consultant and volunteer David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, SOS has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

15.14. Drug Watch International (“DWI”) is [aan incorporated](#) nonprofit organization based in Virginia. Its mission includes promoting “healthy drug-free

cultures” globally, advocating for the prohibition of and abstinence from all drugs including alcohol and tobacco, and opposing the legalization of drugs prohibited by national and international laws. The BEI has directly affected and interfered with DWI’s core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs. Since the BEI was announced, DWI’s board and members have spent considerable time on collecting and disseminating information about cannabis- and hemp-derived products and the BEI to its stakeholders and constituents, thus diverting members from the mission of Drug Watch International, Inc., which seeks to prevent the abuse of all drugs, not just cannabis, through education, prevention, and treatment. DWI’s injury is not abstract policy disagreement but concrete impairment of specific programmatic activities with a consequent drain on organizational resources. DWI’s interest in preventing the expansion of access to drugs has been directly and demonstrably harmed by the BEI. DWI possesses extensive expertise and data regarding the public health risks of cannabis- and hemp-derived products and the impact of expanded drug access on communities, which it would have submitted to the agency as part of a formal rulemaking proceeding. DWI’s member David Evans is a Medicare beneficiary aligned with an ACO REACH participant provider who has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Additionally, DWI has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

~~16~~15. Hillsborough County Anti-Drug Alliance (“HCADA”) is aan incorporated nonprofit organization based in Florida. Its mission includes engaging in community-based alcohol, tobacco, and substance abuse education and prevention activities, as well as participation in the development of related planning strategies statewide. The BEI has directly affected and interfered with its core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its other programs and activities, including legislative advocacy, education, community outreach, and volunteering. Additionally, HCADA has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

~~17~~16. Illinois Family Institute (“IFI”) is aan incorporated nonprofit organization based in Illinois. Its mission includes advancing public policy initiatives consistent with Judeo-Christian teachings and traditions, including opposition to access to illegal drugs, educating citizens so that they can better influence their local communities and the state. IFI possesses extensive expertise and data regarding the public health and moral risks of cannabis- and hemp-derived products and the impact of expanded drug access on communities. The BEI has directly affected and interfered with IFI’s core programmatic activities beyond its issue-advocacy or mission by requiring diversion of resources from its programs. IFI would have submitted detailed comments to CMS opposing the BEI had the agency complied with the notice-and-comment requirements of 5 U.S.C. § 553. IFI has an informational interest in the administrative record that would have been developed

had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

18.17. David Evans is a 78-year-old Medicare beneficiary and a three-time cancer survivor who was treated for two forms of cancer while on Medicare, making him a member of the population most vulnerable to the cardiovascular, neurological, cognitive, and drug-interaction harms documented in the peer-reviewed literature regarding cannabis- and hemp-derived products. Mr. Evans is aligned with an ACO REACH participant provider ~~who~~and has been injured by the denial of his right to participate in notice-and-comment rulemaking, and in the alteration of his healthcare relationship due to the BEI. Mr. Evans is also the owner of a critical care nursing home that may be asked to participate in the BEI process, and he would have sought the opportunity to participate in notice-and-comment rulemaking on behalf of the nursing home before the BEI was implemented. Mr. Evans has extensive personal knowledge of and experience with the harms caused by cannabis and hemp-derived products and possesses extensive evidence of these harms, which he was denied the opportunity to submit to CMS.

18. Kenneth Finn, M.D. is a physician who practices comprehensive pain medicine in Prescott, Arizona. Dr. Finn is Board Certified in Physical Medicine and Rehabilitation, Pain Medicine, and Pain Management, and is certified in Cannabis Science through the University of Colorado. Dr. Finn was an associate professor for the University of Colorado Medical School, is former President of the American Board of Pain Medicine, and has served on their Exam Council for over 25 years. He is editor of Cannabis in Medicine: An Evidence-Based Approach (2020) and is Co-Vice President of

the International Academy on the Science and Impacts of Cannabis. Dr. Finn is employed by an Accountable Care Organization (“ACO”). As a physician who practices pain medicine and has extensive experience with cannabis-related patient care, Dr. Finn will be directly affected by the BEI because the lack of satisfactory research into the cannabis products authorized under the BEI, and the absence of any dosing guidelines or care standards from the FDA, renders him unable to competently prescribe or administer such products for his patients. His practice may lose any Medicare patients who wish to access substances under the BEI. Dr. Finn must also follow the BEI’s legal requirements for any patient he has that elects to receive substances under the BEI, should his ACO opt into the ACO REACH Model. Additionally, due to the known adverse health effects of cannabinoid substances, Dr. Finn and his practice are likely to receive an increase in emergency room visits and may be sued for malpractice by patients that overuse cannabinoid and hemp-derived products due to a lack of dosing requirements or widespread adulteration of such retail products. The BEI exposes Dr. Finn to significant malpractice liability without any regulatory safe harbor or physician indemnification, and creates a dangerous regulatory cliff: the FY 2026 Agriculture Appropriations Act, effective November 2026, resets the legal THC threshold to 0.4 mg total hemp-derived THC per container, potentially rendering products recommended to patients today Schedule I controlled substances by Fall 2026 and creating retroactive legal exposure for physicians. Dr. Finn is aware that approximately 1,500 deaths have been reported in connection with FDA-approved Epidiolex alone, yet products distributed under the BEI are afforded no comparable adverse event reporting mechanisms. Dr. Finn is a

participant in the ongoing Drug Enforcement Administration marijuana rescheduling proceedings as an interested party in opposition to the Notice of Proposed Rulemaking. See Exhibit B. Dr. Finn was deprived of his right to participate in notice-and-comment rulemaking as an interested party. Additionally, Dr. Finn has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of his participatory interest in shaping the regulatory process through providing comments.

19. MMJ International Holdings, Inc. ("MMJIH") is a corporation incorporated in Delaware with its principal business address at 101425 Overseas Highway, Suite 170, Key Largo, Florida 33037. MMJIH is a life sciences company established for the purpose of developing pharmaceutical cannabinoid therapeutics under the FDA's botanical drug development framework, including the Botanical Drug Development Guidance for Industry. MMJIH serves as the parent company of MMJ BioPharma Cultivation, Inc. and MMJ BioPharma Labs, Inc., overseeing regulatory strategy, clinical development planning, chemistry, manufacturing, and controls preparation, and Investigational New Drug ("IND") submissions for cannabinoid-based treatments targeting Huntington's disease and multiple sclerosis. MMJIH has assembled a team of nationally recognized scientists and regulatory professionals, submitted IND applications to the FDA, and obtained Orphan Drug Designation for Δ 9-tetrahydrocannabinol and cannabidiol for the treatment of Huntington's disease pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360bb). Over the past approximately eight years, MMJIH and its subsidiaries have invested over \$10 million into advancing pharmaceutical

cannabinoid therapeutics through the formal federal FDA botanical drug development pathway and the DEA controlled-substance registration framework. The BEI has directly and concretely injured MMJIH by (1) creating a federally supported pathway for the distribution of non-FDA-approved cannabinoid products to Medicare beneficiaries, thereby undermining the economic assumptions underlying MMJIH's multi-year pharmaceutical development investment, (2) diminishing the anticipated reimbursement differentiation between FDA-validated therapies and non-approved cannabinoid products, (3) adversely affecting investor confidence and capital-raising efforts, and (4) creating competitive disadvantage relative to entities that have not undertaken the rigorous scientific validation and regulatory compliance that MMJIH has pursued. MMJIH was excluded from any notice of the BEI and was deprived of the opportunity to participate in notice-and-comment rulemaking, despite being a directly affected regulated party with concrete interests at stake. Additionally, MMJIH has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

20. MMJ BioPharma Cultivation, Inc. ("MMJBC") is a corporation incorporated in Delaware with its principal business address at 101425 Overseas Highway, Suite 170, Key Largo, Florida 33037. MMJBC is a subsidiary of MMJIH formed to support the cultivation and production of pharmaceutical-grade cannabis plant material required for extraction and formulation of the active botanical drug substance used in MMJIH's IND programs. In December 2018, MMJBC submitted an application to the DEA for

registration as a bulk manufacturer of marijuana active pharmaceutical ingredient for use in FDA-authorized clinical trials and drug development. MMJBC's cultivation facility in Westerly, Rhode Island was designed to employ state-of-the-art automated growth chambers capable of generating medical marijuana with exacting and repeatable secondary metabolite profiles at production levels consistent with federal research supply requirements. MMJBC's bulk manufacturing registration application remains pending before the DEA Administrator. The BEI has directly and concretely injured MMJBC as part of the integrated pharmaceutical development platform it operates with MMJIH and MMJBL, by undermining the economic viability of the federal FDA and DEA regulatory pathway upon which MMJBC's operations depend. MMJBC was excluded from any notice of the BEI and was deprived of the opportunity to participate in notice-and-comment rulemaking. Additionally, MMJBC has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

21. MMJ BioPharma Labs, Inc. ("MMJBL") is a corporation incorporated in Delaware with its principal business address at 101425 Overseas Highway, Suite 170, Key Largo, Florida 33037. MMJBL is a subsidiary of MMJIH established to perform analytical testing, formulation support, and regulatory-grade characterization of botanical extracts used in MMJIH's drug development program. MMJBL obtained a DEA Schedule I analytical laboratory registration, issued following a DEA inspection and approval of the laboratory's physical security systems, recordkeeping controls, and diversion-prevention

safeguards, consistent with its Rhode Island state authorization. The BEI has directly and concretely injured MMJBL as part of the integrated pharmaceutical development platform it operates with MMJIH and MMJBC, by undermining the economic viability of the federal FDA and DEA regulatory pathway upon which MMJBL's operations depend. MMJBL was excluded from any notice of the BEI and was deprived of the opportunity to participate in notice-and-comment rulemaking. Additionally, MMJBL has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of its participatory interest in shaping the regulatory process through providing comments.

B. Defendants

19.22. Defendant Robert F. Kennedy, Jr. is the Secretary of Health and Human Services. He is sued in his official capacity. Secretary Kennedy oversees the Department of Health and Human Services, which houses CMSthe Centers for Medicare & Medicaid Services, and bears ultimate responsibility for the adoption and implementation of the BEI.

20.23. Defendant United States Department of Health and Human Services ("HHS") is an executive department of the United States government responsible for administering federal healthcare programs, including the Medicare program.

21.24. Defendant Mehmet Oz, M.D. is the Administrator of the Centers for Medicare & Medicaid Services. He is sued in his official capacity. Administrator Oz publicly announced in December 2025, at the signing ceremony for Executive Order No. 14370, that "millions of Americans on Medicare" would become eligible to receive

cannabis products “as early as April of next year—and at no charge if their doctors recommend them.” Administrator Oz has played a central role in the development and public promotion of the BEI.

22-25. Defendant Centers for Medicare & Medicaid Services (“CMS”) is a federal agency within HHS. CMS administers the Medicare program and operates the Center for Medicare & Medicaid Innovation (“Innovation Center”), which developed and published the BEI.

III. JURISDICTION AND VENUE

23-26. Plaintiffs bring this action under the Administrative Procedure Act (“APA”), 5 U.S.C. §§ 701-706, and the Constitution, amend. V. The APA provides a right of review under 5 U.S.C. § 702 for persons adversely affected or aggrieved by agency action and under 5 U.S.C. § 704 for final agency action for which there is no other adequate remedy in a court.

24-27. This court has subject matter jurisdiction pursuant to 28 U.S.C. § 1331, 5 U.S.C. §§ 701-706 (APA) and 28 U.S.C. § 2201 (Declaratory Judgment Act). The relief requested is authorized by 28 U.S.C. § 2201 (declaratory judgment), 28 U.S.C. § 2202 (injunctive relief), and 5 U.S.C. §§ 701-706 (APA).

25-28. This Court has jurisdiction pursuant to 28 U.S.C. § 1331, which grants the district courts “original jurisdiction of all civil actions arising under the . . . laws . . . of the United States.”

26-29. Venue is appropriate in this Court pursuant to 28 U.S.C. § 1391(e)(1) because the defendants are officers and agencies of the United States and this action is

brought where the agency defendants maintain their principal offices. Venue is also appropriate under 5 U.S.C. § 703.

~~27.30.~~ An actual, justiciable controversy exists between the parties within the meaning of 28 U.S.C. § 2201.

~~28.31.~~ The federal Government has waived sovereign immunity in this action pursuant to 5 U.S.C. § 702.

32. Plaintiffs have exhausted all administrative remedies, ~~the~~.

33. ~~The~~ agency action is final and ripe for review, ~~and all~~.

~~29.34.~~ All Plaintiffs have standing because they are injured in fact because of the defendants' actions or omissions and this ~~court~~Court has the power to redress those injuries.

A. Final Agency Action

~~30.35.~~ The BEI constitutes final agency action because it (1) "mark[s] the consummation of the agency's decision-making process" and is "not . . . of a merely tentative or interlocutory nature" and (2) is "~~one~~ an action" by which rights or obligations have been determined, or from which legal consequences will flow." *Bennett v. Spear*, 520 U.S. 154, 177-78 (1997) (cleaned up); *see also United States Army Corps of Eng'rs v. Hawkes Co.*, 578 U.S. 590, 597 (2016). ~~It~~The BEI was published to CMS's website on March 20, 2026, with an effective date of April 1, 2026. It imposes binding requirements regarding participant election, submission of an implementation plan, eligibility determinations, and quarterly reporting to CMS. These requirements complete CMS's decision-making and produce concrete legal consequences for participating organizations and Medicare

beneficiaries aligned with them. *See Bennett*, 520 U.S. at 178 (action is final where it has “direct and appreciable legal consequences”).

B. The Section 1115A Review Bar Does Not Apply

~~31.36.~~ Section 1115A of the Social Security Act, 42 U.S.C. § 1315a(d)(2), bars judicial review of “the selection of models for testing,” “the selection of organizations, sites, or participants,” and “the elements, parameters, scope, and duration” of Innovation Center models.

~~32.37.~~ Plaintiffs do not challenge any of these enumerated decisions. Plaintiffs challenge the procedures CMS used to adopt and publish the BEI by bypassing APA rulemaking and exceeding its statutory authority. *See Regeneron Pharmaceuticals, Inc. v. United States HHS*, 510 F. Supp. 3d 29, 42 (S.D.N.Y. 2020) (holding that Section 1115A “does not bar review of the propriety of the procedures used” to establish models); *see also Bowen v. Michigan Academy of Family Physicians*, 476 U.S. 667, 670 (1986) (recognizing a “strong presumption that Congress intends judicial review of administrative action”).

C. Medicare Channeling Does Not Apply

~~33.38.~~ Plaintiffs do not seek benefits determinations, reimbursement calculations, or participant-specific Medicare payment review. No adequate administrative remedy exists for this pre-enforcement APA challenge to CMS’s procedural deficiencies in adopting the BEI. *See Shalala v. Illinois Council on Long Term Care*, 529 U.S. 1, 19 (2000) (channeling requirements do not apply where they would result in “complete preclusion of judicial review”).

IV. STANDING

A. Competitor Standing

39. MMJ Plaintiffs have competitor standing under the doctrine established in *Sherley v. Sebelius*, 610 F.3d 69 (D.C. Cir. 2010), and its progeny.

40. MMJ Plaintiffs are direct and current competitors in the cannabinoid therapeutics market. MMJIH, through its subsidiaries MMJBC and MMJBL, has invested over \$10 million and eight years into developing pharmaceutical-grade cannabinoid therapeutics through the formal FDA botanical drug development pathway. MMJIH has submitted IND applications to the FDA for cannabinoid treatments targeting Huntington's disease (IND file number 137754) and multiple sclerosis (IND file number 140712). The FDA granted Orphan Drug Designation for MMJIH's Huntington's disease program. MMJBC has a pending bulk manufacturing application before the DEA for cultivation of pharmaceutical-grade cannabis for clinical trials, and MMJBL holds an active DEA Schedule I analytical laboratory registration.

41. The BEI causes an actual and imminent increase in competition against MMJ Plaintiffs. The BEI expands the competitive landscape by creating a federally supported pathway for non-FDA-approved cannabinoid products to reach Medicare beneficiaries – the same patient population that MMJ Plaintiffs' FDA-validated therapies would target.

42. The competitive injury to MMJ Plaintiffs is concrete and imminent. The BEI subjects MMJ Plaintiffs to direct competition from entities distributing non-FDA-approved cannabinoid products through Medicare without undertaking any of the

rigorous pharmaceutical development requirements that MMJ Plaintiffs have spent years and millions of dollars satisfying.

43. Moreover, MMJ Plaintiffs have suffered competitive injury because the challenged agency action permits entities (hemp-product distributors) to compete in a market (cannabinoid therapeutics for Medicare beneficiaries) where the plaintiffs (MMJ Plaintiffs pursuing FDA approval) previously enjoyed regulatory protection. This amounts to increased competitive activity that courts have recognized constitutes Article III injury.

44. MMJ Plaintiffs' competitive injuries are fairly traceable to the BEI and redressable by a favorable decision. Before the BEI, there was no federally supported reimbursement pathway for non-FDA-approved cannabinoid products in Medicare. The BEI created one. MMJ Plaintiffs' competitive disadvantage flows directly from the BEI's existence. An injunction vacating or staying the BEI would eliminate the competing access pathway, restoring the regulatory framework that previously required cannabinoid therapeutics to proceed through FDA approval before becoming eligible for Medicare reimbursement.

45. Finally, MMJ Plaintiffs satisfy the prudential standing requirement that their interests fall within the "zone of interests" protected by the statutes they invoke. MMJ Plaintiffs' interest in maintaining the integrity of the FDA drug approval framework, and in preventing CMS from creating alternative access pathways that circumvent that framework, falls squarely within the zone of interests protected by the

APA's procedural requirements and the statutory framework governing federal healthcare reimbursement for pharmaceutical products.

~~A. Individual and Associational Standing~~

~~34. David Evans is a 78-year-old Medicare beneficiary with individual standing to sue.~~

~~35. Mr. Evans is a donor, consultant, and volunteer for SAM.~~

~~36. Mr. Evans is Executive Director and Senior Counsel of CIVEL.~~

~~37. Mr. Evans is Executive Director of NCALM, CIPC, and CIVSJ.~~

~~38. Mr. Evans is a consultant and volunteer of DFAF.~~

~~39. Mr. Evans is a consultant and volunteer of SOS.~~

~~40. Mr. Evans is a member of DWI.~~

~~41. Mr. Evans is a Medicare beneficiary who is aligned with Hopscotch Primary Care, PLLC. This provider has joined ACO REACH as part of Physicians Healthcare Collaborative ACO, and faces imminent implementation of the BEI beginning April 1, 2026.~~

~~42.1. Mr. Evans was deprived of his right to participate in notice and comment rulemaking as an interested party. Mr. Evans is opposed to expanded access to cannabis and hemp-derived products, and does not want them provided by his Medicare provider, due to their serious health risks. Mr. Evans also has extensive evidence of the harms caused by these products. Because there was no opportunity for public comment on the BEI, Mr. Evans could not submit this evidence to CMS.~~

~~43. The following Plaintiffs have associational standing: SAM; CIVEL; NCALM; CIPC; CIVSJ; DFAF; SOS; and DWI (collectively, the “Associational Plaintiffs”).~~

~~44. At least one identified member of each Plaintiff, namely Mr. David Evans, has standing to sue in his own right.~~

~~45.1. The interests each Associational Plaintiff seeks to protect—including public health, product safety, and lawful agency procedure—are germane to their purposes.~~

~~46.1. Finally, neither the claims asserted nor the declaratory and injunctive relief requested requires the participation of individual members.~~

B.A. Procedural Standing

~~47. All Plaintiffs assert the denial of their right to participate in notice and comment rulemaking under 5 U.S.C. § 553. They have suffered a “reasonably increased risk of injury” to their particularized interests due to CMS’s decision to create and institute the BEI without the required procedure. *Cap. Area Immigrants’ Rts. Coal. v. Trump*, 471 F. Supp. 3d 25, 38 (D.D.C. 2020); see also *Mendoza v. Perez*, 754 F.3d 1002, 1010 (D.C. Cir. 2014).~~

~~48. Plaintiffs’ concrete interests include: (1) the health and safety of their individual members who are Medicare beneficiaries exposed to the BEI, including Mr. Evans, (2) the informational interest in the administrative record that would have been developed through notice and comment rulemaking, and (3) the participatory interest in shaping the regulatory outcome through the procedures Congress established.~~

~~49. Plaintiffs SAM and CIVEL are also involved in ongoing administrative proceedings opposing the DEA’s efforts to expand access to cannabis through~~

~~rescheduling under the Controlled Substances Act. See Exhibit A (order granting SAM and CIVEL standing in DEA administrative proceeding). They are injured by their inability to comment on the BEI, which seeks to expand access to cannabis for certain Americans.~~

C.B. Organizational Standing

~~50.46.~~ All Plaintiffs except for David Evans and ~~Illinois Family Institute~~Kenneth Finn, M.D. (collectively, the “Organizational Plaintiffs”) have organizational standing to sue.

~~51.47.~~ Organizational Plaintiffs’ primary interest is in proper use of the FDA regulatory process for any cannabinoid products approved for medical use, as well as preventing the expansion of access to cannabis~~products, hemp, and proper use of the FDA medicine approval~~cannabinoid products not approved through this process. They have standing to challenge CMS’s action in creating and instituting the BEI on their own behalf due to concrete and demonstrable injury to these respective interests.

~~52.48.~~ Moreover, CMS’s action has impaired specific, concrete programmatic activities undertaken by certain Organizational Plaintiffs, including direct patient education services, clinician training programs, community health intervention programs, and victim assistance operations, by requiring diversion of resources from these programs to counteract the public health and societal effects of the BEI. This constitutes an injury to each Organizational Plaintiff’s respective organizational interests. *See People for the Ethical Treatment of Animals v. United States Department of Agriculture*, 797 F.3d 1087, 1094 (D.C. Cir. 2015).

53.49. Certain Organizational Plaintiffs have standing to challenge the BEI because counteracting it requires diversion of resources from their efforts to prevent rescheduling of cannabis through the administrative process. Specifically, SAM and CIVEL are directly involved in ongoing DEA administrative proceedings opposing cannabis rescheduling.

50. MMJ Plaintiffs additionally have standing based on direct competitive and economic injury. The BEI created a federally supported pathway for the distribution of non-FDA-approved cannabinoid products to Medicare beneficiaries, thereby directly and concretely injuring MMJ Plaintiffs by undermining the economic assumptions underlying their multi-year, multi-million-dollar pharmaceutical development investment in the federal FDA botanical drug development pathway; diminishing the anticipated reimbursement differentiation between FDA-validated therapies and non-approved cannabinoid products; adversely affecting investor confidence, capital-raising efforts, and strategic partnership positioning; and creating competitive disadvantage relative to entities that have not undertaken the rigorous scientific validation and regulatory compliance that MMJ Plaintiffs have pursued. These injuries are concrete and particularized, actual and imminent, fairly traceable to CMS's adoption of the BEI, and redressable by a favorable decision vacating or enjoining the BEI.

51. MMJ Plaintiffs' standing is further supported by their status as directly affected regulated parties operating under active DEA oversight and FDA IND authorization. The BEI creates a two-track regulatory system in which entities like MMJ Plaintiffs that have complied with the federal pharmaceutical regulatory framework are

subjected to the full weight of FDA and DEA regulatory requirements, while the BEI permits entities that have not undertaken any of those regulatory burdens to access a federally supported cannabinoid distribution pathway. An injunction vacating or staying the BEI would eliminate the competing pathway, restoring the regulatory framework upon which MMJ Plaintiffs relied and protecting their investment in the FDA approval process.

C. Procedural Standing

52. All Plaintiffs assert the denial of their right to participate in notice and comment rulemaking under 5 U.S.C. § 553. They have suffered a “reasonably increased risk of injury” to their particularized interests due to CMS’s decision to create and institute the BEI without the required procedure. *Cap. Area Immigrants’ Rts. Coal. v. Trump*, 471 F. Supp. 3d 25, 38 (D.D.C. 2020); see also *Mendoza v. Perez*, 754 F.3d 1002, 1010 (D.C. Cir. 2014); *Massachusetts v. EPA*, 549 U.S. 497, 517–18 (2007); *Sugar Cane Growers Coop. of Fla. v. Veneman*, 289 F.3d 89, 94–95 (D.C. Cir. 2002). A plaintiff “who alleges a deprivation of a procedural protection to which he is entitled never has to prove that if he had received the procedure the substantive result would have been altered. All that is necessary is to show that the procedural step was connected to the substantive result.” *Veneman*, 289 F.3d at 94–95.

53. Plaintiffs’ concrete interests include: (1) the health and safety of their individual members who are Medicare beneficiaries exposed to the BEI, including Mr. Evans, who is a three-time cancer survivor particularly vulnerable to the health risks posed by the BEI, (2) the professional interests of physicians affected by the BEI, including

Dr. Finn, who faces concrete professional and economic harm, (3) the informational interest in the administrative record that would have been developed through notice and comment rulemaking, (4) the participatory interest in shaping the regulatory outcome through the procedures Congress established, and (5) the competitive and economic interests of MMJIH, MMJBC, and MMJBL (collectively, the “MMJ Plaintiffs”), whose multi-year investment in compliance with the FDA pharmaceutical regulatory pathway is directly impaired by CMS’s creation of a competing access pathway for Medicare patients to access non-FDA-approved cannabinoid products without notice or opportunity for comment. These are not abstract interests in “having the procedure observed.” They are concrete, particularized interests that the notice-and-comment process is designed to protect.

54. Plaintiffs SAM and CIVEL are also involved in ongoing administrative proceedings opposing the DEA’s efforts to expand access to cannabis through rescheduling under the Controlled Substances Act. See Exhibit B (order granting SAM and CIVEL standing in DEA administrative proceeding). They are injured specifically by their inability to comment on the BEI, which expands distribution of cannabinoid products to Medicare patients, as they are involved in administrative proceedings opposing rescheduling of cannabis that remain ongoing.

55. MMJ Plaintiffs are directly affected regulated parties operating under active DEA oversight and FDA IND authorization. They were deprived of any notice of the BEI, and of any opportunity to comment – effectively, of due process. Had CMS conducted notice-and-comment rulemaking, MMJ Plaintiffs would have submitted detailed

comments addressing, among other things, the protection of the FDA drug approval framework, patient safety and dose reproducibility, reliance interests of sponsors following the established FDA pathway for botanical drugs, competitive harm to FDA-compliant developers, the impact on clinical trial incentives, and the need for coordination between CMS and FDA.

D. Individual and Associational Standing

56. David Evans is a 78-year-old Medicare beneficiary with individual standing to sue. Mr. Evans is a three-time cancer survivor who was treated for two forms of cancer while on Medicare, as well as a concussion due to a fall. His cancer may return and he will have to face additional treatment while on Medicare. As a senior citizen enrolled in Medicare, Mr. Evans is a member of the population most vulnerable to the cardiovascular, neurological, cognitive, and drug-interaction harms documented in the peer-reviewed literature regarding these products.

57. Mr. Evans is a Medicare beneficiary who is aligned with Hopscotch Primary Care, PLLC. This provider has joined ACO REACH as part of Physicians Healthcare Collaborative ACO. Because his primary care provider participates in ACO REACH, Mr. Evans faces imminent implementation of a program that will make hemp-derived THC products and other cannabis-derived products available through his healthcare provider beginning April 1, 2026. He may be offered products under the BEI by his own healthcare provider.

58. Mr. Evans was deprived of his right to participate in notice-and-comment rulemaking as an interested party. Mr. Evans is opposed to expanded access to cannabis-

and hemp-derived products that have not been proven safe and effective through the FDA approval process, and does not want such unapproved products provided by or through his Medicare provider, due to their serious and well-documented health risks. Mr. Evans also possesses extensive evidence of the harms caused by these products, including personal knowledge derived from decades of professional and volunteer experience assisting persons harmed by cannabis use. Because there was no opportunity for public comment on the BEI, Mr. Evans could not submit this evidence to CMS.

59. Mr. Evans is also the owner of a critical care nursing home that may be asked to participate in the BEI process. As the owner, he would have sought the opportunity to participate in notice-and-comment rulemaking on behalf of the nursing home before the BEI was implemented.

60. Dr. Kenneth Finn is a physician with individual standing to sue. Dr. Finn practices comprehensive pain medicine in Prescott, AZ. He is employed by an ACO. As a physician who practices pain medicine, and a nationally recognized expert in the harmful effects of unregulated hemp-derived and cannabinoid products, Dr. Finn is directly and concretely affected by the BEI. The BEI requires participating physicians to make individual clinical determinations that the use of eligible hemp products is appropriate for specific beneficiaries, yet CMS does not provide clinical guidelines, evidence-based thresholds, or diagnostic criteria to support such determinations. CMS has explicitly stated it “does not make claims regarding the therapeutic value of these products,” yet the program requires physicians to make a documented clinical determination that hemp use is “safe and appropriate” for a specific patient. Making that

determination without recognized clinical guidelines, an FDA approval framework, or an established evidence base creates significant professional risk, particularly in the elderly Medicare population. The BEI also exposes Dr. Finn to significant malpractice liability: adverse events traceable to physician-endorsed hemp use create direct malpractice exposure, and unlike DEA-registered controlled substance frameworks or FDA-approved drug programs, the BEI contains no explicit indemnification language for participating physicians, no regulatory safe harbor protecting physicians who rely in good faith on their ACO's implementation plan, and no mechanism for physicians to obtain binding CMS guidance on borderline eligibility questions before dispensing. Furthermore, the BEI creates a dangerous regulatory cliff for physicians: the FY 2026 Agriculture Appropriations Act, effective November 2026, resets the legal THC threshold to 0.4 mg total hemp-derived THC per container, potentially rendering products recommended to patients today Schedule I controlled substances by Fall 2026 and creating retroactive legal exposure for physicians whose patient charts document endorsement of now-illegal products. CMS has not provided guidance on how participating physicians should wind down or transition patients if the threshold change takes effect.

61. Dr. Finn was deprived of his right to participate in notice-and-comment rulemaking as an interested party. Additionally, Dr. Finn has an informational interest in the administrative record that would have been developed had the BEI proceeded through formal rulemaking, and has been deprived of his participatory interest in shaping the regulatory process through providing comments.

62. The following Plaintiffs have associational standing: SAM, CIVEL, AALM, NCALM, CIPC, CIVSJ, DFAF, SOS, and DWI (collectively, the “Associational Plaintiffs”).

63. At least one identified member of each Plaintiff, namely Mr. David Evans, has standing to sue in his own right. Mr. Evans is (1) a donor, consultant, and volunteer for SAM, (2) Executive Director and Senior Counsel of CIVEL, (3) a donor, consultant, and member of AALM, (4) Executive Director of NCALM, CIPC, and CIVSJ, (5) a consultant and volunteer of DFAF, (6) a consultant and volunteer of SOS, and (7) a member of DWI.

64. The interests each Associational Plaintiff seeks to protect—including public health, product safety, and lawful agency procedure—are germane to their purposes.

65. Finally, neither the claims asserted nor the declaratory and injunctive relief requested requires the participation of individual members.

V. LEGAL STANDARD

54.66. Under 5 U.S.C. § 706(2), a reviewing court shall “hold unlawful and set aside agency action, findings, and conclusions found to be . . . arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law; . . . in excess of statutory jurisdiction, authority, or limitations, or short of statutory right; [or] without observance of procedure required by law”

55.67. The court must examine whether the agency has “examined the relevant data and articulate[d] a satisfactory explanation for its action including a rational connection between the facts found and the choice made.” *Motor Vehicle Manufacturers Ass’n v. State Farm Mutual Automobile Insurance Co.*, 463 U.S. 29, 43 (1983). Agency action

must be “reasonable and reasonably explained.” *FCC v. Prometheus Radio Project*, 592 U.S. 414, 423 (2021).

56-68. Under *Loper Bright Enterprises v. Raimondo*, 603 U.S. 369 (2024), courts must “exercise their independent judgment in deciding whether an agency has acted within its statutory authority, as the [APA] requires.” *Id.* at 413. Courts “need not and under the APA may not defer to an agency interpretation of the law simply because a statute is ambiguous.” *Id.*

VI. FACTUAL ALLEGATIONS

A. The CMS Innovation Center

57-69. Section 1115A of the Social Security Act, 42 U.S.C. § 1315a, established the Center for Medicare & Medicaid Innovation (“Innovation Center”) within CMS. The Innovation Center’s statutory purpose is to test “innovative payment and service delivery models” to reduce program expenditures “while preserving or enhancing the quality of care” for “individuals who are enrolled under such titles and . . . for defined populations with deficits in care leading to poor clinical outcomes or potentially avoidable expenditures.” 42 U.S.C. § 1315a(a)(1).

58-70. The specific models at issue are ACO REACH (a model for accountable care organizations), the Enhancing Oncology Model or EOM (a model for oncology care), and the LEAD Model (an upcoming model for community-level addiction and overdose treatment). These are payment and delivery models.

59-71. ~~The ACO~~ REACH brings together doctors, hospitals and other healthcare providers into a single team called an Accountable Care Organization (ACO). See *Innovation Models: ACO REACH*, Ctrs. for Medicare & Medicaid Servs.,

<https://www.cms.gov/priorities/innovation/innovation-models/aco-reach>. These teams coordinate patient care, making sure patients get the right tests, follow-up, and preventative services to reduce duplication or unnecessary procedures. *Id.* If the ACO keeps costs below a benchmark while meeting quality standards, the team shares in the savings thereby encouraging providers to work together efficiently to focus on preventive care, chronic disease management, and patient outcomes rather than simply the number of services delivered. *Id.* Currently, there are approximately 74 ACOs made up of approximately 126,000 providers and organizations providing care to approximately 1.7 million Medicare beneficiaries. *Id.*

~~60~~72. The EOM focuses on Medicare patients with certain cancers and tests a new way of paying oncology practices. *See Innovation Models: EOM*, Ctrs. for Medicare & Medicaid Servs., <https://www.cms.gov/priorities/innovation/innovation-models/eom>. Participating clinics are given bundled payments or target budgets for patients' entire course of cancer treatment, rather than being paid separately for every test or procedure. *Id.* The incentive is that if the clinic keeps costs within the target and meets quality and outcome goals, it can earn shared savings bonuses. *Id.* Based on the most recent publicly available information, the total number of Medicare participants is unknown. *Id.* However, 28 physician group practices and one commercial payer are participating, accounting for approximately 2,000 practitioners across more than 350 care sites. *Id.*

~~61~~73. The BEI also applies to another payment model, LEAD, which does not begin until January 1, 2027. *See LEAD (Long-Term Enhanced ACO Design) Model*, Ctrs. for

Medicare & Medicaid Servs., <https://www.cms.gov/priorities/innovation/innovation-models/lead>.

~~62.74.~~ Section 1115A was designed to test ~~payment and delivery models, not to create access to new payment and care delivery approaches for Medicare and Medicaid.~~ The purpose of Innovation Center models under Section 1115A is to improve care quality, lower costs, and promote value-based care by encouraging best medical and financial practices through financial incentives or shared savings/ risk arrangements – not to serve as a distribution system for specific consumer products.

B. CMS’s Position on Cannabis Products

~~63.75.~~ In April 2025, CMS issued a final rule, effective June 3, 2025, that states that “medical marijuana or derivatives, such as cannabis oil, cannot be covered by [Medicare Advantage] organizations as they are illegal substances under Federal law.” 90 Fed. Reg. 15,792, 15,867 (Apr. 15, 2025) (codifying “cannabis products” as non-allowable special supplemental benefits for the chronically ill (“SSBCI”)).

~~64.76.~~ To date, CMS has not rescinded this rule.

~~65.77.~~ Yet, the BEI allows access to cannabis products for Medicare Advantage beneficiaries. This contradictory position was issued without any reasoned explanation.

C. Executive Order No. 14370

~~66.78.~~ On December 18, 2025, President Donald J. Trump signed Executive Order No. 14370, titled “Increasing Medical Marijuana and Cannabidiol Research.”

~~67.79.~~ At the signing ceremony, CMS Administrator Oz publicly stated that “millions of Americans on Medicare” would become eligible to receive cannabis and hemp-derived products “as early as April of next year – and at no charge if their doctors

recommend them.” This announcement predated any agency action by three months and signaled a predetermined outcome.

D. The Substance Access BEI

~~68.80.~~ On March 20, 2026, CMS published the BEI on its website.

~~69.81.~~ The BEI is an optional feature embedded in participation agreements for ACO REACH and EOM (effective April 1, 2026) and the LEAD Model (effective January 1, 2027).

~~70.82.~~ For participants in ACO REACH and EOM who elect the BEI, it is a binding, generally applicable framework that imposes legal obligations on participants and their aligned beneficiaries.

~~71.83.~~ The BEI imposes the following mandatory program mechanics, which include: (a) participant election; (b) submission of a CMS-required implementation plan; (c) CMS approval of the implementation plan, with CMS retaining authority to reject or suspend participation; (d) physician determination of beneficiary eligibility, including that the beneficiary is over 18 years of age and does not have a disqualifying condition²; (e) shared decision-making with beneficiaries; (f) cannabis and hemp-derived products provided are limited to 0.3% delta-9 THC per dry weight of the product and in products

² Beneficiaries are not eligible for the BEI if they are not aligned to a participating organization, meets the model’s frailty exclusion, is pregnant or breastfeeding, or if a physician does not determine the product is appropriate. *See Substance Access Beneficiary Engagement Incentive*, Centers for Medicare & Medicaid Services (accessed Mar. 27, 2026), <https://www.cms.gov/priorities/innovation/substance-access-beneficiary-engagement-incentive>. Public-facing CMS documents do not reveal the actual list of “disqualifying conditions” for the BEI.

that are ingested orally, no more than 3 mg per serving of total tetrahydrocannabinols; (g) a \$500 annual cap per beneficiary; and (h) quarterly reporting obligations.

~~72.84.~~ CMS claims that Medicare does not pay for the cannabis products or hemp-derived THC products approved under the BEI directly, and that they are funded at the expense of participants. However, the limited information available about the BEI makes this unclear.

85. On April 1, 2026, the BEI went into full effect.

E. Absence of Notice and Comment

~~73.86.~~ CMS issued no notice of proposed rulemaking and solicited no public comments before announcing and instituting the BEI.

~~74.87.~~ CMS provided no formal administrative record before announcing and instituting the BEI.

~~75.88.~~ CMS provided no reasonable or reasoned explanation for the BEI or for its departure from its April 2025 final rule, 90 Fed. Reg. 15,792, 15,867.

~~76.89.~~ The BEI was not published in the Federal Register, but was announced on March 20, 2026 with a near-immediate effective date of April 1, 2026.

~~77.90.~~ Public statements by hemp-industry stakeholders and later reporting suggest that selected stakeholders ~~may have~~ had advance notice of the BEI before CMS publicly announced the BEI.

~~78.91.~~ On December 18, 2025, Charlotte's Web announced that it was prepared to participate as a CBD provider in a potential Innovation Center pilot. *Charlotte's Web Serves as a Premier CBD Partner for Landmark Medicare and Medicaid Pilot Program*, Charlotte's Web

(Dec. 18, 2025), <https://investors.charlottesweb.com/press-releases/press-release-details/2025/Charlottes-Web-Serves-as-a-Premier-CBD-Partner-for-Landmark-Medicare-and-Medicaid-Pilot-Program/default.aspx>.

~~79.92.~~ Charlotte’s Web co-founder Jared Stanley confirmed on February 13, 2026 that the program was “internally finalized” by CMS weeks prior, without public announcement or opportunity to comment, and referred to a “briefing” when discussing the pilot program’s anticipated scope. Kyle Jaeger, *Federal Agency Finalized Rule for CBD Medicare Coverage Pilot Program Weeks Ago, Key Hemp Stakeholder Says*, Marijuana Moment (Feb. 13, 2026), <https://www.marijuanamoment.net/federal-agency-finalized-rule-for-cbd-medicare-coverage-pilot-program-weeks-ago-key-hemp-stakeholder-says/>.

~~80.93.~~ Upon information and belief, Charlotte’s Web, a major hemp company, along with other hemp companies that received briefings and communications from CMS regarding the BEI, collaborated with CMS in shaping and finalizing the BEI.

~~81.94.~~ At no point was the public afforded any opportunity to participate in the development of the BEI.

95. At no point was MMJIH or any of its subsidiaries, who are directly affected by the BEI’s market-distorting effects, afforded any opportunity to participate in the development of the BEI.

96. CMS knows how to comply with the APA when it chooses to do so. On April 6, 2026, CMS published the Contract Year 2027 final rule in the Federal Register after full notice-and-comment rulemaking, receiving about 42,632 comments. See 91 Fed. Reg. 17,384 et seq. (Apr. 6, 2026) (“CY2027 Rule”).

97. In the CY2027 Rule, CMS acknowledged that it “does not regulate cannabis and hemp-derived cannabis products” and that its “authority does not extend to the direct regulation of cannabis-derived products.” *Id.* at 17,432–17,433. CMS further stated that “any changes to SSBCI requirements will be made by requesting public comment on a proposed regulation through a Notice of Proposed Rulemaking.” *Id.* at 17,433.

98. The CY2027 Rule confirmed that the only cannabis-derived products currently permissible under applicable federal law are hulled hemp seed, hemp seed protein powder, and hemp seed oil—not the panoply of hemp-derived THC and CBD products that the BEI authorizes for medical distribution. *Id.* at 17,432.

99. The contrast between CMS’s adherence to APA procedures for the CY2027 Rule and its complete bypass of notice-and-comment for the BEI demonstrates the arbitrariness of the action at issue, contradicts the premise of the BEI by limiting hemp-derived products for distribution, and underscores the unlawfulness of the BEI’s implementation.

F. Conflict with the 2026 Agriculture Appropriations Act

82.100. The 2026 Agriculture Appropriations Act, signed by the President, sets a total THC limit of 0.4 mg per container for hemp-derived products, effective November 2026.

83.101. CMS’s BEI permits 3 mg of total THC per serving, which is more than seven times the statutory limit.

84.102. CMS’s only response to this conflict has been that it “will adjust its definition in accordance with the law.” *See Substance Access Beneficiary Engagement*

Incentive, Centers for Medicare & Medicaid Services (accessed Mar. 27, 2026), <https://www.cms.gov/priorities/innovation/substance-access-beneficiary-engagement-incentive>.

~~85.103.~~ CMS has provided no details on when or how this adjustment will occur nor why it promulgated a program in explicit conflict with clearly established law.

~~86.104.~~ Accordingly, CMS launched a program it already knows to be inconsistent with enacted federal law.

G. Conflict with Established and Documented Health Risks of Existing Cannabis and Hemp-Derived THC Products for Medicare Populations

~~87.105.~~ The BEI allows elderly Americans to access cannabis products, which contain substances that provably cause harm to their health.

~~88.106.~~ A 2025 narrative review published in the Journal of the American Medical Association (“JAMA”) of 124 recent randomized controlled trials and meta-analysis found that the evidence that cannabis “treats” disorders such as pain, anxiety, post-traumatic stress disorder (“PTSD”), insomnia, and most other hyped uses is weak or non-existent. M. Hsu et al., Therapeutic Use of Cannabis and Cannabinoids: A Review, JAMA (Nov. 26, 2025).

~~89.107.~~ The position of the American Psychiatric Association (“APA”) as of December of 2025 is that “[t]here is insufficient evidence that cannabis is an effective treatment for any psychiatric disorder.” AM. PSYCHIATRIC ASS’N, *Position Statement in Opposition to Cannabis as Medicine for Psychiatric Disorders* (approved by Board of Trustees Dec. 2025 and Assembly Nov. 2025).

90.108._____ The scientific evidence documenting cardiovascular, neurological, and other health risks from cannabis and hemp-derived THC products is substantial and directly relevant to the Medicare population, which consists predominantly of adults over 65 (the population most vulnerable to these harms).

91.109._____ Heart disease is the leading cause of death among Americans over 65.

92.110._____ A June 2025 meta-analysis published in *Heart* (BMJ), encompassing 24 studies and approximately 200 million participants, found that cannabis use was associated with a two-fold risk of cardiovascular death, a 29% higher risk of acute coronary syndrome, and a 20% higher risk of stroke. Wilhelm Storck et al., *Cardiovascular Risk Associated with the Use of Cannabis and Cannabinoids: A Systematic Review and Meta-Analysis*, 111 *Heart* 1047 (2025).

93.111._____ A 2024 study published in the *Journal of the American Heart Association*, analyzing data from approximately 434,000 U.S. adults, found that daily cannabis users had a 25% higher risk of heart attack and a 42% higher risk of stroke compared to non-users, with risk increasing in a dose-response fashion with more frequent use. Abra M. Jeffers et al., *Association of Cannabis Use with Cardiovascular Outcomes Among US Adults*, 13 *J. Am. Heart Ass'n* e030178 (2024).

94.112._____ A May 2025 study published in *JAMA Cardiology* by researchers at the University of California, San Francisco, found that chronic cannabis use—whether smoked or consumed as THC-containing edibles—was associated with vascular endothelial dysfunction comparable to that observed in tobacco smokers. Vascular

function in chronic cannabis users was reduced by approximately 50% compared to non-users. See Leila Mohammadi et al., *Association of Endothelial Dysfunction with Chronic Marijuana Smoking and THC-Edible Use*, JAMA Cardiology (May 28, 2025).

95-113. Memory and cognitive impairment are already prevalent concerns among older adults. THC products appear to worsen these outcomes.

96-114. A 2025 study found that individuals who presented to the emergency room due to cannabis use were at a 1.5-fold to 3.9-fold increased risk of dementia diagnosis within five years, relative to individuals with all-cause acute care visits and the general population. Daniel T. Myran et al., *Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis*, 82 JAMA Neurology 570–79 (June 2025).

97-115. A 2021 study found that long-term marijuana users scored significantly lower on measures of executive function, processing speed, and general cognition than non-users, and that more frequent and more recent use was negatively associated with working memory. Katie Stypulkowski & Rachel E Thayer, *Long-Term Recreational Cannabis Use Is Associated ~~With~~with Lower Executive Function and Processing Speed ~~In A~~in a Pilot Sample of Older Adults*, J. Geriatric Psychiatry Neurology (Sept. 2021).

98-116. A 2020 study found that fewer than 250 older adults have been included in cannabis studies to date, meaning that there is a substantial body of potential harm to that population that remains unknown to science. Brooke Porter et al., *Cannabidiol (CBD) Use by Older Adults for Acute and Chronic Pain*, 47 J. Gerontological Nursing 7, 6–15 (July 2021).

117. A study examining trends in emergency department visits associated with cannabis use among older adults in California from 2005 to 2019 found that cannabis-related emergency department visits increased by 1,804%, with older Black adults having the highest visit rate and the largest absolute increase. B. Han et al., *Trends in Emergency Department Visits Associated with Cannabis Use Among Older Adults in California, 2005–2019*, 71 J. Am. Geriatr. Soc. 4, 1267–74 (Apr. 2023).

~~99.~~118. CMS did not address this research gap before launching a program directed at older adults.

119. A study examining the health effects of cannabis use for medical and non-medical purposes in older adults found that the available evidence suggests cannabis use may be associated with greater frequencies of depression, anxiety, cognitive impairment, substance use and problematic substance use, accidents and injuries, and acute healthcare use. D. Wolfe et al., *Impacts of Medical and Non-Medical Cannabis on the Health of Older Adults: Findings from a Scoping Review of the Literature*, PLOS ONE (Feb. 17, 2023).

~~100.~~120. Commercially available CBD products are pervasively contaminated and mislabeled. M.O. Bonn-Miller et al., *Labeling Accuracy of Cannabidiol Extracts Sold Online*, 318 JAMA 17 at 1708–09 (2017).

~~101.~~121. A peer-reviewed 2022 study published in *Science of the Total Environment*, analyzing 516 CBD products sold in the United States, found that only 42% of products fell within $\pm 10\%$ of the CBD content claimed on the manufacturer's label. Among 121 edible CBD products tested, lead was detected in 42%, mercury in 37%, arsenic in 28%, and cadmium in 8%. Four edible products exceeded the California

Proposition 65 threshold for daily lead consumption in two servings. Hannah Gardener et al., *Heavy Metal and Phthalate Contamination and Labeling Integrity in a Large Sample of US Commercially Available Cannabidiol (CBD) Products*, 851 Sci. Total Env't 158110 (2022).

102.122. These contamination and accuracy risks are especially acute for older adults, who must carefully manage their medical intake and who are particularly vulnerable to pathogen and toxin exposures. Stacy Cooper Bailey et al., *Longitudinal Investigation of Older Adults' Ability to Self-Manage Complex Drug Regimens*, 68 J. Am. Geriatrics Soc'y 569 (2020); John F. Risher et al., *The Elderly as a Sensitive Population in Environmental Exposures: Making the Case*, 7 Int'l J. Env'tl. Res. Pub. Health 228 (2010).

103.123. A 2025 study found that even small doses of CBD can cause significant elevations in liver enzymes (specifically alanine aminotransferase and aspartate aminotransferase), indicative of possible liver injury, which can lead to fatigue and jaundice—issues of special concern for older adults seeking to avoid unnecessary hospitalizations. Jeffrey Florian, et al., *Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial*, 185 JAMA Internal Medicine 9, 1070–78 (July 2025).

104.124. A 2021 review found that a wide variety of drugs in common use by older people, from blood pressure medications to antifungals, belong to a class called CYP3A4 inhibitors that can interact with CBD and increase the bioavailability of its active chemicals, leading to possible adverse effects. Brooke Porter et al., *Cannabidiol (CBD) Use by Older Adults for Acute and Chronic Pain*, 47 J. Gerontological Nursing 7, 6–15 (July 2021).

~~105.125.~~ The same review noted that older adults can suffer from a condition in which protein binding is inhibited, which can also lead to elevated bioavailability and unintentionally higher dosing. *Id.*

~~106.126.~~ It also noted that patient safety is a concern with CBD use, and that poison phone calls for CBD have increased from 3 in 2014 to 2,218 in 2020. *Id.*

~~107.127.~~ CMS created and instituted the BEI despite the extensive scientific evidence demonstrating that cannabis products, hemp-derived THC products, and CBD will harm elderly Americans.

~~108.128.~~ To date, CMS has not conducted or published any analysis of whether the products permitted under the BEI are lawful under federal law, safe for the Medicare populations at issue, or consistent with the agency's obligations under existing statutory frameworks. CMS has explicitly stated it "does not make claims regarding the therapeutic value of these products," yet the BEI requires participating physicians to make a documented clinical determination that hemp use is "safe and appropriate" for a specific patient – without providing clinical guidelines, evidence-based thresholds, or diagnostic criteria to support such determinations.

~~109.129.~~ CMS has not addressed the cardiovascular risks documented in peer-reviewed meta-analyses, the vascular dysfunction findings involving THC edibles, the pervasive contamination and mislabeling of commercially available CBD products, the drug-interaction risks for older adults on common medications, or the near-total absence of clinical research on cannabis use in populations over 65.

130. Neither the FDA nor the BEI imposes any meaningful safeguards to prevent product adulteration, ensure quality control, or require independent testing. Products distributed under the BEI are afforded no adverse event reporting mechanisms comparable to those required for FDA-approved pharmaceuticals, and approximately 1,500 deaths have been reported in connection with FDA-approved Epidiolex alone – a product that, unlike BEI-authorized products, underwent rigorous FDA safety review.

H. Federal Legal Status of Cannabis Products and Hemp-Derived THC Products

~~110.~~131. Cannabis, including delta-9 THC, remains a Schedule I controlled substance under the Controlled Substances Act (“CSA”), 21 U.S.C. §§ 801–901.

~~111.~~132. ~~Hemp~~Current retail hemp-derived THC products are derived by distilling delta-9 THC and other cannabinoids from hemp plants into a concentrated substance and mixing it into consumable products. As such, hemp-derived THC products contain illegal Schedule I compounds, sometimes (due to mislabeling and poor regulation) in amounts higher than the 0.3% permitted for hemp-derived products under Federal law. The hemp-derived product industry exploits this regulatory loophole for profit, to the tune of \$5.5 billion. Beau R. Whitney, *An Economic Impact Analysis of the Hemp Cannabinoid Industry in Texas* (Mar. 2025), <https://texashempbusinesscouncil.com/wp-content/uploads/2025/07/2024-An-Economic-Impact-Analysis-of-the-Hemp-Cannabinoid-Industry-in-Texas-Whitney-Economics-03-25-Public-Facing-1.pdf>.

~~112.~~133. The FDA has not approved hemp-derived THC products for medical use. Epidiolex, a CBD product that may be used to treat rare seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex, has been

approved by the FDA, but has not been tested for safety for people over the age of 55. See

EPIDIOLEX New Drug Application Letter,

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210365orig1s000ltr.pdf.

~~113.~~134. ~~The~~Besides the existing botanical drug approval framework, the FDA has stated that no federal regulatory framework for CBD or hemp-derived ~~cannabis~~ products exists.

~~114.~~135. The FDA has identified specific safety risks associated with CBD and hemp-derived THC products, including liver injury, drug interactions, and harm to vulnerable populations, and has stated that it has “not found adequate information showing how much CBD can be consumed, and for how long, before causing harm.”

~~115.~~136. These FDA warnings are consistent with the peer-reviewed evidence of cardiovascular, neurological, contamination, drug-interaction, and other health risks from current retail cannabinoid and hemp-derived products detailed above.

I. MMJ Plaintiffs’ Regulatory History and Competitive Injury

137. MMJIH initiated formal regulatory engagement with the FDA’s Center for Drug Evaluation and Research in August 2018 through submission of Pre-Investigational New Drug meeting requests for its cannabinoid drug candidates MMJ-001, intended for treatment of Huntington’s disease, and MMJ-002, intended for treatment of multiple sclerosis. The FDA acknowledged these submissions and opened regulatory files, including IND file number 137754 associated with the Huntington’s disease program and IND file number 140712 associated with the multiple sclerosis program.

138. On January 29, 2019, the FDA's Office of Orphan Products Development granted Orphan Drug Designation for Δ 9-tetrahydrocannabinol and cannabidiol for the "treatment of Huntington's disease" pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act. See 21 U.S.C. § 360bb.

139. MMJBC submitted an application to the DEA in December 2018 for registration as a bulk manufacturer of marijuana-active pharmaceutical ingredient for use in FDA-authorized clinical trials.

140. The DEA commenced its pre-registration Section 303 investigation on June 22, 2021, which concluded with a final on-site visit on October 24, 2021, during which all DEA questions were satisfactorily answered, all security systems and protocols were reviewed, and MMJBC demonstrated that all security and diversion conditions followed applicable regulations.

141. MMJBC's bulk manufacturing registration application remains pending before the DEA Administrator.

142. MMJBL obtained a DEA Schedule I analytical laboratory registration following DEA inspection and approval of its facility's physical security systems, recordkeeping controls, and diversion-prevention safeguards.

143. Over the past approximately eight years, the MMJ Plaintiffs have invested over \$10 million into pharmaceutical cannabinoid development through the formal FDA regulatory pathway.

144. These investments include, but are not limited to: (1) IND submissions and regulatory engagement with the FDA, (2) orphan drug designation positioning for

Huntington's disease, (3) DEA registration activity, including the Schedule I analytical laboratory registration and the pending bulk manufacturing application, (4) formulation development and stability studies conducted in collaboration with Catalent Pharma Solutions, (5) analytical testing and chromatographic characterization performed by Avanti Rx Analytics Inc., (6) regulatory consulting engagements with Haffner Associates, LLC, (7) a development summit and portfolio strategy engagement with Parexel International (IRL) Limited, (8) FDA regulatory counsel services provided by Baker & Hostetler LLP, and (9) engagement of Seaport Global Securities LLC as lead financial advisor in connection with a proposed capital raise of approximately \$45 million in debt and equity securities.

145. MMJ Plaintiffs undertook these investments with the clear expectation that FDA approval would provide the necessary regulatory foundation for coverage determinations of cannabinoid-based treatments and therapeutics by Medicare and other third-party payers.

146. The BEI permits clinician-guided distribution of hemp-derived cannabinoid products outside the FDA drug approval framework, while MMJ Plaintiffs pursuing IND-based botanical drug development remain subject to full pharmaceutical regulatory requirements.

147. By introducing federally supported access to non-FDA-approved cannabinoid products, CMS has weakened incentives for investment in validated botanical drug development programs, created a competitive disadvantage for FDA-compliant developers, and directly impacted the MMJ Plaintiffs' Huntington's disease

program by undermining recruitment pathways, investor confidence, and long-term exclusivity expectations associated with IND-stage cannabinoid therapeutics targeting serious neurological disease.

148. MMJ Plaintiffs were excluded from prior notice of the BEI, while other purveyors of cannabis- and hemp-derived THC and CBD products—including Charlotte’s Web—received advance notice of and may have collaborated with CMS in shaping the BEI. These entities operate outside the FDA IND-authorized pharmaceutical development pathway and would benefit from the BEI’s reimbursement structure without undertaking the rigorous scientific validation and regulatory compliance that MMJ Plaintiffs have pursued.

149. The ongoing operation of the BEI causes continuing and compounding harm to the MMJ Plaintiffs. Each day the BEI remains in effect, unvalidated cannabinoid products gain market access and consumer acceptance in the Medicare population, the competitive landscape for cannabinoid therapeutics is further distorted, the MMJ Plaintiffs’ regulatory investments are further devalued, and the integrity of the federal drug-approval framework upon which the MMJ Plaintiffs relied is further eroded.

VII. PLAINTIFFS’ CLAIMS FOR RELIEF

First Claim for Relief

THE BEI VIOLATED THE APA’S NOTICE-AND-COMMENT REQUIREMENTS (Violation of 5 U.S.C. §§ 552(a)(1), 553, 706(2)(D))

~~146-150.~~ 150. The plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through ~~145~~149 as though fully set forth herein.

~~117~~151. The BEI constitutes a “legislative rule” in that it imposes legally binding obligations on participating organizations, creates a new benefit structure, establishes detailed eligibility criteria, requires CMS approval processes, and has “the force and effect of law.” *Perez v. Mortgage Bankers Ass’n*, 575 U.S. 92, 96 (2015) (quoting *Chrysler Corp. v. Brown*, 441 U.S. 281, 302–303 (1979)). A legislative rule is one that “effects a substantive regulatory change to the statutory or regulatory regime.” *Mendoza v. Perez*, 754 F.3d 1002, 1006 (D.C. Cir. 2014) (quotation omitted).

~~118~~152. Agencies cannot “avoid notice and comment simply by mislabeling their substantive pronouncements.” *See Azar v. Allina Health Services*, 587 U.S. 566, 575 (2019) (courts look to “the *contents* of the agency’s action, not the agency’s self-serving *label*, when deciding whether statutory notice-and-comment demands apply” (emphasis in original)).

~~119~~153. “[A]ny contract provisions that are legislative [in character] are subject to § 553’s notice and comment requirements.” *American Hospital Ass’n v. Bowen*, 834 F.2d 1037, 1054 (D.C. Cir. 1987). CMS “may not hide behind its authority to contract in order to evade the APA.” *Id.* (quoting district court).

~~120~~154. No exception to the APA’s notice-and-comment requirement applies. The BEI is not an interpretive rule because it does not merely clarify an existing statute or regulation. Rather, the BEI creates entirely new programmatic requirements. *See Tennessee v. Dep’t of Educ.*, 104 F.4th 577, 608 (6th Cir. 2024) (legislative rules have “the force and effect of law” and are “subject to notice and comment”). The BEI is not a general statement of policy because it has binding effect through mandatory implementation

mechanics on participating providers. And it is not a rule of agency organization, procedure, or practice because it directly affects the rights and obligations of participating organizations and Medicare beneficiaries.

155. The BEI is not a benefits determination exempt from notice and comment under 5 U.S.C. § 553(a)(2). CMS itself asserts that the BEI does not involve Medicare paying for products directly. No new entitlement is created and no Medicare claim is submitted. Instead, the BEI imposes a binding regulatory framework on participating providers that governs what products they may distribute, how they must screen patients, what implementation plans they must submit for CMS approval, and what reports they must file. Such a framework is not a benefit within the meaning of 5 U.S.C. § 553(a)(2) and is not exempt from notice or comment. Reading 5 U.S.C. § 553(a)(2) to exempt the BEI from notice-and-comment would eviscerate those protections precisely when they are most needed: when CMS is adopting an unprecedented program implicating public health, federal drug law, and healthcare policy.

121.156. Section 1115A does not expressly exempt CMS from APA rulemaking requirements. Under 5 U.S.C. § 559, a subsequent statute supersedes the APA's rulemaking provisions only if it "does so expressly." An exemption is express only when Congress "has established procedures so clearly different from those required by the APA that it must have intended to displace the norm." *Asiana Airlines v. FAA*, 134 F.3d 393, 397 (D.C. Cir. 1998). Section 1115A contains no such express exemption.

122.157. CMS adopted and published a generally applicable policy with legal effect without the Federal Register publication required for substantive rules under the

APA and the Federal Register Act, 44 U.S.C. § 1505. The failure to publish in the Federal Register independently violates 5 U.S.C. § 552(a)(1). *See Appalachian Power Co. v. EPA*, 208 F.3d 1015, 1020 (D.C. Cir. 2000) (an agency “can inform those affected simply by posting its new guidance or memoranda or policy statement on its web site,” but this does not satisfy statutory publication requirements for substantive rules).

~~123.158.~~ The precedent from CMS’s own prior use of Section 1115A authority is instructive. When CMS issued an Interim Final Rule implementing Most Favored Nation (“MFN”) drug pricing using Section 1115A authority without notice-and-comment, multiple federal courts enjoined the rule for failing to satisfy the good-cause exception. *See Regeneron Pharms.*, 510 F. Supp. 3d at 29. The same principle applies here: CMS cannot use Section 1115A to avoid the APA’s core procedural protections simply by embedding a policy change in a participation agreement rather than a formal rule.

~~124.159.~~ The BEI was adopted and published without observance of procedure required by law, in violation of 5 U.S.C. § 706(2)(D).

Second Claim for Relief
THE BEI IS ARBITRARY AND CAPRICIOUS
(Violation of 5 U.S.C. § 706(2)(A))

~~125.160.~~ The plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through ~~124.159~~ as though fully set forth herein.

~~126.161.~~ The BEI is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.

~~127.162.~~ First, CMS’s decision to allow access to cannabis- and hemp-derived products to Medicare recipients, without analysis or explanation, differs from its

approach in a final rule issued only one year ago that cannabis- and hemp-derived products were ineligible for Medicare coverage. CMS has also provided no explanation for its sudden decision to allow access to substances it previously affirmed, in its published April 2025 rule, were illegal under federal law. When an agency changes course, it must provide “a reasoned explanation for disregarding facts and circumstances that underlay or were engendered by the prior policy.” *Encino Motorcars, LLC v. Navarro*, 579 U.S. 211, 222 (2016) (quoting *FCC v. Fox Television Stations, Inc.*, 556 U.S. 502, 516 (2009)). An “unexplained inconsistency” renders a changed policy arbitrary and capricious. *Children’s Hospital Ass’n of Texas v. Azar*, 933 F.3d 764, 773 (D.C. Cir. 2019). CMS quietly inserted the BEI into participation agreements without any explanation for why the prior position is no longer appropriate and has not, to date, provided any analysis for its action.

~~128.163.~~ Second, CMS entirely failed to consider important hazards that arise from this policy reversal. The agency did not address:

~~a.f.~~ the federal legal status of the products under the CSA;

~~b.g.~~ the substantial and growing peer-reviewed evidence of adverse health outcomes or risks associated with the use of cannabis- and hemp-derived THC products by an aging and vulnerable population, namely the risk of cardiovascular harm, liver injury, dangerous drug interactions with medications commonly used by older adults, cognitive harms risk, and pervasive contamination and mislabeling;

~~e.h.~~ the absence of an FDA regulatory framework for CBD;

~~d.i.~~ e.i. the near-total absence of clinical research on cannabis use in populations over 65; or

~~e.j.~~ e.j. the conflict with the FY2026 Agriculture Appropriations Act's THC limits.

Each of these failures independently renders the BEI arbitrary and capricious. *See State Farm*, 463 U.S. at 43 (agency action is arbitrary and capricious if the agency “entirely failed to consider an important aspect of the problem”).

~~129.164.~~ 130.164. Third, CMS's THC limit of 3 mg per serving directly conflicts with the 2026 Agriculture Appropriations Act's limit of 0.4 mg per container, effective November 2026. CMS's admission that it “will adjust its definition in accordance with the law” is itself an acknowledgment that the current program conflicts with enacted and unambiguous federal law. A deliberate decision to launch a program that the agency already knows will be inconsistent with federal law is arbitrary agency action.

~~130.165.~~ 131.165. Fourth, CMS has not demonstrated that the BEI satisfies the statutory prerequisites of Section 1115A, which limits testing to models for “defined populations with deficits in care leading to poor clinical outcomes or potentially avoidable expenditures.” 42 U.S.C. § 1315a(a)(1). The BEI is available to any aligned beneficiary over age 18 without a disqualifying condition. Far from targeting a defined population or reasonably limiting eligibility based on statutory criteria, the model's scope effectively encompasses nearly all Medicare beneficiaries, regardless of clinical outcomes or incurred expenditures, so long as they are aligned with an ACO REACH, EOM, or LEAD participating provider.

~~131.166.~~____ Accordingly, the BEI is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law, in violation of 5 U.S.C. § 706(2)(A).

Third Claim for Relief
THE BEI EXCEEDS CMS'S STATUTORY AUTHORITY
AND VIOLATES THE MAJOR QUESTIONS DOCTRINE
(Violation of 5 U.S.C. § 706(2)(C))

~~132.167.~~____ The plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through ~~131.166~~ as though fully set forth herein.

~~133.168.~~____ Under *West Virginia v. EPA*, 597 U.S. 697 (2022), in “extraordinary cases” where an agency asserts authority of vast economic and political significance, “the agency . . . must point to ‘clear congressional authorization’ for the power it claims.” *Id.* at 723 (quoting *Utility Air Regulatory Grp. v. EPA*, 573 U.S. 302, 324 (2014)). The major questions doctrine applies when the agency’s action is “unheralded” and represents a “transformative expansion” of its authority under vague statutory language, and the regulation is of “vast economic and political significance.” *Nebraska v. Su*, 121 F.4th 1, 14 (9th Cir. 2024).

~~134.169.~~____ CMS has acted in excess of its statutory authority under Section 1115A by creating—for the first time in history—federally sanctioned access to cannabis products and hemp-derived THC products through Innovation Center program amendments, without APA rulemaking, without clear congressional authorization, and in violation of federal law.

~~135.170.~~____ No Innovation Center precedent exists for distributing specific consumer products to beneficiaries. Innovation Center models are used to test payment methods, not to increase access to unapproved drugs.

~~136.171.~~ Congress never authorized CMS to use the Innovation Center to facilitate access to products containing substances listed as Schedule I under the CSA.

~~137.172.~~ The political and policy significance of the program, as evidenced by Administrator Oz's public statements and the Executive Order that preceded it, is considerable.

~~138.173.~~ The BEI's potential reach across multiple models covering substantial Medicare populations, the unprecedented nature of ~~CMSCMS's~~ facilitating access to any specific consumer product, and the absence of any prior Innovation Center precedent for distributing specific products to beneficiaries all confirm that this is an extraordinary assertion of authority requiring clear congressional authorization. *See Missouri v. Biden*, 112 F.4th 531, 537 (8th Cir. 2024) (applying the major questions doctrine where the government asserted "an unheralded power to regulate a significant portion of the American economy" under a long-extant statute (quoting *Util Air Regul. Grp.*, 573 U.S. at 324)).

~~139.174.~~ Under *Loper Bright Enterprises v. Raimondo*, 603 U.S. 369 (2024), the court must exercise independent judgment and not merely defer to CMS's assertion that its action falls within Section 1115A authority.

~~140.175.~~ The BEI exceeds CMS's statutory jurisdiction, authority, or limitations, in violation of 5 U.S.C. § 706(2)(C).

Fourth Claim for Relief
THE BEI IS NOT IN ACCORDANCE WITH LAW
(Violation of 5 U.S.C. § 706(2)(A))

~~141.176.~~ The plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through ~~140~~175 as though fully set forth herein.

~~142.177.~~ The BEI is “not in accordance with law” because it conflicts with controlling federal statutes.

~~143.178.~~ The BEI’s THC limits conflict with the 2026 Agriculture Appropriations Act, which sets a total THC limit of 0.4 mg per container for hemp-derived products, effective November 2026.

~~144.179.~~ The BEI conflicts with the Controlled Substances Act. It facilitates access to products that contain substances illegal under the CSA, including cannabis, delta-9 THC, and other cannabinoids.

~~145.180.~~ The FDA has only approved Epidiolex, a CBD medication, but has not approved any other hemp-derived THC products for medical use and has identified specific safety risks including liver injury, drug interactions, and other harms.

~~146.181.~~ CMS did not conduct or publish any compliance analysis for the BEI before creating and authorizing it. 90 Fed. Reg. 15,792, 15,867 (Apr. 15, 2025). See *PDK Labs., Inc. v. DEA*, 362 F.3d 786, 797-98 (D.C. Cir. 2004) (an agency must “bring its experience and expertise to bear” and evaluate the statutory status of a drug-related product when that status is unclear). In fact, a prior APA-compliant process completed less than one year prior determined that the health effects of medical marijuana, containing the same or comparable ingredients as hemp-derived cannabinoids, were not sufficient to justify use by Medicare patients.

Fifth Claim for Relief
CMS DENIED EQUAL PROTECTION

(Violation of U.S. Const. amend. V)

182. The MMJ Plaintiffs reallege and incorporate by reference the allegations contained in Paragraphs 1 through 181 as though fully set forth herein.

183. The Fifth Amendment’s equal protection guarantee, applicable to the federal government through the Due Process Clause, prohibits the government from treating similarly situated parties differently without a rational basis.

184. The BEI creates a two-track regulatory system that violates the equal protection guarantee. The MMJ Plaintiffs are companies that have complied in good faith with the federal pharmaceutical regulatory framework—investing years and over \$10 million into IND submissions, orphan drug designation, DEA registrations, CMC development, and clinical trial preparation—and are subjected to the full weight of FDA and DEA regulatory requirements. Meanwhile, the BEI permits entities that have not undertaken any of these regulatory burdens, including Charlotte’s Web and other hemp-industry stakeholders, to access a federally supported cannabinoid reimbursement pathway for the same Medicare patient populations.

185. On information and belief, CMS provided advance notice of the BEI to hemp-industry stakeholders including Charlotte’s Web, while excluding similarly situated regulated parties such as MMJ Plaintiffs from any notice of or opportunity to participate in the development of the BEI. Charlotte’s Web co-founder Jared Stanley confirmed on February 13, 2026 that the program was “internally finalized” by CMS weeks prior, without public announcement or opportunity to comment, and referred to a “briefing” when discussing the pilot program’s anticipated scope.

186. This disparate treatment of similarly situated regulated parties—those developing cannabinoid therapies for the same patient populations—was intentional and lacks any rational basis. Both the MMJ Plaintiffs and the hemp-industry stakeholders who received advance notice seek to provide cannabinoid products to Medicare beneficiaries. Yet CMS chose to inform and involve only the latter group in the BEI’s development, while deliberately excluding the former.

187. The MMJ Plaintiffs have been singled out for differential treatment as a “class of one” because they were intentionally treated differently from others similarly situated and there is no rational basis for the difference in treatment. See *Village of Willowbrook v. Olech*, 528 U.S. 562, 564 (2000) (“Our cases have recognized successful equal protection claims brought by a ‘class of one,’ where the plaintiff alleges that she has been intentionally treated differently from others similarly situated and that there is no rational basis for the difference in treatment.” (citations omitted)).

188. The government’s selective engagement with certain cannabinoid industry participants while excluding others who have undertaken greater regulatory compliance constitutes arbitrary and irrational government action.

Sixth Claim for Relief
CMS DENIED PROCEDURAL DUE PROCESS
(Violation of U.S. Const. amend. V)

189. All Plaintiffs who have asserted procedural injury reallege and incorporate by reference the allegations contained in Paragraphs 1 through 188 as though fully set forth herein.

190. The Fifth Amendment's Due Process Clause prohibits the federal government from depriving persons of liberty or property without due process of law. Procedural due process requires, at a minimum, notice and an opportunity to be heard before the government takes action that affects a party's protected interests. Substantive due process prohibits arbitrary government action that infringes on fundamental rights or destroys property interests without adequate justification.

191. All Plaintiffs who asserted the denial of their right to participate in notice-and-comment rulemaking under 5 U.S.C. § 553 suffered a procedural due process violation. CMS implemented the BEI without conducting traditional notice-and-comment rulemaking, without affording any opportunity for public participation, and without publishing the BEI in the Federal Register. The BEI took effect on April 1, 2026, just eleven days after its publication on CMS's website.

192. The Plaintiffs, as interested parties with concrete interests at stake—including the health and safety of Medicare beneficiaries, the informational interest in the administrative record, the participatory interest in shaping the regulatory process, and the competitive and economic interests of the MMJ Plaintiffs—were entitled to notice and an opportunity to participate in a rulemaking proceeding that would fundamentally alter the reimbursement landscape for cannabinoid products in the Medicare system. CMS afforded them no such opportunity.

193. The BEI also implicates substantive due process concerns by retroactively undermining the investment-backed expectations of MMJ Plaintiffs. MMJ Plaintiffs entered the federal pharmaceutical regulatory pathway in reliance on an established and

consistently applied framework: cannabinoid therapies intended for treatment of disease must proceed through FDA drug approval before becoming eligible for Medicare reimbursement. Over approximately eight years, the MMJ Plaintiffs invested over \$10 million into pharmaceutical cannabinoid development through this formal FDA regulatory pathway.

194. The BEI's creation of an alternative reimbursement channel for unapproved cannabinoid products without notice, without comment, and without any opportunity for affected parties to be heard deprives the MMJ Plaintiffs of the economic value of their regulatory compliance without any process whatsoever. This arbitrary government action, which undermines the reliance interests of parties who followed the established federal pathway in good faith, constitutes a denial of substantive due process.

VIII. PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in their favor and grant the following relief:

- a. A declaration that the BEI was adopted and published in violation of the APA's notice-and-comment requirements, 5 U.S.C. § 553, and the Federal Register publication requirements of 5 U.S.C. § 552(a)(1);
- b. A declaration that the BEI is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law under 5 U.S.C. § 706(2)(A);
- c. A declaration that the BEI exceeds CMS's statutory authority under Section 1115A and is in excess of statutory jurisdiction, authority, or limitations under 5 U.S.C. § 706(2)(C);

- d. A declaration that the BEI violates the Fifth Amendment's equal protection guarantee by intentionally treating similarly situated regulated parties differently without any rational basis;
- e. A declaration that the BEI violates the Fifth Amendment's Due Process Clause by depriving Plaintiffs of procedural due process and by arbitrarily undermining the substantive due process rights of the MMJ Plaintiffs;
- ~~d.f.~~ An order vacating and setting aside the BEI;
- e.g. A permanent injunction prohibiting Defendants from implementing, applying, or enforcing the BEI;
- ~~f.h.~~ An award of costs and attorneys' fees as permitted by law; and
- ~~g.i.~~ Such other and further relief as the Court deems just and proper.

Date: ~~March 30~~ April 13, 2026

Respectfully submitted,

 /s/Connor W. Mighell

~~Patrick Kenneally*~~

~~IL Bar #6286573~~

Connor W. Mighell

TX Bar #24110107

D.D.C. Bar ID #TX0032

BURKE LAW GROUP, PLLC

1000 Main Street, Suite 2300

Houston, Texas 77002

Telephone: (832) 987-2214

Fax: (832) 793-0045

connor.mighell@burkegroup.law

Ilya Shapiro*
DC Bar #489100
BURKE LAW GROUP, PLLC
2001 L Street NW, Suite 500
Washington, D.C. 20036
ilya.shapiro@burkegroup.law
*Admission Pending

Patrick Kenneally**
IL Bar #6286573
BURKE LAW GROUP, PLLC
205 N Michigan Avenue, Suite 810
Chicago, Illinois 60601
patrick.kenneally@burkegroup.law
~~connor.mitchell@burkegroup.law~~
*Admission Pending **Pro Hac Vice
Forthcoming

Attorneys for Plaintiffs

CERTIFICATE OF SERVICE

I hereby certify that, on ~~March 30~~April 13, 2026, I electronically filed the foregoing First Amended Complaint for Declaratory and Injunctive Relief, and its attendant Exhibits, and this Certificate of Service, along with an attached Corporate Disclosure Statement, ~~and this Certificate of Service~~ with the Clerk of Court for the United States District Court for the District of Columbia by using the CM/ECF system. ~~In accordance with Fed. R. Civ. P. 4, I am causing to be served one true and correct copy of the filed documents via certified mail, along with a summons, on each of the following persons:~~

~~ROBERT F. KENNEDY, JR.
in his official capacity as Secretary of Health and
Human Services
200 Independence Avenue, S.W.
Washington, DC 20201~~

~~THE UNITED STATES DEPARTMENT OF
HEALTH AND HUMAN SERVICES
200 Independence Avenue, S.W.
Washington, DC 20201~~

~~MEHMET OZ, M.D.
in his official capacity as Administrator of
the Centers for Medicare & Medicaid
Services
7500 Security Boulevard
Baltimore, MD 21244-1850~~

~~THE CENTERS FOR MEDICARE &
MEDICAID SERVICES
7500 Security Boulevard
Baltimore, MD 21244-1850~~

~~JEANINE FERRIS PIRRO
in her official capacity as U.S. Attorney for
the District of Columbia
601 D Street, N.W.
Washington, DC 20579~~

~~PAMELA BONDI~~
~~in her official capacity as Attorney General~~
~~of the United States~~
~~950 Pennsylvania Avenue, N.W.~~
~~Washington, DC 20530~~

/s/Connor W. Mighell

Connor W. Mighell

EXHIBIT B

UNITED STATES DEPARTMENT OF JUSTICE

Drug Enforcement Administration

In the Matter of

**Schedules of Controlled Substances:
Proposed Rescheduling of Marijuana****DEA Docket No. 1362
Hearing Docket No. 24-44****ORDER REGARDING STANDING, SCOPE, AND PREHEARING PROCEDURES****On Standing**

The United States Department of Justice (DOJ) through the Drug Enforcement Administration (DEA or Agency) has initiated rulemaking proceedings to reschedule marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. *Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 Fed. Reg. 44597, 44597 (2024). In another order (General Notice of Hearing or GNoH) published in the Federal Register, the DEA Administrator (the Administrator) subsequently determined that hearing procedures are appropriate and fixed a December 2, 2024 hearing commencement date. *Schedules of Controlled Substances: Rescheduling of Marijuana*, 89 Fed. Reg. 70148, 70148-49. Subsequent correspondence by the Administrator listed twenty-five (25) designated participants (Designated Participants or DPs).¹ Concluding that more information about the DPs was a necessary prerequisite to competently conducting a fair hearing,² I tasked the Government and the DPs with furnishing additional information by November 12, 2024 in an order dated October 31, 2024 (Preliminary Order or Prelim. Ord.). Prelim. Ord. at 3. Most of the DPs timely complied with this directive,³ including the instruction to supply information related to their respective

¹ The American Academy of Hospice and Palliative Medicine withdrew its request to participate in a document filed on November 8, 2024, as did the American College of Occupational and Environmental Medicine on November 12, 2024. Similarly, the National Sheriffs' Association has signaled its intent to submit a hearing waiver. These DPs are no longer parties to this proceeding and no standing recommendations have been made regarding them.

² 5 U.S.C. § 556(c)(5); 21 C.F.R. § 1316.52(c), (g), (h).

³ The International Academy on the Science and Impact of Cannabis (IASIC) and Saint Michael's College (SMC) did not respond to the Preliminary Order. However, Ari Kirshenbaum, PhD is affiliated with SMC, and Kenneth Finn, M.D. is affiliated with IASIC. Neither of these DPs sought to either speak on behalf of these institutions or made any assertions relative to associational standing based on their respective affiliations. IASIC and SMC are no longer parties to this proceeding and this order contains no standing recommendations with respect to them.

arguments for standing under the Administrative Procedure Act (APA) and CSA and its implementing regulations.

The non-legislative transfer of controlled substances from one schedule to another by the DEA⁴ is authorized only “after opportunity for a hearing pursuant to the rulemaking procedures” set forth in the Administrative Procedure Act. 21 U.S.C. § 811(a). Both the Agency’s NPRM and the GNoH expressly invited “interested persons” seeking participation in this potential scheduling action to file applicable requests within specified deadlines. 89 Fed. Reg. at 44598; 89 Fed. Reg. at 70148-79; 21 U.S.C. § 811(a); 21 C.F.R. § 1308.44(a), (b).

The APA provides that “[s]o far as the orderly conduct of public business permits, an interested person may appear before an agency or [one of its ALJs]⁵ for the presentation, adjustment, or determination of an issue, request, or controversy in a proceeding. . . in connection with an agency function.”⁶ 5 U.S.C. § 555(b). When agencies are “charged with administering congressional statutes[, b]oth their power to act and how they are to act is authoritatively prescribed by Congress[.]” *City of Arlington, Tex. v. FCC*, 569 U.S. 290, 297 (2013); *see American Trucking Associations, Inc. v. United States*, 627 F.2d 1313, 1320 (D.C. Cir. 1980) (“When an agency exercises authority expressly delegated to it by Congress it is at the zenith of its powers.”). However, even when operating “at the zenith of its powers,”⁷ the agency is constrained to act within the parameters of the APA, the CSA, and any related regulations, and must refrain from actions which are arbitrary, capricious, and demonstrate an abuse of its Congressionally-authorized discretion. *American Trucking*, 627 F.2d at 1316, 1320-21.

Prior to the commencement of a hearing on the rescheduling of a controlled substance, a threshold determination must be made regarding the proper cadre of hearing participants. Standing to appear in an APA agency proceeding can differ markedly from the rigid standing

⁴ The Attorney General’s CSA authority has been delegated to the DEA Administrator by regulation. 28 C.F.R. § 0.100.

⁵ 5 U.S.C. § 556(b)(3). The APA prescribes only three types of officials that may preside over an agency’s evidentiary hearing: the agency head; one or more members of a body that comprises the agency; or an ALJ appointed in accordance with 5 U.S.C. § 3105. *Id.* at § 556(b). In the Department of Justice, the DEA is organizationally structured to exclusively utilize the third option. The same is true of the Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) and the Bureau of Prisons (BOP). Neither the Attorney General nor the DEA Administrator preside over hearings, and neither agency has been equipped by Congress with a body such as the National Labor Relations Board, the Securities and Exchange Commission, or the National Transportation Safety Board to adjudicate factually contested cases.

⁶ It is beyond argument that the scheduling, rescheduling, and descheduling of controlled substances is an agency function assigned to the DEA and specifically authorized by Congress. 21 U.S.C. § 811(a).

⁷ *American Trucking*, 627 F.2d at 1320.

requirements incumbent on those seeking relief in the federal courts. *Fund Democracy, LLC v. SEC*, 278 F.3d 21, 27 (D.C. Cir. 2002) (“Because agencies are not constrained by Article III, they may permit persons to intervene in the agency proceedings who would not have standing to seek judicial review.”). To ensure proper separation of powers from the political branches, Article III, section 2 of the Constitution cabins the jurisdiction of the federal courts to cases and controversies. As such, those appearing before the courts must possess the requisite elements of Article III standing, *to wit*, a demonstration of a particularized injury that is: (1) actual or imminent; (2) caused by, or fairly traceable to an act that the litigant challenges in the litigation; and (3) redressable by the court. *FDA v. Alliance for Hippocratic Medicine*, 602 U.S. 367, 380-81 (2024); *Gettman v. DEA*, 290 F.3d 430, 432-33 (D.C. Cir. 2002). While this Article III standing threshold is present for a party seeking to challenge an action in the courts (even a person challenging an agency action under the APA),⁸ it is not perforce coextensive with the relaxed level of standing required to appear in an agency administrative proceeding. *Gettman*, 290 F.3d at 433-34. The constraints of Article III standing rest “on considerations about the proper—and properly limited—role of the courts in a democratic society,” *Envirocare of Utah, Inc. v. NRC*, 194 F.3d 72, 75 (D.C. Cir. 1999) (quoting *Warth v. Seldin*, 422 U.S. 490, 498 (1975)), whereas federal administrative agencies are not likewise restricted. *See, e.g., New World Radio, Inc. v. FCC*, 294 F.3d 164, 172 (D.C. Cir. 2002); *Envirocare*, 194 F.3d at 74.

A lower standing threshold is often sensible in view of the potential public policy implications of many agency actions, and the application of this less rigorous procedural bar has been recognized, reviewed, and affirmed by the courts. *See, e.g., Gettman*, 290 F.3d at 433-34; *Animal Legal Defense Fund, Inc. v. Vilsack*, 237 F.Supp.3d 15, 21-22 (D.D.C. 2017). Further, as discussed, *supra*, because agencies are not limited in this way by Article III, they may, in their discretion, permit persons to intervene in their proceedings who would not otherwise have standing to seek judicial review of the agency action ultimately taken. *See, e.g., Fund Democracy*, 278 F.3d at 27. However, this is not to say that everyone must be inexorably welcomed to appear before every agency on every issue that touches widely on society or tugs at the heartstrings. The APA limits the ability to appear before an agency to “interested persons,” which Congress further qualified by the phrase “[s]o far as the orderly conduct of public business permits” 5 U.S.C. § 555(b). Regrettably, the legislative histories of the APA and the CSA

⁸ 5 U.S.C. § 702.

are of negligible assistance when narrowing the definition of who properly rests within the parameters of an “interested person” as it pertains to an administrative scheduling hearing before the DEA.

To be sure, agency adjudications (including DEA adjudications) can and do have their own standing requirements that are baked into the process by the APA, their enabling statutes, and their implementing regulations. It follows then, that leave to appear before an agency in its APA adjudications, that is, discernment of who is an “interested person” takes on a different form based on the fixed navigation points, including (and especially) the agency’s regulations.

“[T]he starting point for an APA standing determination for a litigant before an administrative agency is not Article III, but is the statute that confers standing before that agency.” *Ritchie v. Simpson*, 170 F.3d 1092, 1095 (Fed. Cir. 1999). The courts will generally examine an agency’s enabling statute and implementing regulations to discern the intended, reasonable breadth of those with APA standing. *See, e.g., Ritchie*, 170 F.3d at 1095 (The court interpreted the standing language in the Lanham Act more broadly than did the agency.); *Koniag, Inc. v. Andrus*, 580 F.2d 601, 607-88 (D.C. Cir. 1978) (The court held that Alaska Statehood Act’s attendant regulations indicated a broader class of interested parties than had been interpreted by the Secretary of the Interior.). Thus, the proper inquiry is centered around an interpretation of the statute(s) the agency administers. This analysis involves an examination of existing agency precedent, the legislative history of the statute(s), and/or subsequent regulations which the agencies have sought to carve out the proper scope of the relevant statute(s). *Ritchie*, 170 F.3d at 1095.

Turning to the present case, the Supreme Court has characterized the primary objectives of the CSA as aiming “to conquer drug abuse and to control the legitimate and illegitimate traffic in controlled substances” by protecting against the diversion of drugs from legitimate channels. *Gonzales v. Raich*, 545 U.S. 1, 12-13 (2005). Further, the ultimate goal of protecting the public is served by the CSA’s creation of “a comprehensive, closed regulatory regime criminalizing the unauthorized manufacture, distribution, dispensing, and possession of substances in any of the Act’s five schedules.” *Gonzales v. Oregon*, 546 U.S. 243, 250 (2006). In promulgating controls against diversion through the passage of the CSA, Congress manifested its intent to protect the public from the siphoning of dangerous and fungible controlled substances from the “closed regulatory” system. *Id.*

In delimiting the correct scope of public participation in agency proceedings, the courts have acknowledged that agencies possess broad discretion to limit the participation of interested individuals and organizations. *Nichols v. Board of Trustees of the Asbestos Workers Local 24 Pension Plan*, 835 F.2d 881, 897-99 (D.C. Cir. 1987); *Vilsack*, 237 F.Supp.3d at 21-22. Those who qualify as “interested persons” are entitled to participate in the hearing process⁹ so long as their involvement does not compromise the “orderly conduct of public business.” 21 C.F.R. § 1316.52; 5 U.S.C. § 555(b). This right to participate in the hearing process is not “blindly absolute” and considerations regarding the logistics of the hearing must be factored into the conferral of standing.¹⁰ *Easton Utilities*, 424 F.2d at 852. However, in an agency’s exercise of that discretion to limit participation, the courts will not countenance participation denial policies that are unreasonably overbroad or otherwise arbitrary, or merely based on assertions that interventions are generally burdensome or dilatory.¹¹ *Nichols*, 835 F.2d at 897.

Regrettably, the CSA, its legislative history, and its attendant regulations offer little in terms of guidance on the issue of who is an “interested party” in the context of controlled substance scheduling proceedings. The CSA regulations define the term “interested person” as “mean[ing] any person adversely affected or aggrieved by any rule or proposed rule issuable pursuant to [the scheduling provisions set forth in] 21 U.S.C. § 811.” 21 C.F.R. § 1300.01(b); *see, e.g., Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV*, 78 Fed. Reg. 26701, 26703 (2013). It is noteworthy that, “[t]he phrase ‘person adversely affected or aggrieved’ is a term of art used in many statutes to designate those who have standing to challenge or appeal an agency decision, within the agency or before the courts.” *Dir., Office of Workers’ Comp. Programs, Dep’t of Labor v. Newport News Shipbuilding & Dry Dock*

⁹ The APA intervention right as set forth in 5 U.S.C. § 555(b) “is universally understood to establish” participation rights for interested persons in “on-going agency proceeding[s].” *Block v. SEC*, 50 F.3d 1078, 1085 (D.C. Cir. 1995).

¹⁰ Specifically, the “time of appearance, the status of the proceedings, [and] the administrative avenues established by other statutes and agency rules for participation” should be afforded consideration when fashioning rules of procedure and participation standards in agency proceedings. *Easton Utilities Commission v. Atomic Energy Commission*, 424 F.2d 847, 852 (D.C. Cir. 1970). Further, if the parties participating in an agency proceeding adequately represent the public interest and the interests of the petitioners, limiting the number of parties otherwise entitled to participate may be appropriate to avoid duplicative presentations. *See, e.g., City of San Antonio v. Civil Aeronautics Board*, 374 F.2d 326, 332-333 (D.C. Cir. 1967).

¹¹ A reviewing court’s confidence in an agency’s decision to limit public participation may be further bolstered by an agency’s efforts to adhere to its own rules and procedures as set forth in their governing statutes and implementing regulations. *See, e.g., Easton Utilities*, 424 F.2d at 851 (“We find nothing whatsoever in the record which in any way challenges the reasonableness, the necessity for, or the propriety of this Commission rule. We are confronted only with the Commission’s utilization of this rule under the factual situation of this case.”).

Company, 514 U.S. 122, 126 (1995) (“person adversely affected or aggrieved” interpreted as sufficient to fulfill Article III standing requirements under the APA). By cabining its own scope of the term “interested persons” to include only “person[s] adversely affected or aggrieved by any rule or proposed rule” it is reasonable to conclude that the Agency regulation drafters intended a narrow, somewhat heightened interpretation of those permitted to appear in scheduling actions. 21 C.F.R. § 1300.01(b). There can be little doubt that the stewards of the Agency, at the time the regulation was promulgated, elected to seek input from a potential rules detractors/critics/opponents; in short, those who could demonstrate that they would be “adversely affected or aggrieved”¹² should the proposed rule become law. Stated differently, the Agency was not keen on producing an echo chamber of supportive comments to reinforce its intended result, but focused on hearing from those who feared the consequences of the proposed rule. A restricted standing interpretation is further buttressed by the highly technical nature of the facts to be adduced and analysis employed at a scheduling hearing. 21 U.S.C. § 811(b)-(f). Further, the NPRM, citing 21 C.F.R. § 1308.42, dictates that “the purpose of a hearing would be to receive factual evidence and expert opinion regarding whether marijuana should be transferred to schedule III of the list of controlled substances.” 89 Fed. Reg. at 44599 (cleaned up).

Beyond the stark definition of “interested party”¹³ employed in its regulations, the DEA has not promulgated additional regulations regarding the parameters that could assist in delineating the boundaries of who may appear at its internal proceedings. It is axiomatic that an ALJ may not entertain a challenge to its agency’s regulations,¹⁴ and the DEA has certainly not been bashful about reminding its judges that “[o]nce the [A]gency has ruled on a given matter ... it is not open to reargument by the [ALJ].” *Clair L. Pettinger, M.D.*, 78 Fed. Reg. 61592, 61600 n.13 (2013). Among its published precedential decisions, the Agency has insisted that those seeking APA standing as an “interested person” must, in the hearing request, sufficiently articulate a persuasive basis for their standing. *See, e.g., Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV*, 78 Fed. Reg. at 26703 (The Agency denied a hearing request filed by a commenter “[b]ecause the commenter failed to provide sufficient information

¹² 21 C.F.R. § 1300.01(b).

¹³ *Id.*

¹⁴ *CropLife America v. EPA*, 329 F.3d 876, 882 (D.C. Cir. 2003); *Iran Air v. Kugelman*, 996 F.2d 1253, 1260 (D.C. Cir. 1993) (“It is commonly recognized that ALJs are entirely subject to the agency on matters of law.”) (internal quotation marks omitted); *Oestereich v. Selective Service System Local Bd. No. 11*, 393 U.S. 233, 242 (1968) (Harlan, J., concurring).

to demonstrate that he meets the definition of “interested person” as set forth in the regulations”).

Relaxed is not synonymous with nonexistent, and an *interesting* person (someone the ALJ—or the Administrator—may subjectively believe possesses the potential for objectively meaningful and insightful input) is likewise not synonymous with an “interested person” (a person entitled to request and participate in an APA hearing before DEA involving the scheduling of controlled substances). The potentially relaxed requirements of APA standing notwithstanding, the Agency has a right to exercise some level of control over those who appear in its proceedings,¹⁵ and a concomitant right to expect its ALJs to adhere to its regulations and its precedents.¹⁶ Contrariwise, that the regulations authorize a narrow segment of the population to *request* and participate in a scheduling hearing (in the case of the CSA regulations, a very narrow segment) does not perforce preclude the Agency (or this tribunal) from hearing and considering viewpoints from those unable to shoulder the burden of establishing standing. Stated differently, the Agency may be at liberty to conclude that its proposed action could benefit somewhat by listening to at least some of those who might support its proposed rule (*i.e.*, the echo chamber). Logically, however, the applicable CSA regulations were clearly drafted in a manner that the views of those participants who demonstrate APA standing (within the bounds of reasonable discretion) should be afforded a stronger voice or more weight in the ultimate decision. A contrary conclusion would arguably eviscerate the purpose for the regulation’s standing standards.

With those parameters in mind, a review of available precedent, in the courts and inside the Agency, reveals some considerations that can inform an equitable determination here on the issue of APA standing in scheduling matters before the DEA.¹⁷ Several of the Agency’s

¹⁵ *City of San Antonio*, 374 F.2d at 329 (“No principle [of] administrative law is more firmly established than that of agency control of its own calendar.”).

¹⁶ *Pettinger*, 78 Fed. Reg. at 61600 n.13.

¹⁷ Agencies, including the DEA, are empowered to issue “interpretative rules, general statements of policy, or rules of agency organization, procedure, or practice” without engaging in the formal notice and comment or hearing procedures set elsewhere in the APA. 5 U.S.C. § 553. It is worth noting, that when presented with the opportunity to adjust its stance on the definition of “interested persons,” the Agency has declined to do so and has demonstrated some level of consistency (albeit sparse in analysis) in fashioning its own view of who is “adversely affected or aggrieved.” See *Consolidation, Elimination, and Clarification of Various Regulations*, 62 Fed. Reg. 13938, 13942 (1997); *Consolidation, Elimination, and Clarification of Various Regulations*, 61 Fed. Reg. 8503, 8508 (1996). In its response to a commenter who sought to amend the definition of “interested person” in proceedings involving the importation of controlled substances, DEA concluded that the definition of “interested person” was “sufficiently

previous scheduling endeavors pursuant to 21 U.S.C. § 811 failed to garner hearing requests,¹⁸ however, there are some analytical navigation points, including measures some other federal agencies have taken (with varying levels of success on review in the courts) to assist in shaping the appropriate contours of APA standing in scheduling actions at DEA. To that end, the issue of whether the DPs have alleged sufficient APA standing to participate in this rescheduling hearing should be assessed by balancing the following four considerations (the Standing Considerations or SCs): (1) whether the requestor possesses a substantial interest in the proceedings (*to wit*, would be adversely affected or aggrieved if the proposed rule were promulgated) and/or otherwise satisfies the requirements of Article III standing; (2) whether the request complies with clear, reasonable procedural agency directives; (3) whether the request exceeds the scope of the NPRM; and (4) whether, in the discretion of the Agency, the participation of a particular requestor would meaningfully assist the decisionmaking and/or whether the interests of multiple requestors are amenable to consolidation or exclusion to accommodate orderly proceedings.

APA Standing Consideration One: Whether the DP/Requestor Possesses a Substantial Interest in the Outcome of the Proceedings (*to wit*, would be adversely affected or aggrieved if the proposed rule were promulgated) **and/or Otherwise Satisfies the Requirements of Article III Standing**. Beyond a doubt, by the plain language of the CSA and its implementing regulations, this is the most powerful and issue-dispositive factor. *Ritchie*, 170 F.3d at 1095; *Koniag*, 580 F.2d at 608. Where a requestor demonstrates a substantial interest in the outcome of an administrative proceeding (*to wit*, aggrievement or adverse affect from promulgation of the NPRM), that requestor should ordinarily have a right to participate. *See BPI v. Atomic Energy Commission*, 502 F.2d 424, 427 (D.C. Cir. 1974). Likewise, a demonstration that a requestor would be entitled, when the adjudication is final, to judicial review of an agency action (*i.e.*, the requestor has proffered enough to satisfy the requirements of Article III standing) will ordinarily

precise to fulfill [its] intended purpose.” *Consolidation, Elimination, and Clarification of Various Regulations*, 62 Fed. Reg. at 13938.

¹⁸ See, e.g., *Schedules of Controlled Substances: Removal of Naloxegol from Control*, 80 Fed. Reg. 3468, 3469 (2015); *Schedules of Controlled Substances: Placement of Brivaracetam into Schedule V*, 82 Fed. Reg. 13067, 13067 (2017); *Schedules of Controlled Substances: Placement of Solriamfetol in Schedule IV*, 85 Fed. Reg. 643, 643 (2020).

qualify that person as an “interested person” who normally should be permitted to be heard in an administrative proceeding. *Nichols*, 835 F.2d at 896; *Vilsack*, 237 F.Supp.3d at 21; *but see Envirocare*, 194 F.3d at 75.¹⁹ *Envirocare* notwithstanding, granting APA standing to a requestor who, in its request and attendant filings, has averred sufficient facts to demonstrate that it would have Article III standing to challenge a DEA scheduling action on appeal in federal court is the analytically superior option. Further, the legislative history of the Controlled Substances Act illuminates that requestors that possess sufficient interest in engaging with the dual goals of the Act (to protect the public’s health and ensure the closed regulatory system of controlled substances) will likely have a strong case for establishing their participation rights.²⁰ In view of the DEA’s narrow definition of “interested person” under its regulations,²¹ this aspect of Standing Consideration One, must generally be afforded controlling weight. That is to say, the Agency’s insistence that some demonstration that the person seeking a ticket to appear in its proceedings articulate a demonstration that the interested person will be “adversely affected or aggrieved by any ... proposed rule,” constitutes a condition precedent for APA standing is not unreasonable. Others who are interested, but do not qualify as “interested persons” under the regulations, may not necessarily be foreclosed from a voice in the process, and had the opportunity to file written comments. 5 U.S.C. § 553(c); 21 C.F.R. § 1308.44(g); 89 Fed. Reg. at 44598. That said, a rational, supported application of the APA qualifier language that interested persons may appear “[s]o far as the orderly conduct of public business permits” can trump standing in APA proceedings. 5 U.S.C. § 555(b); *Vilsack*, 237 F.Supp.3d at 22.

APA Standing Consideration Two: Whether the Request Complies with Clear, Reasonable Procedural Agency Directives. While the Consideration One requirements

¹⁹ The *Envirocare* court relied liberally on *Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc.*, 467 U.S. 837, 84-42 (1984), which has been subsequently reversed by *Loper Bright Enterprises v. Raimondo*, 144 S.Ct. 2244, 2273 (2024).

²⁰ The text and legislative history of the CSA appears bereft of any indication that it was promulgated to protect the employment interests of a registrant. *See, e.g., Bonds v. Tandy*, 457 F.3d 409, 415-16 (5th Cir. 2006) (“a pharmacist’s interest in employment is not arguably within the zone of interests protected by the statute. Accordingly, [the pharmacist] is not a ‘person aggrieved’ under [the CSA]”). *See also, Alliance for Hippocratic Medicine*, 602 U.S. at 385-87 (finding that doctors lacked Article III standing when attempting to challenge the regulation of a drug they did not prescribe or use themselves).

²¹ 21 C.F.R. § 1300.01(b).

are of paramount importance, there are also factors that can potentially further narrow participation, and satisfaction of Consideration One is by no means a *carte blanche* to entry into the proceedings. The courts have upheld an agency's requestor denials based on the failure of the requestor to abide the agency's reasonable procedural requirements. *BPI*, 502 F.2d at 427-29 (Participation denial upheld where requestor failed to fulfill agency requirement to specify the basis for the requested participation.); *Easton Utilities*, 424 F.2d at 850 (Participation denial upheld where requestor submitted petition beyond regulatory deadlines and after hearings had been conducted.). In *Easton Utilities* the court held:

We do not believe that the affirmative grant of a right to appear is blindly absolute, without regard to time of appearance, the status of the proceedings, the administrative avenues established by other statutes and agency rules for participation, or most importantly, as 'the orderly conduct of public business permits.'

424 F.2d at 852. As discussed, *supra*, the DEA currently has no regulations specifically directed towards hearing requestor requirements beyond the bare "interested person" limitation and definition in the CSA and its implementing regulations. Accordingly, resort must be had to the relatively sparse collection of (analytically barren) final orders addressing participation requests, the APA and its interpretive precedent, and the terms of the NPRM. Hearing requests have been rejected by DEA in the face of an individual's failure to comply with procedural directives. *See Placement of Controlled Substances: Placement of Cathinone and 2,5-Dimethoxy-4-ethylamphetamine Into Schedule I*, 58 Fed. Reg. 4316, 4316 (1993) (denying a request for hearing because it was not filed in accordance with the directives as established by the regulation); *Schedules of Controlled Substances: Placement of ()cis-4-methylaminorex into Schedule I*, 54 Fed. Reg. 14799, 14799 (1989) (same). The Agency has held that a requestor must supply some specific information regarding his/her/its theory of standing under the "interested person" standard. *See Schedules of Controlled Substances: Placement of Lacosamide into Schedule V*, 74 Fed. Reg. 23789, 23789 (2009). Similarly, the Agency has interpreted its regulations as requiring that "any person requesting a hearing *must state with particularity* his interest in the proceeding." *Id.* (internal quotations omitted) (emphasis supplied). Inasmuch as the Agency has historically demanded a narrow, individualized,

statement of a requestor's adverse outcome or aggrievance to merit participation in the scheduling hearing process, the failure to provide one militates against participation.

The NPRM in this case has similarly required that hearing requests in this rescheduling action must: "(1) state with particularity the interest of the person in the proceeding; (2) state with particularity the objections or issues concerning which the person desires to be heard; and (3) state briefly the position of the person regarding the objections or issues." 89 Fed. Reg. at 44598. In this regard, it is not the place of the ALJ to conduct extra-record research or engage in broad conjecture about the potential benefits of each requestor. These hearing request requirements are not optional, and the evaluation can only be made on the four corners of the Designated Participants' responses to the Preliminary Order (Preliminary Order Responses or PORs).

APA Standing Consideration Three: Whether the Request Exceeds the Scope of the NPRM. Consideration Three presents an additional limitation. As discussed, *supra*, the Agency is authorized to act within the parameters set forth by Congress. In *Olsen v. DEA*, 776 F.2d 267, 267 (11th Cir. 1985), the court upheld a participation denial by members of the Ethiopian Zion Coptic Church (the Church) in pursuit the Church's efforts to acquire a religious exemption for its members to use marijuana. The Church petitioned for rescheduling under 21 U.S.C. § 811, and the court held that an effort to seek a religious exemption fell outside the (scheduling) scope of § 811. *Id.* Thus, a requestor who seeks participation to acquire relief that is outside the scope of rescheduling (*e.g.*, descheduling, decriminalization, etc.) can properly be denied on that basis alone.

APA Standing Consideration Four: Whether, in the Discretion of the Agency, the Participation of a Particular Requestor Would Meaningfully Assist the Decisionmaking and/or Whether the Interests of Multiple Requestors are Amenable to Consolidation or Exclusion to Accommodate Orderly Proceedings. The DEA Administrator has been charged by Congress in exercising discretion in assigning schedule placement for a plethora of potentially dangerous, addictive medications. 28 C.F.R. § 0.100; 21 U.S.C. § 811. It is imperative that she and her Agency possess the latitude to regulate participation

to include requestors who can render meaningful assistance to her determination, and to exclude those who are not objectively in a position to do so. *Cf., Nichols*, 835 F.2d at 897 (agencies should have discretion to exclude requestors who would fail to assist the agency’s decisionmaking); *Cities of Statesville v. Atomic Energy Commission*, 441 F.2d 962, 977 (D.C. Cir. 1969) (agencies should have broad discretion to determine the sources reasonably required to supply the assistance it needs in vindicating the public interest). Thus, if there is a requestor who possesses information that the DEA Administrator deems keenly important to rendering a scheduling determination that is legally correct and consistent with public interest within the meaning of the CSA, she must be afforded a healthy level of discretion to grant participation. This Consideration by no means creates APA standing, but on a pragmatic level, the Administrator, through her Government counsel, are permitted to call witnesses at a contested hearing, and her inclination to hear from a wider spectrum of society is entitled to a level of deference.

Reasonable, pragmatic considerations on the part of the agency are also valid. Even parties with a solid, substantial interest in the proceedings (Consideration One) are not immune from logistical concerns. In upholding the authority of an agency to limit and consolidate an unwieldy number of requestors, the D.C. Circuit rendered the following holding:

Practical problems of calendar administration confront an agency whenever related applications are pending at the same time. Consolidation, scope of the inquiry, and similar questions are housekeeping details addressed to the discretion of the agency and, due process or statutory considerations aside, are no concern of the courts.

City of San Antonio, 374 F.2d at 329. An agency may take reasonable steps to avoid obstructing or overburdening the proceedings, or to avoid unduly broadening the issues considered. *Nichols*, 835 F.2d at 897. Thus, the DEA is not required to accommodate a cast of thousands in conducting its scheduling hearings, and may, where appropriate, prescribe reasonable limits based on size and common interests of the requestors.²² As

²² The court went on to explain in *City of San Antonio* that while true “that a party with a substantial interest in the proceeding has a right to intervene . . . But a finding of substantial interest must be related to a particular proceeding. And a proceeding must be manageable if it is going to be conducted in such a manner as will be conducive to the proper dispatch of business and to the ends of justice.” *Id.* at 332 (internal citation and punctuation omitted); *see also, Cities of Statesville*, 441 F.2d at 977 (*en banc*) (Even in the face of a substantial interest on the part of a requestor “an agency should be accorded broad discretion in establishing and applying rules for public participation,

discussed, *supra*, the APA qualifies the appearance rights of participants with the language “[s]o far as the orderly conduct of business permits,”²³ so long as the discretion is exercised rationally. *Vilsack*, 237 F.Supp.3d at 24. As a result, the consolidation of parties may be a necessary function of the administrative hearing process. When resolving procedural issues, such as consolidation, that are not specifically addressed by the relevant authorities (the APA, the CSA, and their implementing regulations), the Federal Rules of Civil Procedure provide useful guidance.²⁴ Rule 42(a) of the Federal Rules of Civil Procedure authorizes the consolidation of actions that “involve a common question of law or fact” by permitting the judge to “join for hearing . . . any or all matters at issue in the actions;” “consolidate the actions; or” “issue any other orders to avoid unnecessary cost or delay.” The trial judge²⁵ is afforded “large discretion in the matter [of consolidation] which will not be interfered with except in a clear case of abuse . . .” *Davis v. Yellow Cab Co.*, 220 F.2d 790, 791 (5th Cir. 1955). There is no magic quantum of common facts (or law) and likewise no disparity as to which party’s evidence should weigh in (or be omitted from) the analysis. Under the like considerations that support case consolidation, when requestors present overlapping or duplicative interests and proposed testimony, this may pose a powerful and persuasive reason to “avoid unnecessary cost or delay” through either limitation of viewpoints, or even consolidation of parties. Fed. R. Civ. P. 42(a). “Participation in agency [APA rulemaking] proceedings does not necessarily entail full-fledged party intervention. Rather, agencies have ample authority to shape the manner in which intervenors will participate.” *Vilsack*, 237 F.Supp.3d at 24 (quotation marks and internal citation omitted).

As discussed, *supra*, this tribunal has not been furnished with copies of the responses filed by the DPs with the Administrator. Accordingly, the APA standing determinations set forth

including how many are reasonably required to give the agency the assistance it needs in vindicating the public interest”) (internal punctuation and quotation marks omitted).

²³ 5 U.S.C. § 555(b).

²⁴ *But see*, *Roy E. Berkowitz, M.D.*, 74 Fed. Reg. 36758, 36759 (2009) (noting that DEA administrative hearings are not bound by the Federal Rules of Civil Procedure); *Kamir Garcés-Mejías, M.D.*, 72 Fed. Reg. 54931, 54932 (2007) (same).

²⁵ The Supreme Court, in reviewing the boundaries of immunity relative to an agency ALJ, has held that “[t]here can be little doubt that the role of the modern federal . . . administrative law judge within [the framework of the APA] is ‘functionally comparable’ to that of a [U.S. District Court] judge.” *Butz v. Economou*, 438 U.S. 478, 513 (1978). While the scope of this functional equivalence is not without limitations, it is correctly applied to the issuance of procedural rulings within the context of an APA administrative hearing.

herein are rendered based exclusively on an evaluation of the Preliminary Order Responses provided by the Designated Participants. The respective determinations have been made light of the Four APA Standing Considerations (SCs One-Four) discussed above, and (in no particular order) will be herein evaluated *in seriatim*.

Cannabis Bioscience International Holdings (CBIH)

In its POR, CBIH describes itself as “a corporation devoted to research and development in healthcare, particularly in cannabinoid-based formulations aimed at advancing medical treatment options for serious diseases.” CBIH POR at 1. This requestor elaborates that its “mission centers on leveraging the therapeutic potential of cannabis-derived compounds to enhance patient care and broaden the scientific understanding of cannabis in medical applications.” *Id.*

As its basis for APA standing, CBIH represents that it anticipates that the placement of marijuana in Schedule III will “facilitate significant advancements in medical research, patient care, and regulatory clarity, directly impacting [CBIH’s] ability to conduct cannabinoid-based research” and that the proposed rescheduling would be “integral to CBIH’s mission to provide safe, accessible, and evidence-based cannabis-derived treatments, which would be otherwise constrained under the existing Schedule I classification.” *Id.* at 2. Further, CBIH represents that rescheduling would advance its intellectual property goals, and specifically catalogues a list of recently-filed patent applications. *Id.*

The POR regarding this requestor does not specify how it would be “adversely affected or aggrieved” by the *promulgation* of the proposed rescheduling rule, but rather, explains that its research and pecuniary interests would be advanced by rescheduling. This is a requestor who aspires to pursue the purported benefits of marijuana for commercial use. Thus, this requestor has not demonstrated that it would be adversely affected or aggrieved by promulgation of the NPRM, and instead avers that it will not accrue the benefits it aspires to in the event marijuana is not rescheduled into Schedule III. Rescheduling presents a potential benefit to this requestor, but declining to do so will not adversely affect its interests beyond the status quo. Accordingly, consideration of SC One (aggrievement, adverse impact or Article III standing) does not inure to this requestor’s benefit.

Under SC Two (compliance with procedural directives), the RFH was apparently timely, and the POR is clear in its support of the proposed rescheduling, discusses the issues upon which it desires to be heard, and adequately outlines its position. On the whole, this requestor has complied with the relevant Preliminary Order and the procedural directives of the Agency in the NPRM. Thus, SC Two does not disfavor APA standing.

Similarly, inasmuch as the POR is laser focused on the rescheduling depicted in the NPRM and its potential impact on CBIH, SC Three (within the scope of the NPRM) militates in favor a grant of APA standing for this requestor.

Regarding SC Four (Meaningful Assistance/Consolidation Potential), a company dedicated to developing new, medically significant formulations of marijuana products with shared scientific and commercial objectives could potentially have expertise and access to relevant information that could potentially be helpful to the Agency in deciding whether to proceed with its proposed rescheduling rule. Beyond that, the Administrator has identified this requestor as a DP, which is entitled to significant deference. Inasmuch as CBIH shares a pecuniary/commercial concern with other requestors, it may be prudent to consider a consolidation of presentations with other DPs who also favor the proposed rescheduling.

Upon a thoughtful balance of the four SC Factors, CBIH has certainly not demonstrated that promulgation of the NPRM will adversely affect or aggrieve its interests within the unambiguous, directive terms of the regulations. Upon consideration of the powerful Factor One, this requestor has **NOT DEMONSTRATED STANDING BUT MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. Analyzing the other SC Factors (in particular, SC Four, as evidenced by the Administrator's designation) militate in favor of CBIH's participation in these proceedings, but the issue of standing may properly be factored into the weight accorded to its presentation in this recommended decision.

International Association of Chiefs of Police (IACP)

In its POR, the IACP describes itself as "the world's largest and most influential professional association for police leaders ... committed to advancing safer communities through thoughtful, progressive police leadership." IACP POR at 1. This requestor claims to "speak[] out on behalf of law enforcement." *Id.*

IACP's POR opposes the NPRM because, in its view, the proposed rescheduling change would present "a significant shift in federal drug policy with significant implications for public safety, public health and the ability of police agencies to protect the public," presumably all of which would negatively impact on, *inter alia*: policing, firearms regulations, public and workplace safety, impaired driving, impairment standards, and firearms regulation. *Id.* at 2.

In this regard, IACP's assertion of standing under SC One (aggrievement, adverse impact or Article III standing) depends entirely upon its ability to demonstrate associational standing.

An association only has standing to bring suit on behalf of its members when its members would otherwise have standing to sue in their own right, the interests [the association] seeks to protect are germane to the organization's purpose, and neither the claim asserted nor the relief requested requires the participation of individual members in the lawsuit.

Fund Democracy, 278 F.3d at 25 (citing *Friends of the Earth, Inc. v. Laidlaw Envtl. Servs. (TOC), Inc.*, 528 U.S. 167, 181 (2000)). Here, the interests cited by IACP, at least as articulated as adverse (that is, the potentially adverse impact rescheduling could have on the law enforcement efforts to enforce driving and other impairment-related and fit-for-duty laws regularly enforced by many of its members), could conceivably be adversely impacted by promulgation of the NPRM. Accordingly, SC One favors standing in this case.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is entirely within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful Assistance/Consolidation Potential), the POR posits a wide reservoir of access to members with the potential to speak authoritatively on the listed issues of concern, a law enforcement perspective is quite valuable, and even beyond all that, that the Administrator approved IACP's status as a DP is entitled to significant deference. The law enforcement focus expressed by this requestor may well be best served by consideration of consolidation with other like-minded requestors.

Accordingly, inasmuch as all four of the SCs favor standing, this DP has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS.** This requestor may wish to give serious consideration to presentation consolidation with other enforcement-motivated requestors who are unsupportive of the proposed rescheduling.

Veterans Initiative 22 (VI-22)

In its POR, VI-22 defines itself as “a non-profit organization whose mission is veteran suicide prevention” and that its focus is helping veterans, their families and first responders “by providing resources, employment opportunities, and ... advocating for safe access to affordable cannabis” VI-22 POR at 2. The POR does not reference any specific or estimated number of veteran members or beneficiaries or how its services are designed to assist those veterans, but it does posit that the NPRM would facilitate cannabis research, improve veterans’ access to marijuana as an alternative treatment option, and reduce legal barriers to veterans who seek to use marijuana as medicine. *Id.* at 5.

It is not necessary to reach the issue of associational standing. Irrespective of the size of its membership or the scope of its beneficiaries, VI-22’s POR does not specify how it or its beneficiaries would be “adversely affected or aggrieved” by the *promulgation* of the proposed rescheduling rule. It is VI-22’s stated position that those it helps would markedly benefit by DEA’s embracement of the NPRM and rescheduling of marijuana to Schedule III. Specifically, the POR argues that promulgation of the NPRM will encourage research into the substance’s benefits, make it more accessible to veterans, and diminish some legal barriers that affect the organization’s beneficiaries. Thus, this requestor has not demonstrated that it or those it assists would be adversely affected or aggrieved by promulgation of the NPRM. Rescheduling presents a potential benefit to this requestor and its veterans, and will not adversely affect any of its espoused causes related to marijuana. Accordingly, consideration of SC One (aggrievement, adverse impact or Article III standing) does not inure to this requestor’s benefit.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is entirely within the proper scope of the NPRM (SC Three). The POR’s demonstration under SC Four (Meaningful Assistance/Consolidation Potential) is stronger on its commitment to its positions than it is on access to a wide range of relevant experts, but that the Administrator approved VI-22’s status as a DP is entitled to significant deference.

Upon a thoughtful balance of the four SC Factors, VI-22 has not demonstrated that promulgation of the NPRM will adversely affect or aggrieve its own interests or the interests of those on whose behalf it advocates. Placing appropriate regulatory emphasis on the powerful

Factor One, this requestor has **NOT DEMONSTRATED STANDING BUT MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. Consideration of the other SC Factors (in particular, SC Four, as evidenced by the Administrator’s designation) lend some support to allowing this requestor’s participation in these proceedings, but the issue of standing may properly be factored into the weight accorded to its presentation in this recommended decision. The veteran-focused concerns of this requestor may lend itself well to consolidating its presentation with other veteran-focused DPs who also favor promulgation of the NPRM.

Kenneth Finn, M.D.

Dr. Finn’s POR lists his extensive medical qualifications and his considerable experience writing, lecturing, and testifying on the issue of marijuana use. Finn POR at 1. Although affiliated with numerous organizations, including the International Academy on the Science and Impact of Cannabis,²⁶ the POR identifies his interest in the NPRM exclusively as a physician, and not on behalf of IASIC or any other organization, thereby precluding consideration of associational standing. According to the POR, this requestor has multiple relevant board certifications and practices pain medicine. *Id.* Dr. Finn alleges that as a physician, the promulgation of the NPRM would adversely affect him because the lack of satisfactory research into cannabis and the absence of any dosing guidelines or care standards from the Food and Drug Administration (FDA) would render him unable to competently prescribe or administer the substance as a drug for his patients. *Id.* at 1-3.

In *FDA v. Alliance for Hippocratic Medicine*, the Supreme Court held that a group of physicians challenging FDA regulations lacked standing to do so based on anticipated hurdles in patient treatment. 602 U.S. at 380-81. The Court specifically declined to create a “doctor standing” doctrine,²⁷ but was equally unambiguous in holding that the plaintiff-doctors “may present their concerns and objections to the President and FDA in the regulatory process” *Id.* at 397. Which segues nicely to the subject of APA standing. As discussed, *supra*, the requirements of APA standing are not coextensive with standing under Article III, and are principally driven by the applicable agency regulations. *Ritchie*, 170 F.3d at 1095. Here, Dr.

²⁶ *Supra* note 3.

²⁷ *Id.* at 391-92.

Finn has raised issues related to his pain management practice where he claims that he will be adversely affected by the promulgation of the NPRM. Without reaching the issue as to whether any of his anticipated difficulties have merit, this type of allegation clearly sounds within the reach of the APA and CSA's standing requirements under the regulations, and militate in favor of standing under SC One (aggravement, adverse impact or Article III standing).

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is entirely within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful Assistance/Consolidation Potential), the POR essentially offers the potential testimony of Dr. Finn, whose credentials arguably represent a considerable array of subject matter experience and knowledge on subjects relevant to the NPRM determination. Furthermore, the Administrator approval of Dr. Finn's status as a DP is entitled to significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, this DP has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. The medical practitioner-focused interests of this requestor may render it sensible for him to consider presentation consolidation with other, medical practitioner DPs who also disfavor the proposed rescheduling action.

Phillip Drum, PharmD

Dr. Drum's POR lists his extensive qualifications as a pharmacist and his considerable experience writing, lecturing, and testifying on the issue of marijuana use and impairment. Drum POR at 1-2. Dr. Drum alleges that as a pharmacist, the promulgation of the NPRM would adversely affect him because, at least in his view, the FDA did not perform the functions that pharmacists depend upon for the safe, effective, and professional exercise of pharmacy. *Id.* Specifically, the lack of the package inserts required to accompany all medications will, at least in his view, result in an inability to comply with the standards of his profession. *Id.* According to Dr. Drum's POR:

As a [Schedule III] product, marijuana products need an approved package insert listing medical indication for use, scientific evidence of the benefits exceeding the risks, use in the approved indication, the appropriate dosage for various patient populations (age, pregnancy status, metabolic and clearance status, etc.), potential

adverse effects along with the incidence of occurrence, standard concentrations of active ingredients (there are over 100+ cannabinoids in marijuana), storage requirements and clinically relevant drug interactions. Dispensing these products without such information pose[s] a safety risk and inability of a pharmacist to provide required patient education about the safe use of their medicine. None of this information for marijuana has been performed [sic] by the FDA, unlike the package insert currently available for the single [sic] cannabinoid products – dronabinol and cannabidiol.

Id. at 1-2. Thus, by Dr. Drum's reckoning, without research and action by FDA, he cannot do his job and serve his pharmacy patients within the standards of his profession.

As discussed, *supra*, inasmuch as in *Alliance for Hippocratic Medicine*, the Supreme Court declined to create standing for physicians, it is beyond doubt that a similar logic precludes Article III standing for Dr. Drum based exclusively on his status as a pharmacist. 602 U.S. at 396. As has been discussed extensively, elsewhere in this order, the requirements of APA standing are not coextensive with standing under Article III, and are principally driven by the applicable agency regulations. *Ritchie*, 170 F.3d at 1095. Here, Dr. Drum has raised issues related to pharmacy practice, and claims that he and his patients stand to be adversely affected by the promulgation of the NPRM. Without reaching the issue as to whether any of his anticipated difficulties have merit, this type of allegation clearly sounds within the reach of APA/CSA standing under the regulations, and militate in favor of standing under SC One (aggrievement, adverse impact or Article III standing).

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is entirely within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful Assistance/Consolidation Potential), Dr. Drum's POR exclusively offers his own potential testimony, which arguably appears to reflect a considerable breadth of subject matter experience and knowledge on subjects relevant to the NPRM determination. Furthermore, the Administrator approval of Dr. Drum's status as DP's is entitled to significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, this DP has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS.** The medical practitioner-focused interests of this requestor may render it

sensible to consider presentation consolidation with other, medical-practitioner DPs who also disfavor the NPRM.

Community Anti-Drug Coalitions of America (CADCA)

CADCA's POR states that it represents "over 7,000 substance use prevention coalitions that involve multiple sectors of a community including schools, law enforcement, youth, parents, healthcare, media, tribal communities and others who are involved in comprehensively addressing locally identified substance use issues, including marijuana." CADCA POR at 2. According to this DP, the mission of its members "is to keep communities safe, healthy and drug free by stopping, delaying and mitigating initiation into substance use" *Id.* CADCA asserts that promulgation of NPRM would greatly increase funding sources of pro-marijuana entities, and thereby render it more difficult to achieve mission goals within its budget, thereby greatly reducing the support it will be able to render to its coalition members. *Id.* at 6.

SC One (aggrievement, adverse impact or Article III standing) consideration is dependent upon a determination that CADCA has associational standing. That is, that CADCA's "members would otherwise have standing to sue in their own right, the interests [the association] seeks to protect are germane to the organization's purpose, and neither the claim asserted nor the relief requested requires the participation of individual members in the lawsuit." *Fund Democracy*, 278 F.3d at 25 (citing *Friends of the Earth*, 528 U.S. at 181). Assuming (as proffered) that its substance abuse coalitions are uniformly dedicated to the local and national reduction of marijuana use, each one would be adversely affected by a regulatory action that would potentially disproportionately fund pro-marijuana advertising and advocacy efforts. Accordingly, CADCA has demonstrated sufficient associational standing to have that factor militate in favor of standing under SC One.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is entirely within the proper scope of the NPRM (SC Three). On the issue of SC Four, as described in the POR, CADCA's seven-thousand-member-coalition breadth would apparently make a potentially large number of experts with knowledge available to contribute to potentially add meaningful

input to the Agency’s NPRM determination. Furthermore, that the Administrator approved CADCA’s status as a DP is entitled to significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, CADCA has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. The substance-abuse-prevention focus of this requestor may be best served by considering consolidation of its presentation with other abuse-prevention-motivated DPs who also are unsupportive of the proposed rescheduling.

Cannabis Industry Victims Educating Litigators (CIVEL)

In its POR, CIVEL describes itself as “a marijuana industry victims’ advocacy organization” and alleges that its “victims of the marijuana industry ... have been, are being, or will actually be harmed by [promulgation of the NPRM because it] will increase the use of marijuana, reduce the perception of its dangerousness and lower medical standards for deciding what is a medicine”²⁸ CIVEL POR at 4. While not altogether clear from the POR, CIVEL is apparently engaged in the active representation of individuals who claim/have claimed harmful effects from marijuana, and equips trial attorneys and the public with legal citations and tactical approaches for engaging in anti-marijuana litigation. *Id.* at 3-4.

Reviewing its POR under SC One (aggrievement, adverse impact or Article III standing) CIVEL’s APA standing is dependent on whether it has made a persuasive case for associational standing. That is, that CIVEL’s “victims” “would otherwise have standing to sue in their own right, the interests [the association] seeks to protect are germane to the organization’s purpose, and neither the claim asserted nor the relief requested requires the participation of individual members in the lawsuit.” *Fund Democracy*, 278 F.3d at 25 (citing *Friends of the Earth*, 528 U.S. at 181). Assuming (as proffered) that the “victims” it advocates and litigates for allege they have each been harmed by marijuana and an NPRM that could potentially increase its societal prevalence exponentially, each of the “victims” could allege sufficient harm to justify

²⁸ The POR purports to contain citations for two cases where state courts have granted associational standing for CIVEL under state law. CIVEL POR at 4. While a limited, excerpted portion of an unreported New York trial court decision that was supplied by CIVEL appears to find associational standing by placing reliance on an affidavit executed by one of the plaintiffs (*Cannabis Impact Prevention Coalition and Cannabis Industry Victims Seeking Justice, et al v. Hochul, et al*, Albany County, NY, Index No. 905386-23), the other case (*Botteon and CIVEL, et al.*, MID-L-001241-24) is arguably less helpful in this regard.

associational standing for this DP. Accordingly, CIVEL has demonstrated sufficient associational standing to have that factor militate in favor of standing under SC One.

Regarding SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is entirely within the proper scope of the NPRM (SC Three). On the issue of SC Four, as described in the POR, CIVIL's active litigation and litigation support missions provide a sufficient basis to conclude that it would possess knowledge that could be instrumental in an accurate disposition of this NPRM determination. Furthermore, that the Administrator approved CIVEL's status as a DP is entitled to significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, CIVEL has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. The substance-abuse-prevention/victim focus of this requestor may be best served by considering consolidation of its presentation with other, abuse/prevention requestors who also oppose the NPRM.

Hemp for Victory (HFV)

In its POR, HFV defines itself as "a non-profit organization dedicated to educating the public about why veterans are using medical cannabis over prescription pharmaceuticals, including dangerous and addictive opioids and other controlled substances." HFV POR at 1. The POR explains the organization's mission as "educat[ing] and bring[ing] awareness to the natural solution of cannabis as a way for veterans to manage the mental and physical challenges that often result from military service and to ensure that veterans face neither discrimination nor penalty for their use of medical marijuana." *Id.* The POR does not reference any specific or estimated number of veteran members or beneficiaries, but outlines its education and advocacy mission, and asserts that:

Because of marijuana's [S]chedule I status under federal law, [HFV's] veteran [b]oard members and the veterans for whom they advocate currently face both discrimination and liability if they use medical marijuana. As a result, they cannot obtain access to medicine that they need from the Department of Veterans Affairs and are, in many cases, forced to rely instead on the harmful pharmaceutical drugs that are driving much of our veteran suicide epidemic.

Id. at 4.

It is not necessary to reach the issue of associational standing here. Irrespective of the size of its membership or the sincerity of the organization's commitment, HFV's POR does not specify how it or its beneficiaries would be "adversely affected or aggrieved" by the *promulgation* of the proposed rescheduling rule. HFV's POR is not shy about stating that its goal is the descheduling of marijuana altogether (not part of this NPRM in any way). However, it is HFV's stated position that the placement of cannabis into Schedule III would present "an incremental step toward its ultimate goal" of removing marijuana from the list of scheduled drugs entirely. *Id.* at 5. Thus, this requestor has not demonstrated that it or those it advocates on behalf of would be adversely affected or aggrieved by promulgation of the NPRM. Actually, as conceded by its POR, rescheduling presents a potential benefit to this requestor and its veterans, and will not adversely affect any of its espoused educational and advocacy causes related to marijuana. Accordingly, consideration of SC One (aggrievement, adverse impact or Article III standing) does not inure to this requestor's benefit.²⁹

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is generally within the proper scope of the NPRM (SC Three). The POR's demonstration under SC Four (Meaningful Assistance/Consolidation Potential) names a single witness, but that witness certainly presents as a potential source of authoritative information that could prove helpful in the decision the Agency must make. Additionally, the Administrator's approval of HFV as a DP warrants significant deference.

Upon a thoughtful balance of the four SC Factors, HFV has not demonstrated that promulgation of the NPRM will adversely affect or aggrieve its own interests or the interests of those on whose behalf it advocates. Placing appropriate weight on Factor One, this requestor has **NOT DEMONSTRATED STANDING BUT MAY CONTINUE TO PARTICIPATE IN**

²⁹ The balance of this requestor's arguments in favor of standing are wholly unpersuasive. To argue, at this procedural juncture, that the DEA is an improper advocate or sponsor of its own NPRM adds nothing to the standing equation and (at least on the present record) presents little more than an *ad hominem* distraction from the important advocacy and adjudicative work to be accomplished in these proceedings. A separate motion has been filed on this issue and it will be addressed in a separate order. Further, that HFV has been accorded associational standing in unrelated proceedings where a member had the ability to demonstrate Article III standing does not advance its argument in these proceedings regarding its APA standing.

THESE PROCEEDINGS. Consideration of the other SC Factors (in particular, SC Four, as evidenced by the Administrator’s designation) lend some support to allowing this requestor’s participation in these proceedings, but the issue of standing may properly be factored into the weight accorded to its presentation in this recommended decision. This requestor remains a DP, and may be well served by considering a consolidation of presentation with other veteran-access-focused participants who also favor the proposed rescheduling action.

National Drug & Alcohol Screening Association (NDASA)

In its POR, NDASA identifies itself as “a non-profit professional association representing more than 5,000 private and public sector employers and service agents, domestically and internationally, who administer and manage workplace drug and alcohol testing programs.” NDASA POR at 1. Drug testing by NDASA members is carried on in the private and public sectors and regulated by various government standards. In addition to a high level of private-sector testing, the government testing includes the Nuclear Regulatory Commission (NRC) and the U.S. Department of Transportation (DOT). *Id.* at 1-2. The DOT testing is carried out in accordance with mandatory statutory and regulatory requirements. Because, according to NDASA, the authority of the U.S. Department of Health and Human Services (HHS) to test only extends to controlled substances in Schedules I and II (not III), promulgation of the NPRM would cause a cessation of marijuana drug testing in key transportation safety positions, to include the following: “airline pilots, air traffic controllers, school bus drivers, subway and train operators, ferry operators, pipeline operators, and truck drivers.” *Id.* at 3. At least in the view of the requestor, this feature of the NPRM would cause its membership to suffer profound and detrimental financial and professional consequences. For these reasons, and reasons of public safety, NDASA opposes the NPRM.

As its POR is structured, standing under SC One (aggrievement, adverse impact or Article III standing) is dependent upon a determination that NDASA has associational standing. That is, that NDASA’s “members would otherwise have standing to sue in their own right, the interests [the association] seeks to protect are germane to the organization’s purpose, and neither the claim asserted nor the relief requested requires the participation of individual members in the lawsuit.” *Fund Democracy*, 278 F.3d at 25 (citing *Friends of the Earth*, 528 U.S. at 181). Assuming (as proffered) that rescheduling marijuana to Schedule III would inflict financial and

professional harm on its members, NDASA has demonstrated sufficient associational standing to have this critical factor militate in favor of standing under SC One.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is entirely within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful Assistance/Consolidation Potential) NDASA's POR references the organization's executive director, but in view of the size and specialization of this requestor, it would seem that it would have no shortage of qualified witnesses among its five-thousand-strong membership that could prove helpful in the decision the Agency must make. Additionally, the Administrator's approval of NDASA as a DP warrants significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, NDASA has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. This requestor could potentially benefit by considering consolidation with another requestor whose focus is founded in concerns over the potential limitations the NPRM may inflict upon testing for public safety.

The Commonwealth Project (TCP)

In its POR, TCP defines itself as an entity "committed to advocating on behalf of and prioritizing the 65+ population and integrating medical cannabis into mainstream health care for seniors." TCP POR at 1. This requestor appears to be an advocacy group focused on senior citizens and claims to be "rooted in the belief that medical cannabis could be harnessed to not only provide older Americans with an alternative to traditional prescription medications, including opioids, but to reduce soaring health care costs saddling millions of seniors." *Id.* at 2.

On the issue of SC One (aggrievement, adverse impact or Article III standing), the POR's description of TCP renders it unnecessary to reach the issue of associational standing. The POR does not specify how it or its senior-beneficiaries would be "adversely affected or aggrieved" by the *promulgation* of the proposed rescheduling rule. In fact, according to its POR, the only potential aggrivement to this requestor and those seniors it advocates for would be "if rescheduling is rejected or unduly delayed." *Id.* at 3. Not only would the proposed rescheduling not adversely affect or aggrieve this organization, but it has posited that it cannot happen fast

enough for its liking. Accordingly, consideration of SC One does not inure to this requestor's benefit.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR (while perhaps not altogether clear as to how the requestor executes its objectives) is generally responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is within the scope of the NPRM (SC Three). The POR's demonstration under SC Four (Meaningful Assistance/Consolidation Potential) does not identify a particular witness or source of expertise that would be particularly knowledgeable, but a source of the perspective of senior citizens added to the decisional equation would be important and potentially helpful to a resolution of the NPRM. Additionally, the Administrator's approval of TCP as a DP warrants significant deference.

Upon a thoughtful balance of the four SC Factors, TCP has not demonstrated that promulgation of the NPRM will adversely affect or aggrieve its own interests or the interests of those on whose behalf it advocates (just the opposite in fact). Placing appropriate weight on Factor One, this requestor has **NOT DEMONSTRATED STANDING BUT MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. Consideration of the other SC Factors (in particular, SC Four, as evidenced by the Administrator's designation) lend some support to allowing this requestor's participation in these proceedings, but the issue of standing may properly be factored into the weight accorded to its presentation in this recommended decision. This requestor's access-for-seniors focus may be enhanced by consideration of presentation consolidation with other requestors focused on seeking marijuana access for specific groups (*e.g.*, veterans).

The National Transportation Safety Board (NTSB)

The POR filed by the NTSB provides the following account of its background, status, and mission:

The NTSB is an independent federal agency charged by Congress with investigating every civil aviation accident in the United States and significant events in the other modes of transportation—railroad, transit, highway, marine, pipeline, and commercial space.

NTSB POR at 1. According to NTSB, under current law, rescheduling marijuana to Schedule III would place it outside the parameters of authorized drug testing, “prevent[ing] testing for marijuana use by safety-sensitive employees in commercial transportation operations, such as truck drivers, rail conductors, pipeline/hazardous materials operators, air traffic controllers, flight attendants, and airline pilots, among many others.” *Id.* at 2. In NTSB’s view, this result would “create a safety blind spot that could endanger the public, contrary to NTSB’s public safety mission.” *Id.* at 3. NTSB’s POR expresses additional concerns related to the effect of increasing marijuana use in public, due to what it characterizes as “performance-impairing effects” on humans who operate by, with, and in the public transportation sphere. *Id.*

Inasmuch as its representations depict the potential for (in its view) a profound impact on its mission and its ability to safeguard the public in the transportation space, this requestor has established standing under Article III, and its position militates strongly in favor of standing under SC One (aggravement, adverse impact or Article III standing).

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is squarely within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful Assistance/Consolidation Potential) as the lead agency in evaluating major traffic incidents and the relevance and extent of any attendant impairment issues, it is likely that this requestor has access to experts in the field that could meaningfully assist in the adjudication of this NPRM. Additionally, the Administrator's approval of NTSB as a DP warrants significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, NTSB has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. This requestor could potentially benefit by considering consolidation with another requestor whose focus is concerns over the potential limitations the NPRM may inflict upon testing for public safety.

The Doc App, Inc., d/b/a My Florida Green (DocApp)

In its POR, DocApp describes itself as “a company that supports over 43,000 medical marijuana patients in Florida [which] provides a HIPAA-compliant platform offering real-time analytics, data-driven insights, and treatment support for marijuana patients.” DocApp POR at 2.

Even a cursory reading of this Designated Participant's POR reveals that the DocApp's primary interest in these proceedings' rests solely on the utilization of its platform in future actions involving the possible rescheduling of marijuana to Schedule III. To be sure, input into the process is only enhanced by entities with a potential commercial perspective in the proposed rescheduling action. Here, however, in place of expressing a position on the NPRM, the POR characterizes the NPRM as a "positive step," and emphasizes that it is essential that marijuana patients maintain "flexibility to select what best meets their needs, guided by real-time data on strain options, effects, and availability." *Id.* at 3. This emphasis stands in some tension with the CSA's implementing regulations, which unambiguously provide that "[t]he responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription." 21 C.F.R. § 1306.04(a). Furthermore, the Supreme Court has made clear that medical standards are a function of a state's police powers, not the DEA. *Gonzales*, 546 U.S. at 274. Patient control (as contrasted with input to his/her prescriber/pharmacist) is inconsistent with the regulatory dynamic of prescribing controlled substances, and setting a federal standard for the dispensing and prescribing of controlled substances is well beyond the CSA's statutory mandate. *Id.* at 272, 274-75.

A reading of this DP's POR reflects, at best, mild positivity regarding the NPRM and does not indicate any manner in which it, its customers, or its business interests would be even marginally affected by the proposed rescheduling. Accordingly, consideration of SC One (aggrievement, adverse impact or Article III standing) does not inure to this requestor's benefit in any perceivable way.

Under SC Two (compliance with procedural directives), the RFH was apparently timely, and POR provided identifying and mission information. Beyond that, this DP did not comply with the DEA Administrator's directives to state with particularity its interest in the proceeding, state with particularity the objections or issues concerning which it desires to be heard, and state its position regarding objections or issues. 89 Fed. Reg. at 70149. Likewise although responding to the Preliminary Order, the POR did not state "why/how the DP would be sufficiently 'adversely affected or aggrieved' by the proposed scheduling action to qualify as an 'interested person' under the regulations." Prelim. Ord. at 3. Thus, SC Two does not militate in favor of APA standing.

With respect to SC Three (within the scope of the NPRM), as discussed, *supra*, inasmuch as this POR seeks relief that is beyond the NPRM (*to wit*, the adoption of regulations focused on the inclusion of its software or something like it), and even beyond the regulations and the proper scope of the CSA as determined by the Supreme Court, consideration of this factor does not at all support APA Standing.

Regarding SC Four (Meaningful Assistance/Consolidation Potential), as also discussed, *supra*, input from commercial interests are a proper and valuable area of consideration in deciding whether to reschedule marijuana or any other drug, but this DP is not raising a single issue that could or should be addressed by the NPRM. To be sure, the Administrator has identified this requestor as a DP, but the POR filed is so bereft of any demonstration of standing (or even relevance) has **NOT DEMONSTRATED STANDING AND MAY NOT INDEPENDENTLY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. This requestor should expeditiously consider potential consolidation with another, similarly aligned, commercially-motivated requestor. The Administrator's designation is an essential element to be afforded (as evident in the balance of this order) to powerful (and generally controlling) deference regarding participation. But the Administrator did not have the benefit of the POR filed by this DP, and deserves, at a minimum, the analysis offered here. To be clear, based on the content of its POR, this DP has not demonstrated a sufficient (standing or evidentiary) basis to participate in this hearing in the absence of sponsorship by or consolidation with a DP who has demonstrated at least sufficient grounds to be heard.

The State of Nebraska (Nebraska)

In its POR, pertinent to SC One (aggrievement, adverse impact or Article III standing) Nebraska asserts that because under state law, marijuana is "illegal in all circumstances," rescheduling to Schedule III will "supercharge the marijuana industry" and "will increase the many costs and expenditures by Nebraska's law enforcement agencies, its judiciary, and its penal system directly related to or arising from marijuana industry." Neb. POR at 1-2. Inasmuch as its representations depict the potential for pecuniary costs and (in its view) public safety challenges,

this requestor has established standing under Article III, and this militates strongly in favor of standing under SC One.³⁰

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is entirely within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful Assistance/Consolidation Potential) it is self-evident that the official view of a state regarding the impact of the NPRM on its pecuniary and enforcement issues is a vital consideration that could benefit the NPRM process. Additionally, the Administrator's approval of Nebraska as a DP warrants significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, Nebraska has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. This requestor's enforcement-related interests may be best served by considering presentation consolidation with other enforcement-motivated requestors.

Ari Kirshenbaum, PhD

In his POR, Dr. Kirshenbaum identifies himself as a PhD researcher and Psychology professor emeritus who is presently engaged in "research related to cannabis-related impairment of the skills needed for motor vehicle operation." Kirshenbaum POR at 1. The requestor indicates that the current placement of marijuana in Schedule I presents mandatory procedural steps that can result in delays in conducting research. *Id.* at 2. Dr. Kirshenbaum's POR states that he is currently "co-leading a research study out of the University of California San Francisco (Medical School) that has been delayed for over a year due to the regulatory hurdles necessitated by [marijuana's] Schedule I designation." *Id.*

³⁰ Nebraska's alternative argument that standing under the APA, the CSA, and the CSA's implementing regulations is satisfied exclusively by virtue of the fact that the Administrator designated it as a participant misperceives the recommended decision hearing structure. Analogously, although all DEA immediate suspension enforcement hearings commence with the issuance of a charging document by the Administrator, assigning controlling weight to that preliminary decision and binding the ALJ thereby would render the hearing process under the APA as illusory. 21 U.S.C. § 811(a). That cannot be the intent of Congress. To be sure, decisions regarding standing (like all rulings and decisions made by an ALJ) are subject to the Administrator's review, but a final order that is consistent with the recommended decision is stronger than when the contrary occurs. *See generally, Morall v. DEA*, 412 F.3d 165, 177 (D.C. Cir. 2005) ("The Agency's departures from the ALJ's findings are vulnerable if they fail to reflect attentive consideration to the ALJ's decision.").

Dr. Kirshenbaum supports the rescheduling of marijuana into Schedule III so that his studies can be conducted more expeditiously. On the issue of SC One (aggrievement, adverse impact or Article III standing), Dr. Kirshenbaum does not specify how he would be “adversely affected or aggrieved” by the *promulgation* of the proposed rescheduling rule. Not only would the proposed rescheduling not adversely affect or aggrieve this requestor, but he wants it to happen quickly. Accordingly, consideration of SC One does not inure to this requestor’s benefit.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is within the scope of the NPRM (SC Three). Under SC Four (Meaningful Assistance/Consolidation Potential) Dr. Kirshenbaum offers his own testimony, which could potentially bring a knowledgeable and relevant perspective from academia. Additionally, the Administrator’s approval of Dr. Kirshenbaum as a DP warrants significant deference.

Upon a thoughtful balance of the four SC Factors, Dr. Kirshenbaum has not demonstrated that promulgation of the NPRM will adversely affect or aggrieve him. Placing appropriate weight on Factor One, this requestor has **NOT DEMONSTRATED STANDING BUT MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. Consideration of the other SC Factors (in particular, SC Four, in light of the Administrator’s designation) lend some support to allowing this requestor’s participation in these proceedings, but the issue of standing may properly be factored into the weight accorded to his presentation in this recommended decision. Dr. Kirshenbaum may wish to consider the prospect of presentation consolidation with other academic/medical professional requestors who are supportive of the NPRM.

Office of Cannabis Ombudsman, State of Connecticut (OCO)

In its POR, OCO defines itself as “the first-in-the-nation independent state agency with a mission to protect and preserve the needs of medical cannabis patients.” OCO POR at 1-2. The POR explains that OCO is statutorily created and its focus is to provide assistance to

Connecticut residents [as] they navigate the [m]edical cannabis system through direct assistance; outreach and educational activities; meetings, facility visits and continuous communication with current and future suppliers; assessing and implementing needed improvements; and working with research centers,

universities and advocates to monitor and improve [the state] system and bring best-in-class standards to [Connecticut].

Id. at 2. OCO represents that it “generally supports the [NPRM] and removing marijuana from [S]chedule I” due to criminal and other consequences that stem from that designation. But it also says that it “has concerns with a [S]chedule III placement” because state residents seeking medical marijuana could be “confused if cannabis becomes akin to Tylenol 3 and other pharmaceuticals in [S]chedule III.” *Id.* at 3. Confusingly, OCO also expresses additional “concerns” that existing regulations (which apply to all Schedules) “could increase the price and decrease the availability of medicinal cannabis if enforced by DEA, which is currently not the case.”³¹ *Id.* Lastly, OCO is apparently also opposed to quotas and other controls that could be required to bring a Schedule III-marijuana in line with the terms of the Single Convention. *Id.* Thus, OCO is apparently “generally” supportive of rescheduling marijuana, but not supportive of controls that could be required to comply with U.S. treaty obligations.

While Connecticut is doubtless a relatively populous state, the true number of OCO’s beneficiaries cannot be readily ascertained from its POR. Consequently, OCO’s position on the NPRM renders the issue of associational standing irrelevant. The POR does not specify how OCO or any of the state residents that utilize its services would be “adversely affected or aggrieved” by the *promulgation* of the proposed rescheduling rule. In fact, although OCO has taken an arguably nuanced view of the NPRM, it has made it clear that it is “generally” supportive. Accordingly, consideration of SC One (aggrievement, adverse impact or Article III standing) does not inure to this requestor’s benefit.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is generally within the proper scope of the NPRM (SC Three). The POR’s demonstration under SC Four (Meaningful Assistance/Consolidation Potential) supplies little insight into whether it has sources of authoritative information at its disposal that could prove helpful in the decision the Agency must make beyond the perspective of this independent agency within the State of Connecticut,³² but as an independent agency with a mission that is so closely aligned with the

³¹ Enforcement (or past/future Congressional riders precluding enforcement) is not an issue within the scope of the NPRM.

³² It is unclear as to whether OCO is authorized to speak on behalf of the State of Connecticut.

subject of the NPRM, its input certainly carries with it the potential to render a valuable contribution. Beyond all that, the Administrator's approval of OCO as a DP warrants significant deference.

Upon a thoughtful balance of the four SC Factors, OCO has not demonstrated that promulgation of the NPRM will adversely affect or aggrieve its own interests or the interests of those on whose behalf it advocates. Placing appropriate weight on Factor One, this requestor has **NOT DEMONSTRATED STANDING BUT MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. Consideration of the other SC Factors (in particular, SC Four, as evidenced by the Administrator's designation) lend some support to allowing this requestor's participation in these proceedings, but the issue of standing may properly be factored into the weight accorded to its presentation in this recommended decision. This requestor may wish to consider presentation consolidation with other DPs focused on enhancing marijuana access to specific groups and who support promulgation of the NPRM.

Tennessee Bureau of Investigation (TBI)

TBI's POR provides the following account of its duties and mission:

The [TBI] is Tennessee's lead investigative agency with original jurisdiction over drug enforcement and the primary agency for forensic science services for law enforcement in the State. This includes operating the Tennessee Dangerous Drugs Task Force, which collaborates with federal agencies (including the DEA) to combat drug crimes across the State. TBI both investigates and enforces federal and state drug-related offenses, including marijuana offenses.

TBI POR at 1. Additionally, TBI represents that its forensic crime labs process over 30,000 drug submissions annually, many of which involve marijuana. *Id.* at 2. TBI posits that the proposed rescheduling would increase the prevalence of marijuana, would strain its drug-enforcement activities, and result in an immediate and adverse impact on TBI's mission. More specifically, according to TBI, the promulgation of the NPRM would result in "significant time and resources to reassess enforcement priorities, personnel assignments, and adjust asset allocations" *Id.* at 3.

Inasmuch as its representations depict the potential for pecuniary costs and (in its view) public safety challenges, this requestor has established standing under Article III, and its position militates strongly in favor of standing under SC One (aggrievement, adverse impact or Article III standing).

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is squarely within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful Assistance/Consolidation Potential) it is self-evident that the official view of the primary drug law enforcement entity in a state regarding the impact of the NPRM on its pecuniary, training and enforcement issues is a vital consideration that could benefit the NPRM process. Additionally, the Administrator's approval of TBI as a DP warrants significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, TBI has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. This requestor may be well served to consider presentation consolidation with other enforcement focused DPs who oppose the proposed rescheduling.

Village Farms International (VFI)

According to its POR, VFI is a large-scale supplier of products who either is or seeks to be a supplier of marijuana. The requestor broadly describes its mission as seeking "to improve life's journey for the wellbeing of humankind and the earth on which we live." VFI POR at 1. Very broad, to be sure. As its basis for APA standing, VFI represents that it intends to enter the U.S. marijuana market and that the proposed rescheduling of marijuana to Schedule III would "facilitate its goals of researching, manufacturing, importing, and exporting marijuana for scientific and medical purposes consistent with state and federal law ..." and that those goals are hindered by the current Schedule I placement. *Id.* at 4. In VFI's view, numerous, specific regulatory barriers would soften if the NPRM succeeds, and those barriers would include easier access to research, gentler requirements for inventory, export, and ordering. *Id.* at 4-5. These ameliorations, in this requestor's opinion, would result in higher profits and more efficiencies.

The POR has convincingly outlined how placing marijuana in Schedule III would be helpful to its commercial interests, and is likewise clear that its ultimate objective is descheduling or scheduling to an even less restrictive level than Schedule III. The requestor views the NPRM as "an incremental step toward optimizing the U.S.'s legal approach to marijuana" (read: legalization). *Id.* at 6. None of VFI's expanded objectives are contemplated by the present NPRM. The POR regarding this requestor does not specify how it would be

“adversely affected or aggrieved” by the *promulgation* of the proposed rescheduling rule, but rather, outlines how its research and pecuniary interests would be advanced by rescheduling. This is a requestor who aspires to pursue the purported benefits of marijuana for commercial use. Thus, this requestor has not demonstrated that it would be adversely affected or aggrieved by promulgation of the NPRM, but that it will not accrue the potential benefits it aspires to upon the failure of the NPRM. Rescheduling presents a potential benefit to this requestor, but declining to do so will not adversely affect its interests beyond the status quo. Accordingly, consideration of SC One (aggrievement, adverse impact or Article III standing) does not inure to this requestor’s benefit.

Under SC Two (compliance with procedural directives), the RFH was apparently timely, and the POR is clear in its support of the proposed rescheduling (albeit as an incremental measure), discusses the issues upon which it desires to be heard, and adequately outlines its position. On the whole, this requestor has complied with the relevant Preliminary Order and the procedural directives of the Agency in the NPRM. Thus, SC Two does not disfavor APA standing. Similarly, inasmuch as the POR is mostly focused on the rescheduling depicted in the NPRM and its potential impact on its commercial interests, SC Three (within the scope of the NPRM) militates in favor a grant of APA standing for this requestor.

Regarding SC Four (Meaningful Assistance/Consolidation Potential), a reasonable reading of the POR depicts an enterprise with considerable experience in supplying agricultural products on a large scale, a likely result of rescheduling marijuana into medicine. Such input has the potential to bring valuable perspectives to the rescheduling equation. Beyond that, the Administrator has identified this requestor as a DP.

Upon a thoughtful balance of the four SC Factors, VFI has certainly not adequately demonstrated that promulgation of the NPRM will adversely affect or aggrieve its interests within the unambiguous, directive terms of the regulations. Upon consideration of the powerful Factor One, this requestor has **NOT DEMONSTRATED STANDING BUT MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**.³³ Analyzing the other SC Factors (in particular, SC Four, as evidenced by the nature and scale of this requestor’s business,

³³ VFI’s unsupported accusation that the DEA is an improper advocate or sponsor of its own NPRM adds nothing to the standing equation (at least on the present record and at this procedural juncture). The issues at stake in these proceedings are too important to devote time and attention to *ad hominem* distractions. This accusation has also been set forth in a separate motion, which will be addressed in a separate order.

as well as the Administrator’s designation) militate in favor of VFI’s participation in these proceedings, but the issue of standing may properly be factored into the weight accorded to its presentation in this recommended decision. Inasmuch as VFI shares a pecuniary and commercial concerns with other requestors, it may be prudent for this requestor to a consolidation of presentations with other commercially-motivated DPs who also support the NPRM.

Smart Approaches to Marijuana (SAM)

SAM’s POR describes the organization as “a bipartisan alliance of organizations and individuals dedicated to a health-first approach to marijuana ... comprised of medial doctors, lawmakers, treatment providers, preventionists, teachers, law enforcement officers who seek a middle road between incarceration and legalization.” SAM POR at 1. It defines its mission as “equip[ing] policymakers with commonsense proposals, based in reputable science, to promote public health and decrease marijuana use and its consequences.” *Id.*

By the terms of its POR, SAM presents itself as an advocacy organization. The POR references “organizations,” but has made no representations that would sustain associational standing. Thus, the standing justification of this requestor are exclusively founded in its claim that it would be aggrieved and adversely affected by the potential affect rescheduling would have on its training and advocacy expenditures as a marijuana-skeptical material and lecturing source.³⁴ Inasmuch as this requestor has adequately demonstrated that promulgation of this

³⁴ SAM’s alternate theory, *to wit*, that it is somehow magically endowed with APA standing by virtue of the fact that the Administrator sent a DP letter is singularly unpersuasive. SAM POR at 2. First, the regulations apply to DEA – all of DEA. While it is possible to apply to the Administrator “for an exception to the application of any [regulation] by filing a written request . . . stating the reasons for such an exception,” no such written request granted by the Administrator is part of the present record. 21 C.F.R. § 1307.03. Beyond that, SAM’s theory misperceives the structure of adjudications under the APA, the CSA, and the CSA’s implementing regulations. As discussed elsewhere in this order, Congress was crystal clear in placing APA proceedings as a condition precedent to rescheduling by the Agency. 21 U.S.C. § 811(a). Determinations as to standing fixed by the Administrator at the outset of the hearing would obstruct the ALJ’s authority to issue a report including a statement of all “findings and conclusions, and the reasons or basis therefor, on all the material issues of fact, law, or discretion as presented on the record [and] the appropriate rule . . .” 5 U.S.C. § 557(c). Analogously, although all DEA immediate suspension enforcement hearings commence with the issuance of a charging document by the Administrator, assigning controlling weight to that preliminary decision and binding the ALJ thereby would render the hearing process under the APA as illusory. 21 U.S.C. § 811(a). That cannot be the intent of Congress. To be sure, decisions regarding standing (like all rulings and decisions made by an ALJ) are subject to the Administrator’s review, but a final order that is consistent with the recommended decision is stronger than when the contrary occurs. *See generally, Morall v. DEA*, 412 F.3d 165, 177 (D.C. Cir. 2005) (“The Agency’s departures from the ALJ’s findings are vulnerable if they fail to reflect attentive consideration to the ALJ’s decision.”).

NPRM would adversely affect its budget and mission, SC One (aggrievement, adverse impact or Article III standing) militates in favor of APA standing.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful Assistance/Consolidation Potential) it is self-evident that the official view of an advocacy entity that purports to have wide-ranging, bipartisan support and can show adverse impact as a direct result of the proposed rescheduling action has the potential for significant, relevant input here. Further, the Administrator's approval of SAM as a DP (while not necessarily controlling) warrants significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, SAM has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. This requestor may wish to consider the option of presentation consolidation with other DP advocacy groups who do not favor the proposed rescheduling.

National Cannabis Industry Association (NCIA)

The POR filed by NCIA describes itself as “the oldest, largest, and most inclusive [tax-exempt non-profit] trade association representing the legal cannabis industry.” NCIA POR at 2. The POR further represents that NCIA’s “membership is composed of hundred of businesses from all sectors of the industry—from state-licensed cannabis businesses to legal hemp product manufacturers to the wide range of ancillary businesses serving the industry” and styles itself as “the voice of Main Street Cannabis.” *Id.*

NCIA has put forward its APA standing argument in essentially two prongs. The first is not persuasive, but much of the second prong is. Both prongs are underpinned by an associational standing theory. That is, that its standing derives from its theory that one or more of its members would have standing to sue in their own right, the interests to be protected are germane to the organization’s purpose, and the result the organization is pursuing requires the participation of individual members in the lawsuit. *Fund Democracy*, 278 F.3d at 25 (citing *Friends of the Earth*, 528 U.S. at 181).

The first prong is that it (and presumably its members) support rescheduling into Schedule III because that action “would both lessen criminal penalties and preclude the application of [Internal Revenue Code § 280E] ... to marijuana businesses” that are not currently operating in violation of applicable state laws. NCIA POR at 6. Inasmuch as this prong supports the proposed rescheduling action, it would not, at least in this regard adversely affect or aggrieve its membership, and does not further its standing argument under SC One (aggrievement, adverse impact or Article III standing).

The other theory of standing is both more nuanced and more persuasive. NCIA posits that a number of its members would be adversely affected by a new definition of tetrahydrocannabinol which is incorporated into the NPRM. Without engaging in a deep dive into the merits of this issue, NCIA argues that the NPRM definition “could cause currently unscheduled [n]on-[i]ntoxicating [c]annabinoids to be designated as prohibited Schedule I controlled substances without [additional] scheduling actions” on the part of DEA. NCIA POR at 4. A significant weakness in this position is that NCIA has not specifically alleged that any of its members are currently utilizing any particular substances that would be affected (a deficit that could conceivably undermine its standing argument in this regard). However, NCIA’s POR contains the following representation:

NCIA is adversely affected or aggrieved by the [NPRM] because the simultaneous scheduling of certain [n]on-intoxicating [c]annabinoids as Schedule I substances through the [NPRM’s] proposed revisions to the definition of THC would make one or more NCIA members’ businesses federally illegal for the first time.

Id. at 3 (internal quotation marks omitted). Thus, based on the fact that this requestor has alleged that it is properly in a position to exercise associational standing with several of its members who could potentially have their present business enterprises rendered illegal by promulgation of the NPRM, SC One favors standing on this narrow issue.³⁵

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order and the procedural directives of the Agency. Likewise, the subject matter of the POR is somewhat within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful

³⁵ Contrariwise, NCIA’s more speculative arguments regarding what the Agency may do in the future, based on its pronouncements in the past and other interpretations, are unpersuasive and beyond the scope of the NPRM. See e.g., *Id.* at 5.

Assistance/Consolidation Potential), as described in its POR, it seems that NCIA would have the means at its disposal to provide qualified witnesses among its large and diverse membership, and that the commercial perspective available to it would be helpful to the adjudication of this NPRM. That said, its commercial perspective may lend itself readily and effectively to a consolidation with other DPs. Additionally, the Administrator's approval of NCIA as a DP warrants significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, NCIA has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. Inasmuch as this requestor shares a pecuniary and commercial concerns with other requestors, it may be prudent to a consolidation of presentations with other commercially-motivated DPs who also support the NPRM.

Ellen Brown

While Ellen Brown's POR references her position as Research Subcommittee Chair of the Massachusetts Cannabis Advisory Board (MCAB), there is no indication therein that she is authorized (or seeking) to speak for that body.³⁶ Indeed, the POR is written in the first person, and focuses, not on the MCAB, but on her own experiences. Ms. Brown indicates that her position on the MCAB Research Subcommittee has provided her with some exposure to veterans, but evidently, she is not in a group authorized to speak on any behalf beyond her own. Ms. Brown further provides that she is a veteran, and as one under the care of the Veteran's Administration (the VA), she has "personally been aggrieved" by marijuana's current Schedule I placement and is in favor of the proposed rescheduling action set forth in the NPRM. Brown POR at 2.

Ms. Brown's POR does not specify how she would be "adversely affected or aggrieved" by the *promulgation* of the proposed rescheduling rule. It is her stated position that she and other veterans would markedly benefit by DEA's embracement of the NPRM and rescheduling of marijuana to Schedule III, thereby opening marijuana treatment avenues. *Id.* Thus, this requestor has not demonstrated that she would be adversely affected or aggrieved by

³⁶ To the extent this conclusion is incorrect and Ms. Brown is indeed authorized to speak for MCAB, that body or Ms. Brown may file a clarification within five (5) business days from the receipt of this order with a request to reconsider.

promulgation of the NPRM. Rescheduling presents a potential benefit to this requestor and (at least in her view) other veterans. Accordingly, consideration of SC One (aggrievement, adverse impact or Article III standing) does not inure to this requestor's benefit.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is generally responsive, and in some respects consistent with the Preliminary Order as well as the procedural directives of the Agency. Likewise, the subject matter of the POR is within the proper scope of the NPRM to some extent (SC Three). The POR's demonstration under SC Four (Meaningful Assistance/Consolidation Potential) is difficult to gauge. Although Ms. Brown represents that she has spoken to some veterans interested in exploring the benefits of marijuana as medicine, there is no indication about the number of veterans or anything beyond some limited anecdotal, generalized representations. That the Administrator approved Ms. Brown status as DP's is entitled to significant deference, but balancing the powerful SC One and the other SC Factors, Ms. Brown has not made a sufficient (standing or evidentiary) presentation to warrant her participation in these proceedings.

Upon a thoughtful balance of the four SC Factors Ms. Brown has not demonstrated that promulgation of the NPRM will adversely affect or aggrieve her own interests and has noticed little beyond her own experience and expectations about the potential benefits of rescheduling marijuana as sought by the DEA. Placing appropriate regulatory emphasis on the powerful Factor One, this requestor has **NOT DEMONSTRATED STANDING AND MAY NOT INDEPENDENTLY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. Ms. Brown's POR efforts and input may be better suited to consolidation with another DP who has presented a sufficient showing to warrant participation.

Drug Enforcement Association of Federal Narcotics Agents (DEAFNA)

The POR filed on behalf of DEAFNA describes the association as a "[l]aw [e]nforcement [f]raternal [o]rganization representing active and retired DEA Special Agents, Diversion Investigators, Intelligence Research Specialists, and other DEA [p]ersonnel." DEAFNA POR at 2.

DEAFNA's basis for standing is that the rescheduling "has a direct impact on [its] members' ability to implement the necessary regulatory controls which will take years to implement and will come at an unreasonable financial cost." *Id.* This requestor is against the proposed rescheduling because it would present "a significant shift in federal drug policy with

significant implications for ... the ability of law enforcement agencies to protect the public.” *Id.* at 3. As noted *supra*, “[a]n association only has standing to bring suit on behalf of its members when its members would otherwise have standing to sue in their own right, the interests [the association] seeks to protect are germane to the organization’s purpose, and neither the claim asserted nor the relief requested requires the participation of individual members in the lawsuit.” *Fund Democracy*, 278 F.3d at 25 (citing *Friends of the Earth*, 528 U.S. at 181). Here, inasmuch as DEAFNA’s members, as specialized public servants engaged in the regulation and enforcement actions under the CSA, could potentially demonstrate adverse effect from the promulgation of the NPRM, the action is clearly germane to DEAFNA’s purpose, and the members of the organization are not required participants in the action. Here, the interests cited by DEAFNA, at least as articulated as adverse (that is—at least in its view—the potentially adverse impact rescheduling could have on the law enforcement efforts to enforce driving and other impairment-related and fit-for-duty laws regularly enforced by many of its members), could conceivably be adversely impacted by promulgation of the NPRM. Accordingly, SC One favors standing in this case.

With respect to SC Two (compliance with procedural directives), as proffered, the RFH was apparently timely, and the POR is responsive, and consistent with the Preliminary Order as well as the procedural directives of the Agency. Likewise, the subject matter of the POR is within the proper scope of the NPRM (SC Three). On the issue of SC Four (Meaningful Assistance/Consolidation Potential), this requestor organization (at least as noticed in its POR) specializes in law enforcement in the field of controlled substances. It would be reasonable to assume that this requestor has access to members with the potential to speak authoritatively on the listed issues of concern, a law enforcement perspective (particularly this highly-specialized law enforcement perspective) is quite valuable, and even beyond all that, that the Administrator approved DEAFNA’s status as DP’s is entitled to significant deference.

Accordingly, inasmuch as all four of the SCs favor standing, this DP has **ESTABLISHED STANDING AND MAY CONTINUE TO PARTICIPATE IN THESE PROCEEDINGS**. This requestor should strongly consider the option of presentation consolidation with other enforcement-motivated DPs who also disfavor the NPRM.

On Procedure

In accordance with my authority to regulate the course of the hearing,³⁷ the following procedures are herein implemented to ensure fair and orderly proceedings. While the Government, as the burdened party, may present multiple witnesses, each of the remaining DPs (absent leave to the contrary granted by this tribunal) may present the testimony of a single witness. Documentary evidence and proposed witnesses from all the Parties must be disclosed in advance in a written disclosure (Prehearing Statement) as outlined below. No evidence will be admitted to the record without a proper foundation presented at the hearing on the merits.

Within the discretion of the tribunal, and to the extent practicable, each of the Parties will present testimonial and documentary evidence as set forth below.

The Government, as the burdened party, will present its evidence first. Those DPs who support the NPRM (Pro-Rescheduling DPs) will present evidence following the conclusion of the Government's case. The DPs who oppose the NPRM (Anti-Rescheduling DPs) will present evidence following the conclusion of the Pro-Rescheduling DPs' presentations. All DPs (Pro and Anti) will be limited to a single witness each, with direct examination limited to no more than approximately ninety (90) minutes (excluding cross-examination). Anti-Rescheduling DPs may cross-examine all Government witnesses and all Pro-Rescheduling witnesses. Witnesses presented by the Anti-Rescheduling DPs may be cross-examined by the Government and Pro-Rescheduling DPs. In all cases, cross-examination will be limited to approximately twenty (20) minutes per witness for each authorized cross-examiner. Within the further discretion of the tribunal, presentations may be grouped (or even consolidated) by the tribunal in accordance with commonly-expressed viewpoints as set forth in the Parties' respective PORs.

Any Party (to include the Government) who is unprepared to proceed on the date(s) scheduled at the preliminary hearing (with the input of that Party) may forfeit his/her/its ability to present the scheduled evidence or examination.

It is herein **ORDERED** that the Parties, no later than **2:00 p.m. Eastern Time (ET) on November 26, 2024**, shall electronically file with this tribunal and serve on each other, a Prehearing Statement³⁸ containing the following sections:

³⁷ 5 U.S.C. § 556(c)(5); 21 C.F.R. § 1316.52.

³⁸ Absent advance leave by this tribunal on a motion supported by good cause, all filed documents (other than noticed proposed exhibits offered by either party on the merits) *shall be limited to fifty (50) pages* (utilizing 12-point characters and 1-inch margins).

1. **Witnesses.** Names, *curriculum vitae*, and current addresses of all witnesses whose testimony is sought to be presented by each of the Parties.
2. **Summary of Testimony.** Brief summary of the testimony of each witness. The summaries are to state what the testimony will be, rather than merely list the areas to be covered. Testimony not disclosed may be subject to exclusion.
3. **Documents.** A list noticing all documentary evidence, including affidavits and other proposed exhibits, intended to be offered into evidence, specifying the number of pages in each. Each proposed exhibit is to be marked for identification and numbered as follows: (“[name of Party]-Exh. No. ## (ID)”).
4. **Hearing Date Availability.** The NPRM and GNoH in this matter fixes the place of hearing as the DEA Hearing Facility in Arlington, Virginia. The Government and the Parties are expected to provide their representatives’ and their witnesses’ availability for the months of January through February 2025³⁹ at the Preliminary Hearing.
5. **District Court Intervention.** To the extent practicable, each Party should indicate whether he/she/it presently intends to seek the intervention of a U.S. District Court in accordance with *Axon Enterprise, Inc. v. FTC*, 598 U.S. 175 (2023).

It is further **ORDERED** that, in accordance with 21 C.F.R. § 1316.64, **a Preliminary Hearing⁴⁰ in this matter will be conducted on December 2, 2024, at 9:30 a.m. ET in the North Courtroom⁴¹ at the DEA Hearing Facility**, at 700 Army Navy Drive, Arlington, Virginia, 22202.⁴²

It is further **ORDERED** that all proceedings will be governed by the provisions of 21 C.F.R. §§ 1316.41-1316.68.⁴³ Your attention is specifically directed to 21 C.F.R. § 1316.45, which provides, *inter alia*, that “[d]ocuments shall be dated and deemed filed upon receipt by the

³⁹ 21 C.F.R. § 1301.45.

⁴⁰ 21 C.F.R. § 1316.

⁴¹ As set forth in the Preliminary Order, the courtrooms at the DEA Hearing Facility are spacious and modern, but not unlimited. Accordingly, in view of the potentially high number of hearing participants, it is anticipated that admission to the preliminary hearing will be limited to representatives (no more than two, preferably one) and credentialed media as designated by the Agency. The Administrator has directed the proceedings will be livestreamed to afford those physically outside the courtroom an opportunity to observe the proceedings. Naturally, witnesses will be admitted to the courtroom to testify at the merits hearings at times where their testimony is scheduled. No cell phone use by anyone will be permitted in the courtroom at any hearing conducted in this matter. The highest level of decorum will be maintained at all times during all hearings, and court attire is required for anyone participating in any capacity. All representative appearances will be live (not virtual) throughout, and all representatives must plan to arrive sufficiently early to allow security processing through the DEA Visitor Center, which is collocated with the DEA Hearing Facility at 700 Army Navy Drive, Arlington, Virginia, 22202.

⁴² Logistical issues will be coordinated by Law Clerk Laila Mogharabi, Esq., who can be contacted at (202) 307-8188 and at ECF-DEA@dea.gov.

⁴³ Additional helpful information regarding DEA administrative proceedings may be found at the OALJ website, <https://www.dea.gov/administrative-law-judges>.

Hearing Clerk.” Documents (other than proposed exhibits) may be filed electronically or by hard copy. Only one method of document filing may be utilized.

Electronic Filing: The strongly preferred method of filing correspondence in these proceedings is as a PDF attachment via email to the DEA Judicial Mailbox (**ECF-DEA@dea.gov**). The forwarding email on all electronically filed correspondence must indicate that it was simultaneously served on the opposing party via email. The Respondent must ensure that all documents filed with the DEA Judicial Mailbox are simultaneously served on the Government Mailbox at (**dea.registration.litigation@dea.gov**). Any request(s) to modify email addresses of a party or counsel must be made on notice to this tribunal and the opposing party. The email receipt date reflected by the DEA Judicial Mailbox server shall conclusively control all issues related to the date of service of all filed correspondence, provided however, that correspondence received after 5:00 p.m., local Washington, D.C. time, will be deemed to have been received on the following business day. Note: While email is utilized as the method to forward documents for filing—as attachments—no substantive matter communicated through the body of a forwarding email will be considered. The parties are directed to refrain from including social security numbers or personally identifiable information in electronically-filed documents. Proposed evidentiary exhibits will not be accepted via electronic filing. Details regarding evidentiary exhibit filing will be the subject of a subsequent order.

Hard Copy Filing: Alternatively, correspondence may be filed in hard-copy form. Hard-copy filings must be served in triplicate and addressed to my attention at: **The DEA Office of Administrative Law Judges, 8701 Morrisette Drive, Springfield, Virginia 22152**. Because the DEA Hearing Facility is not physically collocated with the DEA mailing address, hard copy filings must be posted sufficiently in advance of the due date to assure timely receipt by this office.

Failure to timely file a prehearing statement that complies with the directions provided above may result in a sanction, including (but not limited to) a waiver of hearing and an implied withdrawal of a request for participation. Prehearing statements should not include motions, which should be filed separately.⁴⁴

⁴⁴ A prehearing ruling setting deadlines will be issued after the prehearing conference.

It is further **ORDERED** that any requests for extension of time to file must be made by written motion sufficiently in advance of scheduled deadlines to be considered and ruled upon.

Dated: November 19, 2024

JOHN

MULROONEY

Digitally signed by
JOHN MULROONEY

Date: 2024.11.19
17:25:51 -05'00'

JOHN J. MULROONEY, II
Chief Administrative Law Judge

CERTIFICATE OF SERVICE

This is to certify that the undersigned, on November 19, 2024 caused a copy of the foregoing to be delivered to the following recipients: (1) James J. Schwartz, Esq., Counsel for the Government, via email at james.j.schwartz@dea.gov; Jarrett T. Lonich, Esq., Counsel for the Government, via email at jarrett.t.lonich@dea.gov; and S. Taylor Johnston, Esq., Counsel for the Government, via email at stephen.t.johnston@dea.gov; (2) the DEA Government Mailbox, via email at dea.registration.litigation@dea.gov; (3) Shane Pennington, Esq., Counsel for Village Farms International, via email at spennington@porterwright.com; and Tristan Cavanaugh, Esq., Counsel for Village Farms International, via email at tcavanaugh@porterwright.com; (4) Nikolas S. Komyati, Esq., Counsel for National Cannabis Industry Association, via email at nkomyati@foxrothschild.com; William Bogot, Esq., Counsel for National Cannabis Industry Association, via email at wbogot@foxrothschild.com; and Khurshid Khoja, Esq., Counsel for National Cannabis Industry Association, via email at khurshid@greenbridgelaw.com; (5) John Jones and Dante Picazo for Cannabis Bioscience International Holdings, via email at ir@cbih.net; (6) Andrew J. Kline, Esq., Counsel for Hemp for Victory, AKline@perkinscoie.com; and Abdul Kallon, Esq., Counsel for Hemp for Victory, via email at AKallon@perkinscoie.com; (7) Erin Gorman Kirk for the State of Connecticut, via email at erin.kirk@ct.gov; (8) Ellen Brown for Massachusetts Cannabis Advisory Board, via email at ellen@greenpathtraining.com; (9) Shanetha Lewis for Veterans Initiative 22, via email at info@veteransinitiative22.com; (10) Jason Castro, Esq., Counsel for The Doc App., Inc. d/b/a My Florida Green, via email at jasoncastro@myfloridagreen.com; (11) Kelly Fair, Esq., Counsel for The Commonwealth Project, via email at Kelly.Fair@dentons.com; (12) Rafe Petersen, Esq., Counsel for Ari Kirshenbaum, via email at Rafe.Petersen@hklaw.com; (13) David G. Evans, Esq., Counsel for Cannabis Industry Victims Educating Litigators, Community Anti-Drug Coalitions of America, Phillip Drum, Kenneth Finn, International Academy on the Science and Impacts of Cannabis, and National Drug and Alcohol Screening Association, via email at thinkon908@aol.com; (14) Patrick Philbin, Esq., Counsel for Smart Approaches to Marijuana, via email at pphilbin@torridonlaw.com; and Chase Harrington, Esq., Counsel for Smart Approaches to Marijuana, via email at charrington@torridonlaw.com; (15) Stephanie E. Masker, Esq., Counsel for National Transportation Safety Board, via email at stephanie.masker@ntsb.gov; (16) Eric Hamilton, Esq., Counsel for the State of Nebraska, via email at eric.hamilton@nebraska.gov; and Zachary Viglianco, Esq., for the State of Nebraska, via email at zachary.viglianco@nebraska.gov; (17) Gene Voegtlin for International Association of Chiefs of Police, via email at voegtlin@theiacp.org; (18) Gregory J. Cherundolo for Drug

Enforcement Association of Federal Narcotics Agents, via email at executive.director@afna.org; (19) Reed N. Smith, Esq., Counsel for the Tennessee Bureau of Investigation, via email at Reed.Smith@ag.tn.gov; and Jacob Durst, Esq., Counsel for Tennessee Bureau of Investigation, via email at Jacob.Durst@ag.tn.gov; and (20) Jim Skinner for National Sheriff's Association, via email at sheriffskinner@collincountytx.gov and ykaraman@sheriffs.org.

**QUINN
FOX**

Digitally signed by
QUINN FOX
Date: 2024.11.19
17:27:19 -05'00'

Quinn Fox
Staff Assistant to the Chief Judge
Office of Administrative Law Judges